feel well live long annual report shareholder navigate help find way lick icon report button mark report navigation strip right panel right hand lick link lick section content take bar take start specific section home search print previous previous view content notice limitation director liability english law company act safe harbour limit liability director respect statement omission report director statement responsibility director contain page independent auditor report include business review page create value financial statement english law director liable company deliver note financial statement party report director contain perform financial statement glaxosmithkline plc error result recklessness know prepare gaap misstatement dishonest concealment material fact liable report director page inclusive comprise report director draw present accordance reliance english company law liability director connection report shall subject limitation restriction chairman statement quarterly trend provide law chief executive review year record marketplace product development pipeline website glaxosmithkline website wwwgskcom strategy growth product competition intellectual property give additional information group grow diversified business share price dividend notwithstanding reference deliver product value annual general meeting annual report glaxosmithkline website information available simplify operating model investor relation registrar website constitute annual report financial architecture taxation information shareholder shall deem incorporate responsible business glossary term reference index cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group financial review current expectation forecast future event investor identify statement financial position resource fact relate strictly financial review historical current fact use word risk factor anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular cover clockwise include statement relate future action phase programme educate group prospective product product approval importance handwash reduce spread disease chris martin future performance result current anticipate product sale effort expense diskus inhaler device outcome contingency legal board develop deliver inhale proceeding financial result group medicine directly respiratory system undertake obligation update forward corporate executive team inpress photography look statement result new governance policy early research new biopharmaceutical information future event share capital control include treatment base antibody committee report take place large centre forwardlooke statement involve inherent stevenage george brooks risk uncertainty group caution law regulation investor number important factor total remuneration include document cause remuneration policy actual result differ materially people work contain forwardlooke statement director emolument total search new medicine factor include limited remuneration vaccine consumer healthcare product discuss risk factor page pierre charbonneau director senior management annual report testing sign malaria children tanzania tom whipps number adjust measure report performance business sensodyne repair protect boost performance consumer healthcare measure define business andy robinson photofarm gsk annual report sciencele global healthcare company innovative medicine vaccine consumer healthcare product million people world allow feel well live long product develop manufacture contribute directly health patient consumer indirectly wider wellbee economy society fundamentally change recent year create balanced business address market challenge deliver sustainable performance return shareholder commit generating performance responsible way visit website wwwgskcom gsk annual report overview sciencele global healthcare company research develop broad range innovative product business primary area business pharmaceutical vaccine consumer healthcare objective deliver sustainable growth portfolio group turnover total turnover billion pharmaceutical vaccine consumer healthcare turnover group turnover group turnover group pharmaceutical business develop vaccine business develop market range make available medicine large world produce consumer health product base treat broad range paediatric adult vaccine scientific innovation lead chronic disease portfolio range infectious disease position main category establish brand newer distribute billion dose overthecounter otc medicine oral innovative patentprotected medicine country healthcare nutritional healthcare supply develop country portfolio include number wellknown brand panadol sensodyne lucozade horlick sale therapy area sale vaccine sale category respiratory boostrix otc antiviral cervarix oral healthcare central nervous system fluarix flulaval nutritional healthcare cardiovascular urogenital flu pandemic metabolic hepatitis antibacterial infanrix pediarix oncology emesis rotarix dermatology synflorix viiv healthcare hiv business sustain investment expenditure allocation spend billion major restructuring billion total search develop new total expenditure medicine vaccine innovative consumer product allocate investment base view scientific opportunity different disease area asset late ability provide significant improvement exist stage pipeline treatment level return generate dedicate research programme disease affect develop world estimate internal pharmaceutical healthcare company research new vaccine vaccine rate return new medicine world health consumer healthcare expenditure organization priority disease hivaid malaria major restructuring tuberculosis calculation result major restructuring describe note financial statement presentation financial statement present consolidated income statement page gsk annual report geographic presence cover country global reach reshape business capitalise high growth potential market outside europe usa territories account employee total sale time restructure developed market employee region business reflect challenge commercial environment market significant global manufacturing presence network manufacturing site large centre usa spain belgium china usa europe emerge markets asia pacific japan turnover region usa europe emerge markets asia pacific japan structure commercial business structure regional turnover segment unit area focus pharmaceutical vaccine operate geographical pharmaceuticals vaccines europe pharmaceutical vaccine segment combine business emerge market pharmaceutical vaccine consumer healthcare business function global japan pharmaceuticals vaccines unit viiv healthcare specialist hiv company asia pacific pharmaceutical vaccine found pfizer viiv healthcare trading trading turnover include canada puerto rico central consumer healthcare vaccine tender sale contract manufacturing sale gsk annual report overview create value business model rely innovation intellectual property protection brand allegiance deliver sustainable growth business model new medicine healthcare product critical element business model vulnerability generic competition need people globe protection intellectual property mark vaccine address illness create develop new treatment biopharmaceutical include enzyme cancer diabetes heart disease technology protection allow monoclonal antibodie large wellcontrolle treat generate income set period molecule create different time scientific research time enable recoup development manufacturing continuously uncover new cost invest research process small molecule understanding disease process product typically patent protection prescription technology difficult expensive manufacture medicine invention element present year western development generic version opportunity investigate develop country time new vaccine biopharmaceutical new improve treatment medicine approve use patient subject different regulatory create value apply science significant proportion exclusivity requirement requirement technology discover develop produce period pass patent carry trial human incur distribute medicine vaccine product prevent additional expense require consumer healthcare product protection challenge generic manufacture small molecule expire place barrier pharmaceutical vaccine generic competition patent protection expire process discover medicine subject competition consumer healthcare develop new medicine vaccine generic manufacturer long expensive require intellectual property protection overhead innovation creativity industry consumer healthcare product able offer product development time typically consumer healthcare business rely considerably low price decline year new medicine vaccine product innovation brand loyalty sale follow patent expiration cost billion trademark protection competitive particularly rapid usa approve product process create value development europe generic pressure different involve thousand patient trial timeline new consumer healthcare emerge market brand allegiance investigate safety efficacy product significantly shorter great influence market potential new treatment pharmaceutical vaccine know heritage brand exist pace innovation rapid medicine onpatent application science consumer value provide opportunity insight key drive successful withstand generic competition product innovation consumer brand pharmaceutical discovery development process research development regulatory market discovery testing review market patent protection patent compound compound compound expiry year year indefinite final patent application product approval patent expiry gsk annual report different fundamentally change broken commitment access business culture help grow traditional hierarchical pharmaceutical actively seek new way improve performance business model create instead deliver healthcare make approach openness small unit encourage great product available affordable challenge innovation affect entrepreneurialism accountability people need way business way work scientist live society external group relationship strive develop new expect right thing employee employee partnership approach adopt good positive impact contribution different mindset business make people live innovative openminde flexible key motivator work gsk effort expand access consultative value new product lead industry breadth business different perspective adopt flexible approach pricing group bring think broadbase balanced medicine vaccine base open work research business pharmaceutical vaccine country wealth ability pay charity academia company non consumer healthcare product result significant reduction governmental organisation pharmaceutical vaccine business price increase demand increase consultation patient include establish brand new product emerge economy payer ensure medicine innovative patentprotected medicine represent good outcome patient develop provide improvement categoryleading brand government shareholder healthcare system value reward consumer healthcare business western market develop committed research new new reimbursement approach diverse portfolio provide well treatment disease impact medicine agree riskshare range product drive business develop world research arrangement payer innovationdriven market centre spain dedicated usa japan provide establish special business discovery work good opportunity growth unit responsible increase company research treatment emerge market rapidly access product vaccine malaria hiv develop economy expand develop country world report positive initial result number people access price patent medicine malaria vaccine successful healthcare treatment region keep world vaccine develop world price reinvest change shape deadly disease flexible fifth profit sale business intend provide intellectual property know territory local healthcare broadlysource sale growth provide area research disease infrastructure project great resilience face market develop world aim challenge loss patent stimulate progress search work agency protection government austerity new treatment distribute vaccine people measure country low price commercial organisation billion vaccine dose new way work pioneer new sale model align deliver change market expectation fundamentally change supply protect people develop customer example organisation deliver large country significant introduce new remuneration system diverse latestage pipeline discovery medicine donation programme target sale representative base organisation structure sustain disease elimination service deliver healthcare flow innovative new medicine professional individual vaccine sale target gsk annual report overview deliver strategy design deliver sustainable growth reduce risk improve longterm financial performance return shareholders strategic priority grow deliver simplify diversified product operate global business value model create balance change organisation change shape business business product portfolio capable well able sustain transforming operating deliver sustainable sale growth industryleade pipeline product model reduce complexity centre business area offer valuable improvement efficient past pharmaceutical vaccine consumer treatment patient healthcare year implement global healthcare access growth provider restructure programme market create business deliver significant saving increase level vulnerable market volatility externalisation research allow time manufacture include generic pressure access new area science business unit relentlessly past year share risk development focus streamline production substantially increase investment partner decision process improve efficiency emerge market japanese early pipeline progression eliminate waste operation global medicine reorganise global support vaccine consumer healthcare significantly differentiate exist function facility real estate business therapy progress procurement centralise break traditional hierarchical maximise promotion group allow business model create small distribution synergy streamline provide significant agile group scientist pharmaceutical vaccine economy scale accountable deliver consumer healthcare business project rapidly grow emerge economy day group turnover proportion new product asset late annual benefit work capital sale outside approval stage pipeline restructuring cycle usa europe programme financial architecture establish new financial architecture align addition improve financial reporting align planning execution performance measurement order closely architecture provide maximise financial performance return shareholder data insight progress make design drive improvement operate margin great business region progress key financial efficiency enhance cash conversion sale driver operational financial efficiency growth focus deliver lead strong start transition report core growth earning share well free cash generation basis enable great visibility underlie performance expect cash flow available dividend reinvestment business business share buyback depend return attractive gsk annual report underlie operating principle strong governance operate responsibly commitment responsible valuesbase business believe responsible business underlie value apply grow create value shareholder society group value operate transparency long term think responsibilitie area demonstrate respect people act integrity remain help improve people health wellbee patientfocuse strong policy compliance live ability pay work support programme expect standard supplier development people community contractor business partner chairman board world behave open honest manner director provide leadership corporate governance grow business protect natural fundamental sound decision making support resource need future executive management implement strategy continue change way business risk oversight compliance council rocc oversee successful sustainable long term management significant business risk include reputational nonfinancial risk compliance law regulation coordination governance body spirit value collaborative approach standard audit assurance group support rocc board audit risk committee provide business product touch different group independent view significant risk manage people medicine organisation product aim work group transparent collaborative manner allow succeed partner approach apply interaction payer regulator healthcare professional work supplier business partner equally seek valuable participant scientific research collaboration researcher share significant scientific development datum appropriate route actively seek work partnership public body nongovernmental organisation help progress health issue present wide societal challenge treatment neglect tropical disease prevention childhood illness develop country gsk annual report overview perform measure performance number key indicator remuneration executive base group turnover operating profit margin major restructuring report underlying growth growth growth margin cer cer cer important perform important perform key objective strategy report turnover fall second key objective improve operate profit exclude legal deliver sustainable broadlysource year past year operate leverage order cost operate income sale growth deliver average annual deliver strong operating profit significantly impact underlie turnover growth growth margin indicate year rolloff pandemic underlie turnover growth adjust cost manage product avandia valtrex impact rolloff include operating profit key sale pandemic product measure avandia valtrex xcluding legal cost million million million calculation underlie turnover describe operating income million million million earning share major restructure free cash flow growth growth pence cer important perform important perform eps show portion profit eps grow significantly measure show cash free cash flow allocate share key compare primarily generate available return impact loss sale indicator performance result low legal charge shareholder reinvest pandemic product avandia return generate business effectiveness valtrex associate convert earning cash receivables legal settlement effective work capital million control investment discipline million million calculation free cash flow describe reconciliation provide calculation result major restructuring describe note financial statement presentation financial statement calculation cer growth describe gsk annual report turnover major growth area new pharmaceutical vaccine product performance growth turnover cer turnover important perform important perform measure focus major turnover business area measure show delivery sale totalling growth area vaccine consumer total billion sale newly launch product billion represent healthcare emerge market asia represent group create incentive improve pharmaceutical vaccine pacific japan dermatology turnover decrease compare performance new product turnover include performance highlight reflect loss define product launch cervarix million progress make deliver avandia valtrex flu year include synflorix million strategy create broadbase pandemic sale key measure rotarix million sale growth resilient volatility cash return shareholder total shareholder return growth dividend buyback important perform continue focus deliver pay dividend dividend growth return free billion spend billion cash flow shareholder repurchase share share buyback offer attractive return glaxosmithkline total return alternative investment glaxosmithkline pharma peer return index ftse total return index index include abbott laboratories astrazeneca bristolmyers squibb eli lilly johnson johnson merck novartis pfizer roche holding sanofi gsk annual report strategic review chairman statement behalf board management team drive late receive fundamental change business promise datum malaria please year improve vaccine prove successful report gsk growth prospect reduce risk potential prevent death deliver enhance financial performance million african child considerable progress demonstrable evidence terrible disease strategy starting deliver despite maintain good corporate governance positively differentiate gsk outlook key priority please challenge economic company sector introduce corporate governance particularly like recognise environment report set sir andrew vision leadership approach regulation identify early scale change guideline underpin decision needed successfully make mindful start execute change current environment executive ultimately aim strategy remuneration remain committed deliver sustainable improve longterm link pay delivery value return shareholder performance set detail year return billion approach remuneration shareholder dividend report share buyback increase change versus board simon dingemans current uncertain economic succeed julian heslop chief environment management risk financial officer judy lewent remain key focus board stacey cartwright appoint senior executive team nonexecutive director judy stacey reach agreement principle bring wealth experience settle group outstanding litigation business finance respective government historic sale knowledge pharmaceutical marketing practice agreement industry consumer brand represents add settlement strong addition board go outstanding litigation significantly forward james murdoch decide reduce overall legal exposure step board year agm offer board continue focus reelection like thank jame strengthen governance contribution board compliance procedure help reduce past year future litigation minimise risk shareholder audit commit continue risk committee retain good improve diversity board level visibility issue challenge aspiration face management work female representation address example finally board pleased complete thorough review sir andrew knight antibribery corruption abac new year honours service programme associate training economy pharmaceutical develop ensure compliance industry welldeserve bribery act recognition sir andrews contribution remain strong belief gsk economy operate responsible ethical way essential success gsk chairman corporate responsibility committee please progress year improve global access medicine include agreement supply large quantity number vaccine poor country sir christopher gent world fraction western price chairman gsk annual report chief executive review gsk record year deliver underlie emerge market future pricing sale growth strong cash generation pressure rule demonstrate significant progress result organic investment succeed increase shareholder return target bolton acquisition billion complete continue expect strategy create deliver growth ahead market underlie sale growth reflect region balanced business deliver portfolio breadth mix business japan outstanding sustainable financial underlie sale group grow year market innovationdriven growth broadly source performance provide gsk launch profile see strong performance area exceptional year new value patient business pharmaceutical japanese sale grow vaccine consumer consumer launch new product healthcare include cervarix especially expect saw transition follow implementation report sale performance national immunisation programme year effect loss sale like japan usa proinnovation avandia valtrex flu pandemic environment gsk emerge product diminish report sale period substantial patent year expiration half second half significantly reshape business clearly reflect change redesign commercial organisation create business align well change payer balance vulnerable volatility environment confident include generic pressure business place deliver performance achieve improved performance despite continue economic pressure overall environment remain political instability europe challenge volatility emerge market inevitable continue expect underlie sale growth translate report sale growth drive cash generation return shareholder gsk continue highly cash generative legal settlement billion net cash inflow operating activity billion free cash flow billion year announce year ordinary dividend complete billion share repurchase longterm programme announce return net proceed sale noncore north american otc brands shareholder payment supplemental dividend pay fourth quarter ordinary dividend skoorb egroeg gsk annual report strategic review chief executive review continue focus productivity continue focus summer announce new return improve return update pricing structure vaccine calculation expect rate diarrhoeal disease offer gavi key element strategy return investment alliance vaccine fraction improve return productivity increase cost develop western market please progress healthcare company save countless life organisation make publish analysis extremely future sustainable achieving encourage progress recoup cost good medicine vaccine track deliver long term goal manufacture phase iii development cusp create highlight start operate transparency world malaria vaccine know receive datum responsibility firsthand devastating impact expect complete disease africa live development programme late remain committed operate year stage asset indication transparency responsibility run business region course readout year multiple advance october latestage trial confirm positive overall balance agenda ensure behaviour promise see far show importantly see productivity action meet exceed vaccine reduce risk translate real filing approval expectation society malaria half african child new medicine approve continue focus strongly aged month usa europe procedure compliance market ready sufficient datum inhouse file reiterate commitment sell particularly usa price vaccine level covers example establish new cost generate small return new drug compensation system reward plough vaccine approve usa sale representative quality research generation new molecular entity service customer sale malaria medicine vaccine peer volume deliver outlook come positive indication environmental strategy replenish pipeline please look ahead clearly mindful ongoing basis make progress ambitious potential pressure face give goal set march current global environment complete comprehensive entire value chain raw material continue expect drive review discovery performance product disposal shareholder return seek unit unit comprise grow sale business scientist group focus priority align improve operational leverage early stage discovery particular commercial success form new financial efficiency deliver strong disease pathway base review partnership tackle healthcare cash generation believe progress need people develop country medicine latestage development early gsk begin supply conclusion like thank year pneumococcal vaccine kenya gsk employee partner innovative financing mechanism work world know advance market outstanding contribution support commitment large fund help deliver successful design single vaccine create new opportunity dramatically increase sustainable access growth performance vaccine baby africa sir andrew witty chief executive officer gsk annual report marketplace difficult market general overview austerity measure take correct public deficit debt condition stem global economic growth mix common event tsunami international earthquake japan political unrest pharmaceutical market financial crisis continue north africa middle east sale world pharmaceutical market turbulence eurozone affect worth billion constant impact world international economy economic exchange rate cer month environment year economy end september particularly influence large budget billion prior year sale world deficit develop world require significant action represent growth pharmaceutical market country greece italy growth year early show significant pressure share global sale fall usa prompt fear recession remain pharmaceutical regional variation country despite improvement market europe number sector include sale rise rest world world pharmaceutical market world pharmaceutical market share price usa end expect continue grow point start year growth mature market limited fall europe ftse compare emerge market index lead share end year doubledigit growth expect low dax germany factor influence growth lower cac france japans main share index significant need medicine nikkei close low endofyear healthcare treatment level chinas shanghai world number factor composite index lose reason optimistic ability grow business research base external assessment manufacturing selling healthcare outlook global economic growth treatment particularly new remain uncertain shape business exist recovery likely slow factor affect performance unbalanced risk mature economy success researchbase healthcare great develop one company exact impact social political unrest arise difficult predict value compound growth world pharmaceutical market geographic region total sep sep usa europe rest world emerge market asia pacific japan canada total sale world market therapeutic class total central nervous system antineoplasticimmunomodulatory cardiovascular alimentary tract metabolic antiinfective bacterial viral fungal exclude sale growth world vaccine pharmaceutical market respiratory datum market share market growth rate gsk estimate base recent datum independent external source include im health value cer constant exchange rate gsk annual report strategic review marketplace continue growth emerge marketsincrease estimate change world population millions access medicine treatment fastdevelope economy wealth create expand opportunity people benefit medicine vaccine consumer healthcare product emerge market china india large population market expect grow significantly year pop year pop year pop mature market year world population project increase substantially current level big proportional growth old age group lifestyle change population growth source im world population rapidly increase number people live long world population relative percentage number impact regulatory background health risk change biopharmaceutical newly approve agency requirement continue grow success treat infectious disease medicine continue rise rise particularly aspect product impact life expectancy biotechnology quality safety addition pattern physical activity price control evaluation benefit risk continue food alcohol tobacco consumption paramount consideration change low middleincome country price approval new medicine usa country face double burden pharmaceutical product control food drug administration fda increase chronic noncommunicable law government increasingly focus safety condition communicable influence price control medicine approval disease traditionally affect poor national healthcare organisation postmarkete phase product bear large cost prevalence chronic disease supply medicine consumer fda approve high increase middleincome country recent government healthcare reform number new molecular entity begin impact country france spain nearly approval develop country germany restrict pricing therapy treat rare disease line fda priority advance science technology reimbursement address public health need special scientific advance continue translate usa currently population enforcement compliance new medicine technology government price control private activity increase manufacturing difficult predict sector purchase federal law require global supply chain one rate instance pharmaceutical manufacturer pay drug advertising promotion follow development monoclonal rebate certain medicine eligible fda develop goal renewal antibodie biopharmaceutical reimbursement state prescription drug user fee act manufacturing technique past federal healthcare programme pdufawith focus enhance decade new biopharmaceutical rebate increase health science drug development improve medicine approve reform law affordable care act quality evidence application aca come effect provide efficient predictable review process maintain public rise biotechnology pressure control healthcare cost confidence continue government spending healthcare europe follow adoption programme crossborder trade revise european union legislation acceleration generic market new measure aim strengthen comparative effectiveness research safety monitor medicine pharmaceutical pricing issue discussion implement importance industry july continue healthcare debate usa new law protect citizen prescription otc biotechnology regulatory pressure threat pose fake medicine proportion biotechnology sale pharmaceutical vaccine adopt discussion continue draft compare global prescription otc industry highly regulate regional legislation improve citizen access pharmaceutical sale world reliable information medicine countryspecific law regulation drug european medicine agency ema major factor determine source evaluatepharma publish information product develop approve gsk annual report vision outline fiveyear strategic registration critical ensuring sell seretide trademark plan road map expect reasonable return investment protection generally extend develop commission continue long trademark renew policy try obtain patent review regulation clinical necessary gsk trademark commercially important protectable trial europe legislative proposal important maintain brand invention discover develop expect identity product enforce activity patent trademark right prevent infringements regulatory environment emerge protection new active ingredient market asia pacific continue available major market competition evolve number country patent obtain new revise regulatory review system drug formulation manufacture pharmaceutical industry participate number specific process medical use device competition come regional national regulatory administer product company make patentprotected initiative provide opportunity medicine indication treat meaningful scientific regulatory obtain patent similar disease medicine dialogue industry agency product prevent manufacturer make generic copy stakeholder continue challenge medicine follow patent expiration expire grant patent include broad set patient population principal pharmaceutical mean issue patent number country vaccine competitor include necessarily hold valid enforceable medicine development programme court court determine abbott laboratories amgen astrazeneca order increase global patient access patent hold invalid non bristolmyers squibb eli lilly new innovative medicine optimise infringe unenforceable johnson johnson merck novartis regulatory approval example china protect market party pfizer roche holding sanofi takeda russia india emerge market entry prior patent expiry significant teva pharmaceutical country update regulation litigation concern challenge consumer healthcare market local clinical experience summarise note financial challenge consumer population registration statement legal proceeding demand well quality well package new chemical entity value retailer consolidated treatment neglect tropical consumer healthcare industry globalise strengthen disease little commercial subject national regulation comparable negotiation power principle market stimulate research reward prescription medicine competitor market include innovation area take testing approval manufacturing labelling flexible approach help speed colgatepalmolive johnson johnson marketing product high standard new medicine include procter gamble unilever pfizer technical appraisal frequently involve flexible patent novartis lengthy review approval process provide access knowhow addition small company new product launch resource share datum compete gsk certain market generic pressure research community objective outlook ensure see barrier patent expire medicine muchneede research spur operate environment remain medicine subject development new well treatment challenge significant competition generic product neglect tropical disease progress restructure effect particularly acute rigorous returnsbased approach capital western market generic product life patent country allocation expect underlie sale rapidly capture large share year filing date momentum translate report market follow patent expiration long development time new medicine growth constant exchange generic manufacturer typically mean substantial rate despite anticipate pricing incur significant cost research patent life erode prior reduction market development education market launch market possible development able offer lose time restore outlook timing impact product considerably low price lead variation substitutable competition seretideadvair brand competitor pressure patent life actually available europe usa uncertain apply significantly vaccine product market uncertainty intellectual property trademark significant regulatory manufacturing requirement need satisfied intellectual property important commercial product produce inhale medicine aspect business effective protect register trademark seretideadvair addition patent legal protection intellectual major market local delivery device seretideadvair property patent trademark variations example usa reference risk register design copyright domain trademark advair cover product factor page gsk annual report strategic review strategy growth grow diversified global business overview create balanced business product portfolio capable deliver sustainable sale growth centre business area pharmaceutical vaccine consumer healthcare substantially increase investment highergrowth area operation emerge market japan global vaccine consumer healthcare business access new market broadlybased business create vulnerable volatility include generic pressure significant competitive advantage synergy ability distribute pharmaceutical vaccine consumer healthcare product particularly rapidly grow emerge economy progress record demonstrate success approach report turnover fall deliver underlie sale growth past year anticipate underlie sale growth translate report sale growth detail underlie growth addition group turnover generate outside usa europe shift sale away reliance white pill western market broad base include emerge market vaccine consumer healthcare clear gsk annual report group turnover total sale perform underlying report report turnover decline growth growth underlie turnover cer cer rise second consecutive year turnover turnover turnover diversify sale away white pill western market sale perform continue proportion sale white pill western market decline reduce susceptibility generic pressure market priority progress create balanced business sale outside usa europe perform sale market outside usa europe increase total sale group turnover turnover major growth area turnover major growth area perform turnover major growth area vaccine consumer healthcare emerge market asia pacific japan pharmaceuticals dermatology total billion group turnover calculation underlie turnover describe gsk annual report strategic review grow diversified global business continue usa pharmaceutical vaccine good marketplace year report sale decline compare mark low progress aim healthcare market continue sale pandemic product avandia change significantly response generate sustainable sale valtrex underlie sale year government reform patient healthcare flat billion despite impact growth challenge provider payer demand healthcare reform higherquality care low cost well market environment health outcome despite fall report sale operating profit increase keep passage healthcare reform effort simplify standardise legislation government pay value work process produce efficiency majority healthcare help control cost offset decline year reform continue sale certain product combine implement healthcare provider high asset disposal income turnover payer change provide pay healthcare pharmaceutical business report turnover decline underlying payer demand evidence turnover decline sale value study compare growth economic effectiveness large product advair decline cer follow drop market ics treatment regimen therapie laba combination product follow increasingly link provider reimbursement health outcome revise class labelling implement food drug administration healthcare provider physicians fda hycamtin sale decline operate profit consolidating group practice generic competition join integrate delivery zovirax sale decline follow network hospital consolidate divestment brand january effort obtain scale resource establish promote product growth need perform effectively system account business cer reward value volume perform strongly patient behaviour change include contribution payer institute high copayment respiratory business particular ventolin doctor visit prescription drug cardiovascular drug lovaza patient involved neuroscience medicine pharmaceutical vaccine interested cost quality lamictal new oncology turnover care receive product promacta arzerra votrient farreache change environment operate vaccine business report opportunity work turnover increase reflect patient payer healthcare provider strong performance flulaval meet evolve need infanrixpediarix rotarix partly offset performance decline cervarix sale growth pharmaceutical vaccine number fda cer business emerge period approval potiga benlysta horizant respiratory substantial patent expiration usa new indication boostrix antiviral see fall sale central nervous system lamictal benlysta develop past year focus cardiovascular urogenital gsk human genome science reshape business resource metabolic new area growth oncology achieve result antibacterial oncology emesis rescale presence primary care work hard transform business vaccine redesign commercial include implement industry dermatology organisation align well lead incentive compensation system change payer environment sale professional work directly healthcare provider change way incentivese sale team gsk annual report change way incentivise sale team alter way reward customerface pharmaceutical vaccine sale professional new system reward sale professional quality interaction healthcare professional include element customer evaluation achieve individual sale target approach align core value put interest patient goal share healthcare provider improve patient health substantial number increase transparency support community fda approval potiga conduct business add million grant city benlysta horizant voluntary disclosure payment philadelphia youth development healthcare practitioner white house meet new include payment healthcare education reform pledge million indication boostrix professional conduct clinical research year keep build commitment longterm support science lamictal publish payment education healthcare professional work new environmentally friendly speaker adviser facility philadelphia navy yard continue longstanding area construct commitment provide patient high possible international designation access medicine improve green building highly access oncology speciality efficient energy water use medication launch care manufacturing site zebulon gsk comprehensive programme north carolina reduce water offer speciality reimbursement consumption service free medicine past year work achieve oncology copay assistance programme goal send zero waste landfill provide help eligible patient limited insurance coverage gain well access oral oncology speciality medicine segami yttegekcol naes gsk annual report strategic review grow diversified global business continue europe pharmaceutical vaccine economic climate marketplace pharmaceutical business report turnover decline underlying government austerity healthcare system europe turnover decline sale volume face dilemma ageing population measure impact seretide asthma copd product increase chronic illness lifestyle increase revenue decline sale revenue disease create grow demand price cut mild flu season improve healthcare flu season impact antibacterial continue focus economic climate force government portfolio sale decline tighten healthcare budget expand range new oncology product votrient promacta result governmentled price cut arzerra perform sale product enhance costsave initiative create challenge duodart avodart treat benign transparency way impact prostatic hyperplasia grow austerity measure double despite duodart market operate compare access approval france italy outlook european gain approval economy highly uncertain expect government market new product turnover pressure pricing addition continue challenge government regulator add new product prolia treatment requirement evidence osteoporosis benlysta lupus value new medicine seeing launch majority market growth long lead time bring product europe cer market vaccine business report think current pricing turnover decline underlying reimbursement policy need turnover reflect austerity redesign achieve sustainable drive price cut few tender order framework ensure patient cervarix operate profit access effective treatment payer implementation gsk new financial stability pharmaceutical global standard enterprise resource industry encourage continue planning system design standardise invest research improve financial commercial growth cer performance process complete successfully germany deployment new european business sale european supply chain continue compose large contribution respiratory cardiovascularurogenital continue focus product vaccine evolve business great pharmaceutical vaccine transparency way operate turnover european management team introduce new global standard remain resilient challenge govern share scientific environment report turnover clinical datum medicine ensure fall billion underlie clear distinction scientific turnover exclude revenue dialogue promotional activity pandemic product avandia valtrex decline continued government change way reward austerity measure impact underlying pharmaceutical field sale staff replace growth region approximately individual sale target basis growth percentage point reward qualitative criterion overall cer business financial achievement performance underpin respiratory individualindexed performance measure antiviral reduce operating cost compare central nervous system continue invest continue work local cardiovascular urogenital product recent launch despite community support charitable metabolic initiative operating profit fall programme innovative antibacterial primarily loss sale sustainable strengthen oncology emesis pandemic product avandia valtrex healthcare infrastructure financial vaccine support year total dermatology million europe exclude gsk annual report grow diversified global business continue emerge market pharmaceutical vaccine underlie growth marketplace continue scale business offpatent product emerge market commercial environment report sale grow billion emerge market present diverse outpacing growth help acquisition challenge include political phoenix argentina pharmaceutical market instability part north africa flagship heritage medicine antibiotic middle east toughening augmentin celebrate year work bring competition aggressive pricing market turn growth control country include diverse range relevant antiinfective cns russia turkey portfolio contribute affordable medicine pricing pressure rule growth area people result organic report vaccine sale investment target bolton possible acquisition complete million underlying sale rise million continue expect deliver growth flexible pricing approach synflorix successful launch ahead market region emerge market sale performance million turnover approach emerge market consolidate recent base grow pharmaceutical acquisition nanjing meirui vaccine businesses pharma ltd china expand increase access new patent portfolio inlicensing protect brand offpatent arrangement strengthen growth cer brand medicine vaccine business sign innovative technology agreement early establish broad portfolio year transform vaccine joint affordable international brand venture neptunus china pharmaceutical vaccine believe whollyowne operation offer significant competitive operating profit advantage key strength adopt range flexible business emerge market pricing model emerge market base countrys ability pay report turnover growth year introduce approach flexible underlie growth growth pricing avamys avodart cer outpace growth market see volume sale increase consecutive year underlie key market growth drive relatively consistent respectively introduction flexible pharmaceutical growth pricing cervarix enable year operating profit fall deliver double number dose reflect loss sale pandemic pharmaceutical vaccine vaccine cervical cancer product avandia valtrex turnover woman region latin american business see attractive return especially strong grow report sale announce significant underlying basis commitment accelerate access india grew report underlie vaccine childhood illness sale significant longstanding partnership market disruption middle eastern gavi alliance june countries social unrest commit supply rotavirus result middle eastafrica business vaccine gavi fraction growth grew report sale develop world price cer underlie basis respiratory announce extension antiviral sale patentprotecte pneumococcal vaccine agreement central nervous system medicine improve approximately gavi cardiovascular urogenital billion report basis metabolic underlie antibacterial oncology emesis vaccine dermatology gsk annual report strategic review grow diversified global business continue japan pharmaceuticals vaccines gsk japan achieve marketplace receive approval lamictal bipolar disorder significant underlie japanese pharmaceutical market arixtra receive additional indication grow growth growth despite treatment venous thrombo helped partly embolism end major earthquake government price revision drug development pipeline consist pricing scheme government project tsunami march announce intention continue regulatory review prepare provisional drug pricing scheme respond quickly new product approval submission introduce price phase iii pipeline includes provide financial revision treatment rare disease product donation help market orphandesignate compound implementation funding disease organise employee preventation cervical cancer vaccine business record sale million pneumoccocal vaccine volunteer million exclude sale flu performance pandemic vaccine million performance drive market japan encourage turnover sale cervarix reach innovation gsk perform strongly million follow introduction pharmaceutical vaccine government national funding past year launch programme cervical cancer prevention product indication growth cer potential launch number july japanese regulator approve new product indication rotarix mark second approval year gsk vaccine exclude pandemic vaccine country rotarix report turnover billion flat launch november compare underlie vaccine japan prevention operating profit turnover grow operate profit rotavirus gastroenteritis infant fall reflect loss sale copromote daiichisankyo pandemic product follow natural disaster report pharmaceutical sale grow earthquake tsunami march growth billion reflect strong cer support people affect growth adoair seretideadvair provide substantial financial rose performance newly product donation establish launch product avolveavodart team volunteer name team xyzal antihistamine license orange initial stage ucb pharmaceutical vaccine provide critical supply turnover cns paxil remain leader affect area antidepressant market sale later volunteer provide labour fall recent introduction team medical professional antidepressant medicine provide offer medical counselling support range prescribing option support activity scholarship physicians student pharmaceutical study maintain contribute region recovery growth cer respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine dermatology gsk annual report grow diversified global business continue asia pacific pharmaceuticals vaccines asia pacific region marketplace lead vaccine provider asia pacific region report contributor gsk economic growth region vaccine sale growth continue exceed global average success show underlying growth support pharmaceutical market primarily sale new positive underlying gross domestic product growth exceed vaccine rotarix million world develop economy cervarix million growth market pricing pressure number synflorix million particularly country region public market performance manufacture intellectual property strong performance particularly strong continue challenge likely offset supply cervarix national malaysia vietnam growing population increase immunisation programme malaysia income emerge middle class successful award new emerge market business zealand national pneumococcal vaccine continue expect deliver growth tender synflorix ahead market region flexible pricing help turnover performance build business asia pacific region increase overall volume business asia pacific base product sell main pillar vaccine offpatent growth establish pharmaceutical product indonesia reduce price cer augmentin ventolin brand ensure medicine recently launch medicine reach people need votrient tyverb duodartavodart result volume increase neighbour singapore strong performance see price reduction antibiotic pillar asia pacific business operating profit augmentin lead threefold increase report sale asia pacific business volume sale grew reach billion thailand launch initiative underlie sale growth reach patient access growth exclude pandemic product avandia programme lead brand cer valtrex business seretide augmentin couple outperform market growth price reduction region product access increase asia pacific operating profit increase address distribution channel pharmaceutical vaccine turnover increase government hospital introduce turnover reflect favourable operating leverage flexible reimbursement policy private hospital agree reduce price pay portfolio new brand sale patient seretide reach million rise product tykerb avamys contribute significantly growth continue strong performance establish brand ventolin achieve sale million growth cer augmentin reach respiratory million antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine dermatology gsk annual report strategic review grow diversified global business continue consumer healthcare consumer marketplace nutritional healthcare grew drive strong rest world healthcare business develop market recent economic result acquisition turmoil weaken consumer demand perform face europe lead sport nutrition brand slow growth consumer healthcare maxinutrition early year horlick economic uncertainty market increase competitive pressure continue register strong growth main competitor increase india functional beverage register turnover boost spending marketing begin strong result emerge market discount aggressively effort gain strong key brand lead doubledigit growth lucozade market share ribena africa business performance growth investment brand include benefit enhance consumer emerge market consumerdriven scientific innovation availability innovative specific industryleade consumer packaging market market critical differentiate oral healthcare sale grow product maintain profitable strong performance brand like growth market sensodyne sensitivity acid erosion turnover emerge market continue register business grew drive strong economic consumer healthcare launch sensodyne repair protect category growth unprecedented brand ongoing rollout emerge number household enter consumer market denture care deliver high growth segment nearly world consumer singledigit growth doubledigit cer healthcare growth forecast come growth key emerge market bolster market year good growth japan usa performance build growth evaluate structure consumer consumer healthcare business business reshape enable operating profit base global approach create sustainable growth change main area lead market brand overthecounter otc medicine oral healthcare nutritional healthcare significantly refocus brand growth turnover growth year portfolio identify large high cer compare estimate market growth value category define business drive continue focus footprint wellness oral health nutrition innovation geographic expansion skin health aim operate profit year grow world successful fastmove consumer healthcare company drive breakdown turnover strong growth emerge science value market include africa middle east china initiative announce india position intention div noncore success emerge market product predominantly usa onethird global europe aggregate annual sale consumer healthcare sale approximately million aim leadership positions key category divestment realise value india china asian african shareholder simplify business middle eastern market allow focus priority brand growth market cer sale develop market flat overthecounter medicine strong performance japan january complete oral healthcare australia offset decline north divestment brands usa nutritional healthcare america europe post canada prestige brand holding fall million cash brand include goodys beano ecotrin fiberchoice otc sale year flat tagamet generate sale panadol franchise register growth approximately million gastrointestinal health core divestment impact report brand tum eno growth month respectively performance offset decline sale alli gsk annual report net cash proceed shift allow build strong addition brand car transaction return global brand enhance global driver overall lucozade supply shareholder supplemental dividend consumer insight design retail sport nutrition product play penny share pay marketing capability enable integral role driver preparation time fourth interim dividend development category strategy focus performance recovery process divestment emerge market work mclaren develop analytical remain noncore otc performance management tool build gsk partnership brand continue subject delivering improve ability fast mclaren september lucozade appropriate shareholder value decision longerterm investment announce fiveyear performance allocation new product development shift responsibility category partnership vodafone mclaren innovation brand strategy category team mercede formula motor race team share profit loss accountability geographic region sensodyne strength sensodyne repair protect strong contributor growth consumer healthcare business everyday fluoride toothpaste contain novamin technology prove repair sensitive tooth launch february sensodyne repair protect available market europe asia middle east additional launch plan sensodyne franchise register doubledigit growth consecutive quarter patent novamin technology help repair vulnerable area tooth hydroxyapatite natural building block tooth come contact saliva novamin release calcium phosphate form protective mineral layer vulnerable area enamel segami ytteg etybkcots mrafotohp nosnibor ydna gsk annual report strategic review grow diversified global business continue viiv healthcare viiv healthcare marketplace viiv healthcare operating profit decline reflect increase comprehensive recognition year ago hiv investment support major epidemic big portfolio pipeline ongoing phase iii trial public health challenge approximately integrase inhibitor dolutegravir medicine million people worldwide live hiv million die comprehensive approach improve distinctive operate aidsrelated illness access medicine country hard hit hiv remain critical model enable scientific progress improvement viiv healthcare multifacete global public health programme flexible responsive access medicine approach cover commitment universal access country include middleincome need hiv create improvement quality country lowincome country availability care community develop country subsaharan recent year multiple new market africa lowincome entrant increase number develop country subsaharan generic competitor usa africa people europe hiv treatment remain hiv currently live viiv healthcare competitive dynamic marketplace offer royaltyfree voluntary licence turnover notforprofit pricing middleincome performance country approach case viiv healthcare independent bycase basis take account company focus hiv found local need tieredprice policy growth gsk pfizer grew report turnover base gross domestic product cer billion burden epidemic improve performance drive primarily affordability growth brand epzicomkivexa viiv healthcare great progress selzentrycelsentri strong community partnership performance brand connection collaboration operating profit complement later broad hiv community positive anticipate entry generic form action vida digna programme central epivir usa soften america tackle stigma expect decline sale viiv discrimination community growth healthcare mature product portfolio vulnerable hiv continue grow cer sale epzicomkivexa grow cover additional country million sale selzentry usa positive action southern celsentri million growth initiative extend total drive state additionally support breakdown turnover increase earlyline use usa global effort reduce motherto broad uptake genotypic tropism child transmission hiv viiv test europe expansion selzentry healthcare broaden reach celsentri continue region scope donation positive action firstline usage launch japan children fund pacf responsible market authorisation russia business expansion reflect important strategic focus viiv healthcare international market country growth exclude europe north america cer growth continues build combivir epivir key focus region epzicomkivexa establish strengthen local lexiva partnership example selzentry partnership jsc binnopharm trizivir deliver local secondary manufacturing number viiv healthcare antiretroviral product russia gsk annual report grow diversified global business continue sale performance disclose reconciliation report turnover underlie turnover exclude pandemic product avandia valtrex set believe underlying measure report turnover assist shareholder gain clear understanding turnover performance growth underlie prospect size nature loss sale product growth show growth cer clearly group turnover pandemic product avandia valtrex operational performance underlie group turnover business growth cer pharmaceutical vaccine turnover pandemic product avandia valtrex underlie pharmaceutical vaccine turnover growth cer pharmaceutical turnover pandemic product avandia valtrex underlie pharmaceutical turnover growth cer vaccine turnover pandemic product underlie vaccine turnover sale product geographic region segment emerge trading usa europe markets asia pacific japan unallocate total pandemic product avandia valtrex emerge trading usa europe markets asia pacific japan unallocate total pandemic product avandia valtrex gsk annual report strategic review strategy growth deliver product value overview change organisation well able develop sustain industryleade pipeline product offer valuable improvement treatment patient healthcare provider increase level externalisation research allow access new area science share risk development partner decision early pipeline progression medicine believe significantly differentiate exist therapy progress ensure early stage research investment science suggest great opportunity create small agile group scientist accountable progressing project discovery development underpin focus improve rate return rigourous allocate investment pharmaceutical vaccine consumer healthcare progress confident right model improve productivity return past year new drug vaccine approve usa peer sustain significant latestage pipeline asset sign recent review discovery research give confidence replenish pipeline ongoing basis gsk annual report prioritie progress contribution sale new product perform total sale product launch past year exclude pandemic vaccine grow investment perform proportion investment latestage portfolio continues grow total expenditure remain relatively flat new product approval perform gain product approval usa benlysta potiga horizant improve return sale new pharmaceutical vaccine product growth cer pharmaceutical expenditure discovery development new product approval usa new drug vaccine approve usa year project rate return perform encouraged progress project rate return investment track reach longterm goal gsk annual report strategic review deliver product value continue investment research primary goal develop cost incur stage carefully innovative new medicine safely manage maximise likely future development critical efficiently concentrate return consistent overall ensure develop new medicine offer objective increase irr significant improvement exist activity current level sustainable business treatment option return generate primarily provide value patient determine eventual commercial continue pay medicine impact new product achieve offer new medicine regulatory approval launch people work vaccine consumer majority base large start mark beginning centre usa spain belgium critical twoyear period product help china pharmaceutical vaccine pipeline people live long end expect split budget report phase iii data latestage healthy life pharmaceutical vaccine consumer asset discuss progress healthcare aim allocate follow page detail expenditure consistently latestage development pipeline area level investment highlight base good pharmaceutical vaccine asset set page datum receive opportunity market pipeline chart page science fix phase iii asset website proportion sale total investment hold constant rate return rate return investment rise pharmaceutical vaccine discovery development process remain focused improve long expensive uncertain return investment possible predict project major pharmaceutical expenditure allocation succeed fail risk inherent company publish internal rate process describe fully return irr investment risk factor section risk indicate value realise deliver commercially investment choice successful product organisation expenditure early estimate rate major restructuring billion return investment monetary term recently launch latestage pipeline remain relatively flat past approximately year work update analysis calculate pharmaceutical reduce fix cost rationalisation rate return increase vaccine infrastructure reinvest equivalent basis track consumer healthcare surplus discovery deliver longterm goal improve major restructuring development research return shift balance spending project rate return include early stage project fund grow product launch january late stage pipeline expenditure compound phase iib iii discuss section follow development process calculation respect business base actual sale financial review forecast sale relevant product allocate investment adjust reflect expect reference potential return failure rate broadly line available target therapeutic standard industry failure rate market technical cost base calculation commercial risk associate product comprise estimate attributable pipeline factor review cost actual project milestone phase development process payment appropriate estimate central decision proceed profit margin capital investment stage work capital requirement factor calculation base historical performance gsk annual report deliver product value continue pharmaceutical successful pharmaceutical therapy area review expenditure billion identify scientifically promise longterm need major restructuring area drug discovery investment people work pharmaceutical organisation static culture business view research reinvestment exist area make pipeline project early stage discovery late result therapy area rebalancing stage development process change business model lead new medicine move away industrial launch new value sized therapy group small agile medicine benlysta treatment focus discovery performance unit patient systemic lupus erythematosus horizant dpus scientist dpu work treatment moderatetosevere pay treatment particular disease pathway restless leg syndrome trobaltpotiga responsible potential new medicine adjunctive treatment epilepsy early stage clinical trial new medicine completion phase lla highlight vaccine approve usa new model dpus newly approve medicine new molecular entity give budget threeyear benlysta horizant trobalt pharmaceutical window complete specific task company year active period early stage progress review business plan dpu identify latestate pipeline activity data seven new collaboration sign specific target investment latestage medicine announce multiple year plan include anticipate sufficient opportunity collaboration datum inhouse file promacta pharmaceutical investment external organisation large hepatitis relovair copd small company academia mek inhibitor new potential treatment internal expertise give strong melanoma basis identify form year see failure collaboration drug discovery termination otelixizumab type typically inlicense diabete overall balance acquire ownership asset progression versus failure positive development commercialisation expect complete optionbase development programme exclusive opportunity license asset latestage asset indication depend performance different development stage discovery pharmaceutical development spending remain relatively flat original business plan dpu acilitie central support shift investment initially review discovery discovery development reflect investment board dib panel create increase number latestage asset advise investment decision dib portfolio proportion total evaluate proposal identify area expenditure development improvement suggest agree latestage portfolio continue grow progress target investment level membership dib comprise senior management commercial discover new medicine external individual expertise early stage drug discovery area life science investment seeks identify biological target payer perspective chair svp involve development medicine discovery development disease create small threeyear mark dpus molecule biopharmaceutical reach progress interact disease target dpus review dib ultimately lead new medicine approach drive assessment wide range scientific discovery potential return investment make essential highly scientific quality opportunity selective inv drug discovery resource focus area consider likely lead significant medical advance gsk annual report strategic review deliver product value continue pharmaceutical continue early stage investment startup company pitch venture capitalist fund discovery performance unit dpus gsk demonstrate value business plan review discovery investment board dib budget dpus present remain relatively flat progress threeyear plan dib fund allocate shift base scientific quality spend discovery opportunity potential return investment result dpus development reflect grow shrink close increase number new dpus create latestage asset portfolio external discovery engine external discovery engine compare enhance discovery effort open new area science share risk partner hope reduce time breakthrough clinic uaennobrahc erreip gsk annual report overall review positive portfolio investment board pib scientific review board srb lead new investment allocation replace pipeline governance board govern body accountable discovery research result assess technical commercial scientific assessment portfolio new dpus create investment case project support investment decision closed remain dpus progress development pib pib srb establish view receive increase investment cochaire chairman overall scientific promise investment decrease president north america asset development plan deliver pharmaceutical include head asset cost effectiveness clinical form alliance pharmaceutical region plan opportunity risk likely external organisation accelerate head global manufacturing product profile gap evidence discovery new medicine miss remain uncertain share scientific understanding pib accountable investment ultimately improve patient care decision fund allocation important sign seven new collaboration latestage pharmaceutical governance board take alliance medicine discovery development technology investment board make external group complement biopharm oncology stiefel rare investment decision new platform internal discovery unit disease emerge market technology licencing option allow investment decision base collaboration point individual discovery project holistic way ensure entry clinical trial new product annual expenditure balance diversity asset differ supply board govern body total annual expenditure risk profile novelty opportunity accountable technical feasibility decision investment continue development cost potential infrastructure assessment cover science present reimburse payer aspect physical product compelling case remain supply chain need new treatment project review pib key decision point commit medicine gsk chief medical officer chair develop medicine patient development commit phase iii global safety board accountable compound advance latestage commit file launch funding oversee major decision development typically generally allocate patient safety global phase iia undergo large scale key decision point typically safety board responsible approve study human investigate year ahead pib pivotal study investigate efficacy safety time carry annual latestage funding issue relate patient safety arise work optimise compound review investment project development programme physical property formulation review adjust necessary postlaunch information gsk produce efficiently prioritise individual latestage clinical trial available clinical sufficient quantity project incur annual expenditure study register gsk website manufacturing process convert total annual wwwclinicaltrialsgov result activity file expenditure announce submission regulatory agency governance develop global regulatory board medicine development team enhance compliance company change small unit people wide standard regulatory service governance structure ensure clear responsibility compound efficient agile align accountability oversight strategic later stage development filing capability business need global issue overall budget management regulatory agency local level lead own asset latestage development new role chief regulatory officer executive team dib pib control comprise individual investment decision early late project stage describe previously actively seek opportunity add product latestage portfolio alliance company latestage asset typically form inlicense deal copromotion arrangement company likely align exist area therapy expertise investment gsk annual report strategic review deliver product value continue vaccine consumer vaccine invest nearly million vaccine investment vaccine increase line centre discover scientist work investment high growth area develop development new vaccine discovery research prophylactic currently vaccine discovery development new development range disease vaccine complex process require therapeutic vaccine malaria tuberculosis longterm investment typically take cancer currently vaccine protect people year develop new vaccine candidate late stage development infectious disease trial zoster malaria quadrivalent vaccine discovery begin identify influenza vaccine therapeutic new antigen specific cancer chronic vaccine magea structure pathogen viruse bacteria disorder vaccine candidate regulatory filing parasite cancer cell meningitis menhibrix recognise immune system nimenrix usa europe produce pathogen yeast bacteria mammalian cell highlight vaccine genetically manipulate result adjuvante key highlight malaria vaccine candidate rtss purify formulate vaccine antigen create phase iii study conduct seven filing usa europe bodys immune response country africa year work menhibrix nimenrix present promise result work academia phase iii datum announce initial phase iii data candidate biotech industry identify malaria vaccine milestone malaria new vaccine antigen case formulation vaccine clinical effort focus lot involve mix antigen gsk development new prophylactic proprietary adjuvant system therapeutic vaccine alongside lifecycle management vaccine market consumer healthcare people usa examples innovation include develop drive differentiate india china dedicate oral healthcare business speedofaction claim aim effort consumer healthcare launch new breakthrough alleviate strong pain invest million dental care sensodyne implement new million repair protect repair protect programme increase flow pace develop sustainable flow new formulation everyday value innovation portfolio scientificallydifferentiate product fluoride toothpaste contain align new fastmoving innovation portfolio critical patent novamin technology consumer healthcare model element consumer healthcare nutrition category develop strategy include new expand product offer model aim combine industry technology formulation maxinutrition range include lead scientific capability product line extension maximilk chocolate strawberry superior consumer insight develop carry ongoing research assess new flavour cyclone valuedrive global pipeline efficacy value product muscle growth shake gsk newly form global validate claim acquire maxinutrition make category oral health wellness consumer product base protein nutrition skin health enhance functional nutritional innovation product launch beginning year establish new past year contribute sale million otc continue roll global regulatory structure consumer healthcare sale key panadol advance market local regulatory staff report centrally contribute product include launch panadol extra advance enable drive rapid sensodyne repair protect brand contain efficient rollout innovation sensodyne rapid relief horlick optizorb superior patent biscuit panadol extra advance dissolution technology gsk annual report vaccine manufacturer use adjuvant milestone malaria improve specific immune system response antigen contain vaccine innovate area year work adjuvant system year milestone development malaria vaccine candidate proprietary adjuvant system rtss reach combine adjuvant publication phase iii datum appropriate immune response show vaccine provide young specific antigen expertise allow african child significant understand combination protection clinical severe antigen adjuvant system help malaria acceptable safety body mobilise effective tolerability profile trial immunological pathway provide continue datum infant age maximum protection specific week expect end disease target population read corporate candidate vaccine usually responsibility report combination antigen final composition vaccine antigen adjuvant change time preclinical research usually take year failure discovery process relatively low failure likely later stage clinical trial candidate expect fail discovery new vaccine early development project support latestage project inclusion new antigen exist vaccine create new generation vaccine traditionally vaccine prevent illness pioneer different approach antigen specific cancer immunotherapy ascis approach design programme bodys immune system fight exist disease represent new treatment model therapeutic vaccine key decision point board overall view evaluate asci concept vaccine development process commit project early advanced project variety tumour type research decide invest resource vdcb core member come early clinical development commit organisation vdcb governance phase iii registration launch recommendation progress project revise organisation commit lifecycle management submit vib vaccine discovery development consider pursue vib final decision team simplify infrastructure generation product extend invest project take account focus timely decisionmake viability product scientific commercial perspective enhance clarity accountability oversight key decision rest review vdcb vib evaluate vaccine research development lead body vaccine development public health benefit business project team vaccine leadership commercial board vdcb opportunity development cost team responsible day vaccine investment board vib risk project time overall today progress include identify vdcb review research project evolution portfolio vaccine develop new product strategy advise scientific vib responsible assess technical commercial feasibility overall fit project vaccine portfolio sppihw mot gsk annual report strategic review deliver product value continue late stage pipeline summary diverse product development pipeline highlight project comprise new chemical entity biological entity vaccine new combination new indication exist compound phase iii file approval recently approve advanced status show include approval asset move phase iii approvals usa development registration january terminate crohns disease enlysta belimumab systemic lmorexant primary insomnia lupus erythematosus usa olutegravir sgsk telixizumab type diabetes abacavir sulphate lamivudine robaltpotiga retigabineezogabine evoladepromacta eltrombopag hiv infection epilepsy partial seizures usa chronic liver disease induce dabrafenib metastatic thrombocytopaenia melanoma orizant gabapentin enacarbil otrient pazopanib tykerbtyverb restless leg syndrome usa trametinib metastatic lapatinib inflammatory breast melanoma cancer vilanterol copd vodart dutasteride reduction risk prostate cancer duchenne muscular dystrophy asthma key phase iii large comparative study compound versus placebo andor establish treatment patient establish clinical benefit safety file follow successful phase iii trial file product approval regulatory authority approval approval grant begin market medicine vaccine pipeline page website inlicence alliance relationship party gsk annual report phase iiiregistration pharmaceutical vaccine pipeline summary therapeutic area compound indication phase iii file approve biopharmaceutical albiglutide type diabetes arzerra ofatumumab chronic lymphocytic leukaemia line therapy arzerra ofatumumab diffuse large cell lymphoma relapse patient arzerra ofatumumab follicular lymphoma refractory relapse patient benlysta belimumab systemic lupus erythematosus benlysta belimumab systemic lupus erythematosus xgeva denosumab bone metastatic disease cardiovascular metabolic darapladib atherosclerosis immunoinflammation crohns disease infectious disease relenza zanamivir influenza neuroscience ipx parkinson disease horizant gabapentin enacarbil postherpetic neuralgia horizant gabapentin enacarbil restless leg syndrome trobaltpotiga retigabine ezogabine epilepsy partial seizure oncology dabrafenib metastatic melanoma trametinib metastatic melanoma revoladepromacta eltrombopag hepatitis induce thrombocytopaenia tyverbtykerb lapatinib breast cancer adjuvant therapy tyverbtykerb lapatinib gastric cancer tyverbtykerb lapatinib head neck squamous cell carcinoma resectable disease votrient pazopanib ovarian cancer maintenance therapy votrient pazopanib renal cell cancer adjuvant therapy tyverbtykerb lapatinib metastatic breast cancer combination trastuzumab votrient pazopanib sarcoma respiratory copd immunoinflammation vilanterol copd asthma vilanterol copd relovair vilanterol asthma relovair vilanterol copd paediatric vaccine mosquirix malaria rtss malaria prophylaxis plasmodium falciparum menhibrix hibmencytt neisseria meningitis group haemophilus influenzae type disease prophylaxis nimenrix menacwytt neisseria meningitis groups disease prophylaxis vaccine zoster herpe zoster prevention flu pre pandemic prepandemic pandemic influenza prophylaxis flu vaccine seasonal influenza prophylaxis pumarix pandemic influenza prophylaxis antigen specific cancer magea treatment melanoma immunotherapeutic asci magea treatment nonsmall cell lung cancer rare disease duchenne muscular dystrophy adenosine deaminase severe combine immune deficiency migalastat hcl fabry disease dermatology duac low dose acne vulgaris sorilux mild moderate scalp psoriasis tazarotene foam acne vulgaris hiv dolutegravir sgsk hiv infection dolutegravir sgsk abacavir sulphate lamivudine hiv infection inlicence alliance relationship party gsk annual report strategic review strategy growth simplify operating model overview business continue change shape transform operating model reduce complexity improve efficiency past year implement global restructuring programme design deliver significant saving support investment high growth market offset significant pressure saving derive improvement manufacturing operation consolidation streamline support function increase efficiency progress date restructuring programme take billion annual cost business identify annual saving approximately million bring total annual saving expect programme billion restructuring programme allow reduce spend global function aim streamline organisation significantly reduce footprint manufacturing pharmaceutical gsk annual report prioritie progress restructure saving perform restructure programme introduce continue deliver saving expect annual saving cost billion realise annual saving billion time complete footprint perform making pharmaceutical operation efficient centralise activity reduce fix cost possible manufacturing footprint perform seek create streamlined global manufacturing function exit site year add business acquisition support function cost perform reduced support function cost annual saving pharmaceutical footprint footprint support function cost pharmaceutical consumer healthcare manufacturing site site gsk annual report strategic review simplify operating model continue reduce cost increase efficiency substantial transformation operate big cost saving model reduce cost complexity programme generate progress objective improve efficiency continue manufacture support simplify operation significant saving generate function organisation restructure programme reduce inefficiency reinveste focus reduce fix cost rationalisation business offset pressure infrastructure footprint result loss sale generic pharmaceutical footprint usa europe cut past restructure business year key element reshape period manufacturing business implement organisation achieve annual highlight global operational excellence saving approximately annual restructure saving restructure programme million restructuring initiate end rationalise network streamline billion achieve operating model improve global support function spending meet original target site performance compare billion annual cost saving exit manufacturing site include identify additional selling close factory annual saving approximately reduce total number million bring total annual manufacturing site saving expect programme billion programme expect cost billion reduce cost recycle pilot project recycle waste plastic track provide million carbon rebate reduce shipping cost year time cut carbon footprint project kick ribena bottle plant convert postindustrial plastic waste site material new bottle coleford site tonne rpet recycle polyethylene terephthalate year bottle ribena time manufacturing site france produce tonne waste material suitable recycling disposal pet tray delivery material initial result suggest reduce raw material ribena bottle annually addition anticipate cut tonne annual carbon dioxide emission reduction shipping cost material use skoorb egroeg gsk annual report key source saving global manufacturing supply programme global support function finance facility report network site announce intention function centralise country global manufacturing build new manufacturing allow well budgetary oversight supply gm responsible facility supply control significant saving produce deliver medicine biopharmaceutical product subject generate include great consumer product world introduction patent box use share service outsourcing legislation government people work facility example facility build gms network internal outsource technical workplace exist gsk site barnard external manufacturing site help security global vendor castle ulverston north compete large range market reduce cost england irvine montrose ensure patient customer scotland represent overall support function cost receive quality product fair price investment reduce compare supply chain model design million pound key objective programme ensure supply quality security gms comprehensive global release resource invest product region anticounterfeite strategy growth strategy significant portion world closely monitor industry leader anticounterfeite saving generate delivery product ensure packaging feature hologram reinveste business area offer customer security seal complex background potential future profitable growth stock medicine product pattern difficult emerge market vaccine need photocopy scan consumer healthcare similarly saving fix cost reinveste discovery achieve reduce number pack skus development research implementation service delivery europe japan model focus partner emerge market balance saving gsk business unit standardisation focus standardise remain offset pressure increase productivity pack format improve packaging group margin result loss business time focus efficiency cost significant sale usa europe operation performance generic period addition manufacturing coordinate internal process organisation actively seek improve conscious impact standardisation datum system procurement process particular employee change outline provide well decisionmake purchase active ingredient remain committed information chemical intermediate package consultation internal forum key enabler delivery benefit component partfinishe external group appropriate cbs enterprisewide finish product release possible attempt enterprise resource planning erp cost efficiency allow reduce redeploy affect employee system significant investment work capital part business make global erp programme consumer healthcare business focus simplification year enable cbs redesign supply chain create standard business process system year plan form integrate endtoend process datum support growth build infrastructure footprint align customer change agenda multiple business rationalisation achieve commercial operation erp programme simplify business business process convert countrybase commercial configure support highgrowth follow support function centralisation system single sap system region emerge market early create core business replace numerous fragmented non change expect reduce cost service cbs group direct standardise application freeup work capital streamline economy scale system go live germany element global support european pharmaceutical mark start erp deployment function service provide vaccine supply chain gsk business standardise redesigned simplify operation implement change consolidate distribution location year cbs deliver supply chain process help supply reduce inventory increase service level promise early result expect chain efficiency significantly cut operating cost saving simplify product portfolio year gsk annual report strategic review financial architecture key objective establish new financial expect group core operate architecture align planning margin begin improve gradually deliver execution performance measurement improvement sustainable sale growth order maximise financial return year rate strategy design drive extent depend new financial improvement operate margin precise mix business great financial efficiency enhance delivery rate pipeline architecture design cash conversion sale growth drive sale growth high margin enhance return focus deliver innovationle market shareholder drive strong growth addition improve core earning share well free cash operate margin enhance strategy generation expect cash flow financial efficiency key driver enhance cash conversion earning cash flow growth available dividend share buyback review manage reinvestment business cash balance relative debt depend return portfolio source debt attractive access intend number sale growth change believe take advantage current interest rate key objective strategy reduce cash balance delivery sustainable broadly reduce effective net interest cost source sale growth report sale result overall effective financing fall year rate expect reduce year deliver average annual underlie sale growth expect underlie tax second area sale growth translate report opportunity improve efficiency sale growth sale headwind shape group change loss sale avandia valtrex materially recent year pandemic product diminish align tax strategy tightly change shape operating leverage financial identify opportunity allow efficiency reduce tax rate want drive operating leverage approximately begin financial efficiency business approximately order maximise operate good progress profit earning cash generate reduce tax rate sale growth remain exclude disposal quest focus manage cost base effectively improve financial efficiency organisation gsk annual report financial architecture drive return sale growth ep operate leverage focus focus return return return shareholder financial efficiency free cash flow cash flow growth cash conversion earning cash flow generation return free cash flow shareholder pay billion significant opportunity sale growth operational leverage great dividend ordinary dividend enhance cash conversion great financial efficiency cash conversion grow addition buy focus cash generation capital drive enhance earning billion share allocation share free cash flow long term programme start year support objective enhance particular focus work return proceed return shareholder strategy capital programme sale noncore north american otc reduce cash conversion cycle free cash flow expect brand shareholder supplemental day work capital enhance cash charge dividend payable fourth percentage turnover associate longstanding quarter ordinary dividend focus deliver restructure programme continue expect deliver continue improvement cycle decline free cash flow dividend growth addition give medium term expect benefit demand current market condition intend cash fund previously announce legal repurchase billion share settlement diminish reduction work capital measurement report cash conversion cycle focus return investment return shareholder improve financial reporting day align closely financial cash generate deploy invest architecture provide business deliver return data insight progress shareholder make business improve capital allocation region progress process consistently key driver operational rigorously base return investment financial efficiency start metric particularly cash flow return transition report core investment cfroi basis enable great visibility able benchmark opportunity underlie performance business internal external investment detail transition core business consistently report provide return available share buyback return shareholder gsk annual report strategic review responsible business believe recognise research recognise barrier development manufacture sale obstacle path well health responsible business product raise ethical issue commit find new good gsk aim open innovative way tackle address understand work partnership society help important communicate challenging way thing group individual business prepare change way create product affect seek understand view business aim find innovative patient healthcare transparent setback solution create value society experience progress shareholder allow payer need value successful sustainable business help operate grow business access healthcare develop world efficiently gain culture ensure decision easy solution guide value commit challenge provide sustainable access trust stakeholder transparency respect people healthcare develop country demonstrate high integrity foster right poverty single big barrier conduct patientfocuse country people condition growth grow business sustainable food access supply clean business responsible way focus area water access hospital clinic provide professional help health help improve treatment challenge people health wellbee important contribute regardless live ability pay committed play people community work address healthcare challenge support development people develop world take community world innovative responsible sustainable behaviour behave open approach gsk make contribution honest manner develop country healthcare guide value number area include planet grow business tiere pricing vaccine protect natural resource medicine cap price need future develop country ldc board committee chair invest target disease chairman regularly particularly affect develop review company policy world performance detail give flexible intellectual corporate responsibility committee property pursue open report innovation strategy approach key area community investment activity follows publish information approach performance partnership foster effective healthcare capacity build corporate responsibility report find website seek innovative partnership report publish march solution include reinvestment profit healthcare infrastructure health ldc work medicine preferential pricing viiv healthcare vaccine consumer healthcare access medicine index antiretroviral hivaid product available affordable comprehensive approach people need help rate leader possible irrespective live biannual access medicine ability pay aim generate return need atm index publish atm able sustain business invest foundation research new product gsk annual report vaccine develop world organisation unicef pan american health organization paho gavi alliance help save children life protect people health increase access immunisation poor country lead vaccine supplier organisation billion vaccine dose business ship go develop country include develop low middle income country june offer supply million dose rotavirus vaccine rotarix gavi dose small fraction develop world price supply million dose pneumococcal vaccine synflorix gavi heavily discount price help expand immunisation programme develop country sign agreement supply synflorix cervarix rotarix paho expand protection woman virus lead cervical cancer protect child pneumonia gastrointestinal diarrhoeas cause rotavirus continue build october founder product pricing partnership member wipo research commitment help improve healthcare consortium group develop world report company academic institution fully progress corporate government research body establish responsibility report provide access intellectual property highlight follow pharmaceutical compound technology importantly october publish encourage knowhow datum available research initial phase iii result malaria development neglect tropical vaccine candidate show disease tuberculosis malaria reduce malaria half young african child aged month sppihw mot gsk annual report strategic review responsible business continue tre canto open lab open people community employee region spanish medicine invest people community development campus dedicated research disease develop help ensure longterm sustainability business world end year employment practice design seven project visit scientist help create right workplace culture develop employee feel value develop world respect empower inspire significant increase resource want community global community need work prosper business support provide access usa grow community investment resultant medicine vaccine europe sustainable progress strengthen business support emerge market local economy operate asia pacific significant barrier stand help build relationship base japan way well access healthcare mutual understanding boost tackle share responsibility employee morale sector global society government international agency charity academic recruit develop institution pharmaceutical industry engage employee business evolve change affect employee want gsk employer choice remain committed consulting invest significantly change number talent development level internal consultation forum recruit develop engage discussion european work employee critical meeting council similar body country sustain business objective national practice overall performance assessment process align core set diversity gsk competency ethic focus create inclusive integrity central engage environment empower global view talent employee continually contribute strategic capability look organisation enable quality depth breadth talent achieve strategic business objective world strive good inclusive environment good succession plan place critical business bring different position organisation knowledge perspective experience proactive initiative place recruit working style enhance creativity specialist leadership talent innovation aim attract maintain robust leadership strategy diverse workforce reflects identify develop highly skilled community operate leadership group offer employee proportion people employ range learn opportunity emerge market asia pacific japan tailor development programme grow increase performance development total employee planning process mean employee senior manager businessaligne objective report executive team come behavioural goal reward system region focus promote high performance help attract retain good people performancebase pay bonus visit scientist work sharebased equity plan align employee interest business target project tre canto open lab gsk annual report commit employment policy free discrimination environment tolerate harassment discrimination actual perceive race colour ethnic national origin age gender sexual orientation gender identity andor expression religion belief physical abilitydisability andor chronic health condition genetic makeup protect characteristic relevant country healthy highperforming workforce zero harm meet mission strategy employee health safety initiative focus factor enable employee perform high level sustain energy engagement drive zero harm workplace provide resource tool programme employee support adopt healthy lifestyle manage pressure work life available language range option immunisation smoke control weight management process safety cuttingedge programme team personal resilience ergonomics driver safety energy performance companywide programme living safety design build culture zero harm goal environment health safety incident positive action child fund support global effort eliminate mothertochild transmission hiv viiv healthcare broaden reach scope donation positive action child fund pacf highlight programme grant care international future project seek empower community address effect sexual violence reduce stigma north kivu democratic republic congo promotion service empowerment communitybased campaign ground highlight new million small grant scheme support community base project country globe project select receive funding effort specifically aim improve health welfare woman child family affect hiv viiv healthcare dnuf noitacude utnubu gsk annual report strategic review responsible business continue work community programme support design behaviour longterm sustainable impact investment community commitment responsible value set ambitious commitment aim improve health education base business underlie work experience partner increase access medicine strong policy encourage employee involve healthcare service target support compliance programme expect volunteering initiative need standard supplier orange day programme contractor business partner approach include fund longerterm pulse scheme importantly build innovative programme improve global community investment strong culture base value health community engagement million overall give transparency respect people behavioural change donating remain constant exclude integrity patient focus medicine expertise reinveste donation million dose profit improve healthcare recognise need open vaccination total infrastructure invest science include donation product worth education support relief effort challenge face million value follow natural disaster average cost good know research maximise benefit high wholesale acquisition price development manufacture sale community investment working believe accurate reflection product raise ethical issue partnership nongovernmental true cost gsk meet consistently high quality organisation select project ethical standard research product donation primarily enable apply expertise development part business programme patient resource country operate assistance program million recognise aspect benefit community humanitarian product donation research raise ethical concern investment strengthen business million donation albendazole include relate animal improve reputation boost tablet lymphatic filariasis research study experimental employee morale help elimination programme million medicine people build trust build relationship base mutual cash give million stakeholder meet understanding range group include total target expectation behaviour primarily health education transparent open challenge initiative include reinvestment discussion profit develop country healthcare ethical conduct infrastructure million ethical conduct priority gsk failure uphold high ethical standard community investment cash donation erode trust company type allocate product damage reputation result financial legal consequence code conduct set fundamental standard employee support employee guide business conduct available language help employee ethical decision emphasis value internal compliance system cash health design identify address breach product education code reinforce gsk value kind art culture continual external pressure management environment enhance system compliance oversight internal audits help drive change compliance programme design embed valuesbase culture gsk gsk annual report launch compliance reflect commitment consistently carbon initiative improve consistency high standard sale marketing longterm vision entire policy implementation monitoring review expand global value chain carbon neutral business unit code practice promotion carbon footprint different country operate customer interaction code result supply chain fully investigate suspect breach cover area provide propellant release appropriate disciplinary action information healthcare professional inhaler include dismissal appropriate sample payment healthcare professional gift hospitality grant fifth total impact zerotolerance approach donation deploy come directly operation bribery corruption set sale marketing employee continue increase energy prevent corrupt practice policy train revise code efficiency use renewable establish antibribery energy site focus corruption expert forum meet planet supply chain use weekly answer employee question revise environmental product especially inhaler advise antibribery corruption sustainability strategy focus issue member forum include begin footprinte key carbon water waste environmental representative legal product identify priority stewardship compliance function external develop sitebase event operation value consultant answer post analyse local carbon reduction potential chain raw material product intranet employee visit act opportunity disposal strategy set reduce energy consumption ambitious goal key impact operation greenhouse include reduction carbon gas emission use inhaler footprint reduction water use rise value chain zero waste landfill double mass efficiency efficiency use material new pharmaceutical product aim carbon neutral entire supply chain gsk annual report strategic review responsible business continue water aim reduce volume continue improve packaging use recycle material understand environmental water particularly important natural possible encourage impact purchase resource recognise gsk consumer recycle use material begin work play positive role manage revise green packaging guide key supplier hold detailed sustainably endorse united help designer choose discussion lead supplier nation ceo water mandate sustainable option begin develop carbon footprint material working signatory waste plastic ribena bottle datum improve develop disclosure methodology provide quarter environmental performance aim agree measure annual bottle requirement saving company water impact environmental management approximately value chain essential step manage gsk total water impact tonne emission year new environmental sustainability steering team responsible shaping reduce water consumption environmental stewardship environmental sustainability operation increase efficiency strategy integrate waste use material priority target business strategy realistic achieve mass efficiency new stretching manage environmental goal zero waste go landfill pharmaceutical product transfer issue occupational health reduce waste manufacturing safety management system generation operation longterm aspiration achieve align recognise international reduce waste send landfill mass efficiency time standard environmental health year continue trial typical level pharmaceutical safety datum subject external takeback scheme recycle industry reduce input material assurance read inhaler follow success usa waste average mass environmental strategy performance extend initial trial efficiency new product transfer corporate responsibility report operative supermarket chain manufacturing reach cut carbon carbon footprint come propellant release inhaler year extend takeback scheme inhaler usa working pharmacist seek encourage patient return inhaler collect new inhaler recycle plastic send remanufacture remain aerosol propellant reuse nonmedical application save propellant avoid equivalent tonne emission ssenne nai gsk annual report financial review use number adjust measure report performance transition core measure report business measure management planning reporting purpose discussion announce intention introduce core measure presentation investment analyst rate agency operate profit earning share report define measure define ifrs performance group onwards primary comparable similarly describe measure purpose approach remove volatility create company item impairment intangible asset legal charge asset disposal gain loss believe underlie turnover provide clear view underlie performance core underlie turnover exclude sale pandemic product avandia business expect comparable valtrex believe underlying measure assist shareholder majority peer gain clear understanding turnover performance addition emerge market asia pacific prospect size nature loss sale pharmaceutical vaccine region amalgamate product reconciliation present region segmental reporting purpose free cash flow nonprescription stiefel brand transfer pharmaceutical business consumer healthcare free cash flow net cash inflow operating activity capital expenditure interest dividend pay noncontrolle brand name interest plus proceed sale property plant equipment dividend receive joint venture brand name appear italic report associate undertaking free cash flow growth calculate trademark own andor license glaxosmithkline sterling basis reconciliation present associate company exception benlysta trademark human genome sciences bonivabonviva working capital conversion cycle trademark roche levitra trademark bayer nicoderm working capital conversion cycle calculate number trademark elan johnson johnson merrell novartis sanofi day sale outstanding plus day inventory outstanding glaxosmithkline potiga trademark valeant prolia day purchase outstanding xgeva trademarks amgen vesicare trademark astella pharmaceutical country yamanouchi white pill western market pharmaceutical certain country volibris trademark gilead white pill western market refer sale tablet simple xyzal trade mark ucb glaxosmithkline injectable exclude biopharmaceutical vaccine north certain country licence group america europe revolaire trade mark glaxosmithkline group cer growth company use brand revolaire ffvi approve regulatory authority world order illustrate underlying performance practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate commentary report present term cer state gsk annual report financial review financial review continue risk financial review discuss operate financial group turnover geographic region performance group financial outlook financial resource compare result year primarily report turnover underlie turnover result precede year performance explain growth growth growth growth cer cer variety measure review discuss result usa major restructuring basis total basis europe growth rate include financial review constant emerge market exchange rate cer state calculation asia pacific underlie turnover describe japan group turnover division report turnover underlie turnover cer represent growth constant exchange rate represent growth growth growth growth growth actual exchange rate turnover quarter give page cer cer group sales outside usa europe account pharmaceutical turnover report sale growth underlie growth vaccine reflect strong growth business pharmaceutical geographic region vaccine consumer healthcare group turnover segment report turnover underlie turnover report turnover decline underlie turnover increase reflect underlying growth area growth growth growth growth cer cer business pharmaceutical vaccine consumer pharmaceutical healthcare breadth mix product geographic vaccine portfolio help mitigate economic volatility year usa report group turnover fall billion europe pharmaceutical vaccine pharmaceutical emerge market vaccine billion consumer asia pacific healthcare sale billion sale pandemic relate japan product avandia valtrex decline billion viiv healthcare million significant adverse impact trading report pharmaceutical vaccine sale growth region unallocate pharmaceutical underlie turnover growth pharmaceutical vaccine vaccine consumer healthcare consumer healthcare underlie pharmaceutical growth reflect contribution new product partly offset generic competition old usa pharmaceutical vaccine report turnover product usa europe increase impact decline underlie turnover flat contribution european austerity measure year incremental impact new product offset competition older establish sale european austerity price cut healthcare reform products europe pharmaceutical vaccine report approximately million growth underlie vaccine turnover fall underlie turnover decline sale primarily reflect strong performance cervarix result austerity price cut mild flu season emerge synflorix rotarix consumer healthcare strong growth market report turnover grow underlying growth oral healthcare nutritional healthcare partly offset flat drive relatively consistent pharmaceutical growth overthecounter sale year reflect dermatology acquisition strong vaccine growth underlie quarterly volatility tender phasing report vaccine sale emerge market decline political economic uncertainty impact performance number territory emerge market gsk annual report japan report turnover flat large driver antiviral underlie growth cervarix asia pacific antiviral decrease billion sale growth report turnover increase underlying growth impact low sale relenza million principally come respiratory product vaccine viiv compare significant sale relate pandemic flu healthcare sale grow consumer healthcare sale grow addition valtrex sale continue decline result decline usa europe reflect generic competition usa europe difficult economic condition offset consistent strong million sale zeffix grow million growth rest world market strong growth emerge market offset small pharmaceutical turnover decline market growth growth central nervous system cns cer cns sales decrease billion performance respiratory primarily impact decline seroxatpaxil sale antiviral million partially offset lamictal sale growth central nervous system million benefit growth japan product cardiovascular urogenital sale double million continue strong metabolic performance lamictal usa antibacterial oncology emesis cardiovascular urogenital dermatology cardiovascular urogenital sale increase billion viiv healthcare hiv primarily drive avodart franchise million launch new combination product duodartjalyn usa europe avodart japan pharmaceuticals turnover therapeutic area lovaza million volibris sale double million arixtra decline turnover decline billion growth million result start generic competition cardiovascular urogenital respiratory dermatology anti usa quarter bacterial hiv oncology emesis offset decline metabolic antiviral central nervous system metabolic respiratory metabolic sale decrease billion primarily reflect loss sale avandia addition sale boniva respiratory sale increase billion reflect strong negatively impact termination copromotion performance japan emerge market asia pacific agreement certain european country seretideadvair sale flat growth japan asia pacific offset small decline usa europe addition ventolin antibacterial grow million avamysveramyst sale antibacterial sale grow billion growth million category lead sale augmentin emerge market usa sale advair billion million category hold austerity price line estimate underlying growth year cut mild flu season northern hemisphere volume decline partly offset positive impact price oncology emesis mix flovent grow million ventolin grow million oncology emesis sale increase billion reflect strong growth new product votrient promactarevolade europe respiratory sale seretide sale arzerra double million billion impact price reduction partly offset generic competition old product european government offset volume increase votrient achieve total prescription share emerge market respiratory sale grow growth advanced renal cell carcinoma market headtohead datum product portfolio seretide sale flat eventdriven study compare votrient million volume growth offset continue current market leader sutent market share impact price cut particularly russia turkey approximately expect votrient regulatory review usa europe new indication softtissue sarcoma ongoing launch promactarevolade continue sale outside usa grow million million sale usa grow million strong performance new oncology product partly offset impact generic competition usa hycamtin continue decline zofran fall million gsk annual report financial review financial review continue risk dermatology strong report growth rotarix million primarily reflect impact product market dermatology sale grow billion report growth benefit addition sale business acquire late early offset effect sale fluarixflulaval million strong disposal zovirax north america exclude growth usa million offset low factor growth category growth emerge sale europe primarily price cut china market benefit ongoing launch stiefel sale product include infanrix franchise decline product new market offset impact price cut million sale usa grow million europe generic competition evoclin usa help cdc stockpile order pediarix kinrix sale viiv healthcare hiv europe decline million primarily price cut sale emerge market decline million primarily viiv healthcare sale grow billion usa result low sale china europe emerge market rest world growth primarily drive epzicomkivexa hepatitis franchise decline million largely million selzentry million partly offset result austerity price cut europe reduce cdc funding decline mature portfolio million adult hepatitis immunisation return market competitor vaccine quarter epzicomkivexa sale growth drive strong performance usa europe usa sales epzicom sale new pharmaceutical vaccine launch million reflect relatively equal mix volume price growth volume growth europe growth growth cer benefit improve position regional local avamysveramyst guideline kivexa continue grow japan mexico lamictal number develop market asia pacific requip selzentry sale growth primarily drive increase treximet market share usa sale million coreg europe sale million duodartjalyn volibris decline mature portfolio include combivir promacta decline million primarily drive decline arzerra western market result new treatment option tyverbtykerb vaccine sale votrient cervarix growth growth rotarix cer synflorix total vaccine sale vaccine sale exclude pandemic relate product total sale new product launch begin exclude pandemic vaccine billion grow vaccine loss flu pandemic vaccine sale year result launch new product underway decline report vaccine sale billion exclude benlysta lupus launch usa effect flu pandemic vaccine sale underlie sale grow global partnership human genome sciences inc reflect growth cervarix synflorix rotarix product recently introduce germany partly offset low sale hepatitis franchise infanrix turnover million year reflect share gross profit impact change pharmacopeia china usa total sale market underlie vaccine sale grow strongly region trobalt adjunctive addon treatment partial onset europe sale decline reflect austerity price cut seizure form epilepsy seizure begin specific few tender order cervarix area brain launch europe cervarix sale double million primarily additionally product approve fda reflect national hpv vaccination programme japan brand potiga follow review drug start end catchup vaccination cohort enforcement administration launch product expect japan include age group majority vaccine half support programme ship horizant treatment moderatetosevere primary remainder ship early restless leg syndrome adult receive fda approval year launch product underway synflorix grow million reflect continued growth additionally august supplemental new drug arise tender emerge market application snda submit fda request approval horizant management postherpetic neuralgia adult accept october gsk annual report consumer healthcare turnover result major restructure total result october board approve implementation growth growth cer detailed formal plan announce significant new overthecounter medicine operational excellence restructure programme second formal oral healthcare plan represent significant expansion operational excellence nutritional healthcare programme approve board announce february expansion approve board announce february cer represent growth constant exchange rate represent growth actual exchange rate turnover quarter give restructure programme comprise detailed formal plan cover area business include manufacturing sell growth growth cer infrastructure saving identify usa year estimate total cost increase approximately europe billion expand programme expect deliver row annual pretax saving approximately billion time substantially complete approximately expand programme cost incur december consumer healthcare sale grow billion compare approximately expect incur estimate market growth market majority balance incur total approximately compete net impact acquisition disposal cost expect cash expenditure significant expect asset writedown exclude otc brand target divestment consumer give extent cost operational excellence restructure healthcare sale grow approximately likeforlike basis programme believe material impact operating disposal north american otc brand complete result manner business conduct january sale brand million present restructuring cost incur solely direct result result impact report growth month operational excellence restructure programme process divest remain noncore otc brand amount million million separate continue subject deliver appropriate shareholder value column income statement title major restructure otc medicine addition restructuring cost operational excellence programme major restructuring column income statement otc sale flat billion strong growth include restructure cost incur solely direct result subcategorie offset decline alli panadol franchise restructuring programme follow relate material register growth gastrointestinal care core acquisition operation acquire business overlap brand tum eno respectively extensively exist operation oral healthcare restructuring activity follow relate acquisition oral healthcare sale increase billion lead nature undertake operational sensodyne continue benefit successful launch excellence programme carry follow detailed repair protect ongoing geographic expansion formal plan consider appropriate present pronamel acid erosion business cost restructuring activity manner nutritional healthcare restructuring cost incur direct result acquisition stiefel laboratories inc july million nutritional healthcare grow billion lead strong growth million restructuring cost incur direct horlick combine inclusion maxinutrition february result acquisition reliant pharmaceuticals inc nutritional healthcare growth exclude maxinutrition acquisition october meet criterion set regional performance charge pay strong growth rest world partly offset small result cost operational excellence programme decline usa europe rest world market continue acquisitionrelate restructuring programme meet criterion lead growth increase sale growth particularly describe present separate column income strong emerge market africa middle east statement describe result major restructuring china india latin america presentation adopt clearly result cost restructure programme europe record decline sale largely result low believe presentation assist shareholder gain clear sale alli respiratory health product partly offset understand financial performance make projection inclusion maxinutrition range february future financial performance result include cost environment europe continue challenge result virtue size nature limited comparative value economic pressure competitive market dynamic presentation consistent way assess sale decrease result temporary interruption financial performance nicorette gum supply decline sale alli combine difficult economic condition outweigh strong growth sensodyne gsk annual report financial review financial review continue risk restructuring cost incur solely direct result profit tax total result operational excellence programme restructure total result include restructure cost relate operational programme follow reliant stiefel acquisition excellence programme acquisition reliant stiefel report major restructuring column income statement growth restructuring cost principally arise impairment cer property plant equipment termination turnover employment contract staff redundant cost sale restructuring activity set note financial sell general statement major restructure programme asset impairment administration staff redundancie account million research million restructuring cost incur report development major restructuring column operate income remain cost million arise operating profit miscellaneous expenditure incur solely direct result restructure programme include termination cost sale lease accelerate depreciation site closure cost consultancy cost sale increase turnover project management fee cost include million reflect impact reduction high margin sale associate propose divestment noncore pandemic relate product avandia valtrex consumer healthcare brand cost arise effect regional mix impact healthcare reform ongoing operating activity report major european austerity price cut adverse impact partially restructure column offset low restructuring cost low inventory writeoff restructuring cost arise solely direct result great saving operational excellence programme operational excellence programme restructuring sell general administration programme follow relate acquisition meeting criterion describe continue report operate sga cost turnover compare expense result major restructuring cost legal cost million million primarily include restructuring cost relate minor acquisition arise additional charge year product liability million cost million income relate case paxil poligrip product restructuring activity initiate commencement government investigation reflect good estimate operational excellence programme restructure additional amount expect necessary resolve activity material impact operating result dispute exclude legal cost sga cost manner business conduct turnover percentage point lower reflect low restructuring charge ongoing cost saving include anticipate duration operational excellence operational excellence programme partly offset programme currently expect incur material impact reduction sale pandemic relate product restructuring cost related programme avandia valtrex healthcare reform levy acquisition meeting criterion describe million continue investment growth business new unanticipated material restructuring cost arise product launch period expect include major restructuring advertising promotion decline sell distribution decline general administration exclude legal operating profit profit taxation taxation profit increase collectively item account decline year discuss term total result sga legal cost include major restructuring cost result major restructuring research development remain focused deliver improve return investment sale contribution reduce attrition cost reduction important driver improve internal rate return expenditure determine percentage sale instead capital allocate strict return base criterion operation pharmaceutical broadly split discovery activity completion phase iia trial development work phase iib onwards table analyse group expenditure category gsk annual report profit disposal interest associate pretax profit disposal interest associate discovery million million tax primarily reflect development disposal remain share quest diagnostic facility central support function pharmaceutical share tax profit associate joint venture vaccine share tax profit associate million consumer healthcare million arise principally group hold major restructure aspen pharmacare decline reflect disposal major restructuring share quest diagnostic february total profit taxation total result proportion pharmaceutical investment latestage portfolio continue grow total taking account net finance cost profit disposal pharmaceutical cost interest associate share profit associate total profit taxation million compare expenditure turnover compare million increase cer reflect low restructuring cost efficiency saving sterling term reflect impact low legal charge low intangible asset impairment partly offset increase investment latestage pipeline profit tax result major restructuring operating income result major restructuring set operating income million million growth primarily comprise royalty income million cer million profit asset disposal million turnover million partly offset equity investment cost sale impairment million million restructuring sell general cost million nil associate propose administration divestment noncore consumer healthcare brand research operating profit total result development operate operate profit restructuring charge million income million year end december operating profit million increase cer sterling term compare exclude legal cost million cost sale million operating profit million cost sale increase turnover compare increase cer term sterle term principally reflect impact reduction high margin reflect decline turnover low cost sale low sale pandemic relate product avandia valtrex expenditure high operating income effect regional mix impact healthcare net finance cost reform european austerity price cut adverse impact partially offset low inventory writeoff great finance income saving operational excellence programme interest finance income sell general administration fair value movement sga cost turnover compare legal cost million million primarily finance cost arise additional charge year product liability case interest cost paxil poligrip product unwind discount liabilitie government investigation reflect good estimate remeasurement fair value movement additional amount expect necessary resolve finance expense dispute exclude legal cost sga cost turnover percentage point higher reflect impact reduction sale pandemic relate product net finance expense fall slightly million million avandia valtrex healthcare reform levy reflect relatively stable level net debt million continue investment growth business group strong cash generation fund share repurchase new product launch partly offset ongoing cost saving billion increase dividend payment include operational excellence programme advertising promotion decline sell distribution decline general administration exclude legal cost increase owe healthcare reform levy collectively item account decline sga exclude legal cost gsk annual report financial review financial review continue risk research development profit taxation result major restructuring table discussion take account net finance cost profit disposal operating income interest associate share profit associate profit operating income million million tax major restructuring million compare primarily comprise royalty income million million cer increase million profit asset disposal million increase sterling term million partly offset equity investment taxation charge impairment million million operating profit result major restructuring operating profit major restructuring million corporation tax statutory rate increase cer term result lower legal double taxation relief cost overseas taxation exclude legal cost million million current taxation operate profit million year defer taxation operate profit margin exclude legal charge taxation total profit operating income fall percentage point decline resulted loss sale tax profit major restructuring charge amount high margin pandemic product avandia valtrex adverse million represent effective tax rate regional mix austerity price cut introduction exclude impact tax disposal healthcare reform levy continue investment growth quest share tax rate approximately businesse new product launch partly offset ongoing benefit early realisation tax strategy cost saving include operational excellence programme continue believe adequate provision net finance cost liability likely arise open assessment ultimate liability matter vary amount provide dependent outcome litigation proceeding finance income negotiation relevant tax authority interest income fair value movement profit year growth finance cost cer interest cost total profit taxation unwind discount liability year remeasurement fair value movement total profit attributable finance expense shareholder basic earning share penny basic earning ad net finance expense fall slightly million million result major restructuring reflect relatively stable level net debt profit taxation year group strong cash generation fund share repurchase result major restructuring billion increase dividend payment profit attributable shareholder profit disposal interest associate adjust earning share penny adjust earning ad pretax profit disposal interest associate weight average number million million tax primarily reflect share million disposal remain share quest diagnostic dilute total earning share penny share tax profit associate joint diluted total earning ad venture dilute weight average number share million share tax profit associate million million arise principally group hold total result include restructuring cost produce basic eps aspen pharmacare decline reflect disposal compare eps major share quest diagnostic february restructuring year compare exclude legal charge ep major restructuring decline cer term sterling term gsk annual report adverse percentage point currency impact eps ustomer rebate offer key manage care group major restructuring arise predominantly strengthen purchasing organisation gpo direct indirect sterling dollar partly offset weakening customer arrangement require customer achieve sterling japanese yen certain performance target relate value product purchase formulary status predetermine market share dividend relative competitor accrual customer rebate board declare interim dividend result dividend estimate base specific term agreement year penny pence increase penny historical experience product growth rate share board declare supplemental interim medicaid programme stateadministere programme dividend penny share relate disposal certain providing assistance certain poor vulnerable patient noncore otc brand north america complete medicaid drug rebate program establish january pay time fourth interim reduce state federal expenditure prescription drug dividend note dividend patient affordable care act law reporting shareholder participate provide rebate state accrual medicaid rebate calculate base specific term individual previously announce number change way state agreement combination historical experience report include transition core eps measure introduce product population growth anticipate price increase detail impact contracting strategy critical accounting policy ash discount offer customer encourage prompt consolidated financial statement prepare accordance payment accrue time invoicing ifrs adopt use european union adjust subsequently reflect actual experience ifrs issue iasb follow accounting policy approve board describe note financial historical experience customer return statement accounting principle policy require record accrual estimate sale return apply estimate assumption affect amount historical experience customer return amount asset liability revenue expense report financial invoice market relate information stock statement actual amount result differ level wholesaler anticipate price increase competitor estimate activity critical accounting policy information reconciliation gross turnover net turnover judgement estimate give note financial pharmaceutical vaccine business follow statement key accounting judgement estimate relevant detailed note financial statement indicate relate follow area gross turnover turnover taxation note chargeback legal dispute note manage care medicare property plant equipment note gpo goodwill note rebate intangible asset note government pension postemployment benefit note state programme cash discount information judgement estimate area customer return give note financial statement key accounting prior year adjustment judgement estimate item respect turnover accounting policy large business total deduction pharmaceutical vaccine market net turnover complex arrangement rebate discount allowance overall return rebate rate decrease year follow briefly describe nature arrangement primarily low sale highly discount brand particularly existence pharmaceutical vaccine business manage medicaid segment adjustment prior year arrangement certain indirect customer estimate customer able buy product wholesaler reduce price chargeback represent difference invoice price wholesaler indirect customer contractual discount price accrual estimate chargeback calculate base term agreement historical experience product growth rate gsk annual report financial review financial review continue risk total accrual rebate discount allowance return meeting appropriate detail status significant pharmaceutical vaccine business follow litigation governmental investigation review matter number claim notify information potential claim notify assessment validity claim december december progress settle claim recent settlement level restate potential reimbursement insurer chargeback meeting include assessment manage care medicare sufficient information available able reliable gpo rebate estimate potential outcome dispute external government state programme counsel assist litigation matter cash discount investigation assist briefing board senior customer return management follow discussion matter possible reliable estimate total provision require level provision legal dispute review adjust appropriate information relate restate follow change classification item include certain category financial position resource accrual rebate government state programme property plant equipment increase result healthcare reform implement business sciencebase technologyintensive highly regulate governmental authority allocate significant monthly process operate monitor inventory level financial resource renewal maintenance property wholesaler abnormal movement process use gross plant equipment minimise risk interruption production sale volume prescription volume base party datum achieve compliance regulatory standard source information receive key wholesaler aim number process use chemical hazardous material maintain inventory consistent level year year base pattern consumption total cost property plant equipment december million net book value basis pharmaceutical vaccine inventory level million land building represent wholesaler distribution channel december million plant equipment million asset estimate approximately month construction million invest million turnover calculation use party information accuracy new renewal property plant equipment mainly totally verify believe sufficiently relate large number project renewal improvement reliable purpose expansion facility worldwide site property respect accounting policy legal dispute mainly hold freehold new investment finance liquid follow briefly describe process determine resource december capital contractual level provision necessary commitment future expenditure million operating lease commitment million believe facility accordance requirement ias provision adequate current need contingent liability contingent asset provide anticipate settlement cost outflow resource observe stringent procedure use specialist skill manage consider probable reliable estimate environmental risk activity environmental issue likely outcome dispute legal expense arise date operation modify discontinued claim group involved report environmental sustainability significant legal proceeding respect possible note financial statement legal proceeding reliable estimate expect financial effect goodwill result ultimate resolution proceeding case appropriate disclosure case include goodwill increase year million annual report provision position december million increase primarily change time assurance reflect goodwill arise acquisition maxinutrition loss result outcome legal proceeding group holding limit million partly offset exceed material provision weaken overseas currency report group financial statement intangible asset like pharmaceutical company face intangible asset include cost intangible acquire complex product liability antitrust patent litigation party computer software net book value investigation operation conduct governmental intangible asset december million regulatory agency year general counsel million decrease reflect group head group legal function senior vice amortisation impairment exist intangible partly offset president head global litigation group addition million business combination responsible litigation government investigation routinely addition brief chief executive officer chief financial officer board director significant litigation pende group governmental investigation group gsk annual report financial position investment hold investment include associate joint venture carry value december million asset million market value december noncurrent asset million million large property plant equipment investment associate aspen pharmacare holding goodwill limited book value december intangible asset million million investment investment associate joint ventures theravance inc book value december investment million million investment include equity defer tax asset stake company group research collaboration derivative financial instrument provide access biotechnology development potential noncurrent asset interest interest company arise business total noncurrent asset divestment current asset derivative financial instrument asset inventory noncurrent current derivative financial current tax recoverable instrument hold fair value million million trade receivables majority relate interest rate swap derivative financial instrument foreign exchange contract designate accounting hedge liquid investment cash cash equivalent inventory asset hold sale inventory million increase million total current asset year increase reflect high vaccine stock principally total asset cervarix national hpv programme japan partly offset liability initiative reduce manufacture cycle time reduce current liability stockholde day efficient use inventory shortterm borrowing supply chain trade payable trade receivables derivative financial instrument current tax payable trade receivables million decrease shortterm provision reflect specific action take reduce overdue total current liability receivables initiative reduce work capital derivative financial instrument liabilitie noncurrent liability longterm borrowing hold current noncurrent derivative financial instrument defer tax liability hold fair value million million relate pension postemployment benefit primarily foreign exchange contract represent hedge provision intercompany loan deposit legal provision derivative financial instrument designate accounting hedge noncurrent liability trade payable total noncurrent liability total liability trade payable amount million net asset increase reflect work capital initiative extend supplier term day term objective equity share capital provision share premium account carry defer tax provision shortterm retain earning noncurrent provision million december reserve million respect estimate future liability shareholder equity million million relate legal noncontrolle interest dispute provision legal total equity dispute indemnify disposal liability employee relate liability cost restructure programme extent balance sheet date legal constructive obligation exist reliably estimate gsk annual report financial review financial review continue risk pension postemployment benefit summary movement equity set account pension postemployment arrangement accordance ias deficit net surplus allow deferred taxation million total equity beginning year million pension arrangement million total comprehensive income year million unfunded postemployment liability dividend shareholder pension liability increase follow decrease asset value share issue reduction rate discount pension change noncontrolle interest liabilitie pension liability forward contract relate noncontrolle partly offset low long term inflation rate interest deficit reduction contribution million million share purchase cancel hold treasury share december scheme purchase insurance contract consideration receive share transfer guarantee payment specify pensioner liability esop trust contract value million december share acquire esop trust net debt sharebase incentive plan tax sharebase incentive plan distribution noncontrolle interest total equity end year cash cash equivalent liquid investment share purchase borrowing repayable year borrowing repayable year employee share ownership plan esop trust acquire net debt million share gsk plc million share hold trust satisfy future exercise option award net debt increase million free cash flow asset group share option award scheme proportion disposal proceed largely fund dividend shareholder share hold trust respect award share repurchase rule scheme require satisfy exercise market movement net debt purchase issue new share share hold trust match option award grant december esop trust hold million net debt begin year million gsk share future exercise decrease cash bank overdraft share option share award carry value million cash inflow liquid investment million deduct reserve net repayment shortterm loan market value share million debt subsidiary undertaking acquire million exchange movement february announce commence movement new longterm share buyback programme million share net debt end year repurchase cost million note total equity share capital intend repurchase billion exact time future december total equity decrease purchase share hold treasury million december million share cancel determined company decrease arise principally share repurchase year dependent market condition factor december hold million share treasury share million share cost million million deduct retain earning period january march million share purchase cost million commitment contingent liability financial commitment summarise note financial statement commitment contingent liability obligation respect short longterm debt set note financial statement contingent liability note financial statement net debt gsk annual report amount provide pension postretirement benefit contingent liability set note financial statement pension follow table set contingent liability comprise postemployment benefit amount provide restructure discount bill performance guarantee letter credit programme legal environmental dispute set item arise normal course business note financial statement provision expect expire contractual obligation commitment total yrs yrs yrs follow table set contractual obligation commitment december fall payment guarantee contingent liability total yrs yrs yrs total loan normal course business provide interest loan indemnification guarantee respect business disposal finance lease obligation legal dispute subsequently arise finance lease charge provision outflow resource consider operating lease probable reliable estimate likely outcome commitment dispute include note financial intangible asset statement provision property plant equipment purchase noncontrolle provide outcome tax legal dispute interest outflow resource consider probable reliable investment estimate outflow december purchase commitment dispute provision pension possible reliable estimate potential outflow commitment fund require settle dispute possibility total outflow remote ultimate liability matter vary significantly commitments respect loan future interest payable amount provide dependent outcome loan disclose take account effect litigation proceeding negotiation relevant tax derivative authority discuss risk factor page enter number research collaboration note financial statement taxation develop new compound pharmaceutical company legal proceeding term arrangement include upfront fee equity cash generation conversion investment loan commitment fund specify level research addition agree payment summary consolidated cash flow set future milestone achieve agreement relate compound early stage development milestone payment continue net cash inflow operating activity number year compound successfully net cash outflow investing activity development process generally close product net cash outflow financing activity market approval great possibility success decrease cash bank overdraft amount show intangible asset represent exchange adjustment maximum pay milestone achieve cash bank overdraft beginning year include billion relate externalised project cash bank overdraft end year discovery portfolio number new commitment licensing agreement include cash bank overdraft end year arrangement theravance inc janssen biologics comprise cash cash equivalent commitment purchase noncontrolle interest overdraft investment represent maximum amount payable reach agreement trustee net cash inflow operating activity taxation pay pension scheme additional contribution year million decrease million sterling term period eliminate pension deficit identify compare december actuarial funding valuation table show commitment exclude normal ongoing annual net cash outflow investing activity million funding requirement approximately million million lower primarily reflect information pension obligation note financial proceed disposal shareholde quest statement pension postemployment benefit diagnostic inc low purchase intangible asset year million million gsk annual report financial review financial review continue risk free cash flow capital expenditure financial investment free cash flow cash generate business cash payment tangible intangible fix asset amount meet obligation interest tax dividend pay million million disposal realise noncontrolle interest capital expenditure million million cash payment acquire noncurrent tangible intangible asset equity investment million million year sale equity investment realise million million free cash flow free cash flow growth future cash flow free cash flow adversely impact legal settlement expect future operating cash flow sufficient fund million million free cash flow exclude operate debt service cost satisfy normal level legal settlement million compare capital expenditure meet obligation exist licensing million decline reflect low contribution agreement meet expenditure arise major pandemic product avandia valtrex low restructuring programme precise time uncertain reduction working capital compared partly offset outlined note financial statement major restructuring low restructuring payment low tax payment programme meet routine outflow include tax dividend subject risk factor discuss page commitment use free cash flow support increase time time additional demand finance dividend undertake share repurchase return acquisition share repurchase access attractive reinvest business include bolton acquisition source liquidity short longterm capital market intend use net proceed disposal bank financial institution addition cash noncore otc brand fund increase return shareholder flow operation need reconciliation net cash inflow operating activity work capital close equivalent ifrs measure free cash flow show work capital percentage turnover reconciliation free cash flow work capital conversion cycle day work capital reduce million compare net cash inflow operating activity reduction million reduction purchase property plant equipment boost approximately million cash relate purchase intangible asset pandemic receivables work capital conversion cycle reduce disposal property plant equipment day result low receivable high payable interest pay payment policy interest receive group company responsible monitoring manage dividend receive joint venture work capital term sale collection supplier associate undertaking payment reflect local commercial practice distribution noncontrolle interest free cash flow company subsidiarie policy ensure supplier pay time particular investment appraisal company seek formal process assess potential investment settle term payment supplier agree proposal order ensure decision align overall term transaction strategy process include analysis impact project earning return invest capital ensure supplier aware agree term assessment return base discount cash flow payment discount rate perform financial analysis decide abide term payment internally allow determination extent policy permit arrangement accelerate payment small investment cover cost capital specific investment supplier discount rate adjust account country risk weighting payment performance december average number day payable outstanding represent trade payable parent company nil nil respect company subsidiary aggregate day day gsk annual report maturity profile gross debt equivalent gbp bonds eur bond usd bond bank borrowing lease treasury policy return free cash flow asset disposal proceed shareholder balance dividend glaxosmithkline plc report sterling pay dividend share buyback pay billion dividend sterling profit role corporate treasury manage complete billion share repurchase monitor external internal funding requirement longterm programme elect return net financial risk support strategic objective treasury proceed sale noncore north american otc activity govern policy procedure approve brand shareholder payment supplemental board director recently july dividend treasury management group tmg meeting chair detail note financial statement financial chief financial officer take place monthly basis review instrument relate disclosure treasury activity member receive management information relate treasury activity liquidity capital management december cash liquid investment hold follow financial strategy regularly review board manage capital structure group appropriate mix debt equity deliver good return shareholder whilst maintain credit rating maximise flexibility bank balance deposits access debt capital market attractive term treasury treasury repo money market fund capital structure group consist net debt corporate debt instrument billionsee note net debt shareholder equity government security billion consolidated statement change equity total capital include provide non control interest billion billion centrally manage cash reserve amount billion allocate capital deliver good return december available month exclude shareholder commitment use free cash flow support billion centrally manage cash hold viiv healthcare dividend undertake share repurchase return own subsidiary date shortterm attractive invest bolton acquisition investment opportunity borrowing repayable year billion continue assess strict financial criterion net debt billion december table summarise cash gross debt effect hedge significant level patent trademark protection pharmaceutical product compete largely product efficacy differentiation price selling margin sufficient cover normal operating cost operation continue cash liquid investment highly cash generative legal settlement billion gross debt fix net cash inflow operating activity billion float free cash flow billion noninterest bear net debt gsk annual report financial review financial review continue risk policy borrow centrally order meet anticipate interest rate risk management funding requirement cash flow forecast funding gsk objective reduce effective net interest cost requirement monitor tmg monthly basis rebalance mix debt fix float interest rate european medium term note programme billion time policy interest rate risk management limit december billion note issue float interest payment prescribe percentage programme shelf registration statement trading profit december billion billion note use series interest rate swap redenominate issue programme bond float interest rate duration swap gsk longterm borrowing mature date match duration principal instrument interest rate longterm debt rating remain unchanged derivative instrument account fair value cash flow february currently gsk rate stable outlook hedge relevant asset liability standard poor stable outlook moodys investors foreign exchange risk management service moodys shortterm debt rating standard poor moodys respectively foreign currency transaction exposure arise internal external trade flow hedge exposure overseas gsk access shortterm finance billion operating subsidiary transaction risk minimised matching commercial paper programme billion commit local currency income local currency cost purpose facility facility renew october internal trading transaction match centrally manage increase billion billion time consider intercompany payment term reduce foreign currency risk level commit facility adequate give current exceptional foreign currency cash flow hedge selectively liquidity requirement information facility management corporate treasury tmg refer note financial statement net debt possible manage cash surplus borrowing requirement commit facility gsk substantial cash subsidiary company centrally forward contract hedge cash equivalent liquid investment amount future repayment originate currency billion december review cash order reduce foreign currency translation exposure seek balance relative debt portfolio source debt denominate borrowing currencie principal asset access order improve efficiency balance cash flow primarily denominate dollar euros sheet result intend reduce effective net funding sterle certain borrowing swap cost maintain low level cash diversify currency require source funding give current low interest rate environment borrowing denominate swap foreign currency treasury operation match investment overseas group asset treat objective treasury activity manage posttax net cost hedge relevant asset forward contract income financial operation benefit earning major currency reduce exposure investment corporate treasury operate profit centre use overseas group asset tmg review ratio borrowing variety financial instrument finance operation asset major currency monthly derivative financial instrument manage market risk counterparty risk management operation derivative principally comprise forward foreign currency contract interest rate currency swap policy counterparty risk management work swap borrowing liquid asset require select group relationship bank global counterparty limit currency manage exposure funding risk change assign gsk banking investment counterpartie foreign exchange interest rate base longterm credit rating moodys standard poor corporate treasury usage limit hold issue derivative speculative purpose monitor daily corporate compliance officer cco treasury policy specifically prohibit activity transaction operate independently corporate treasury breach financial instrument undertake manage risk arise limit report cfo immediately cco underlie business activity speculation monitor credit rating counterpartie change rating occur notifie corporate treasury change investment level authority limit appropriate counterparty analysis present tmg annually approval gsk annual report financial review antiviral antiviral decrease billion accordance sec disclosure requirement follow discussion compare result year december relenza sale million million result year december previous year significant government pandemic order receive valtrex sale decline million financial information discussion follows present reflect generic competition usa europe basis gsk organise manage central nervous system cns pharmaceutical turnover cns sale decrease billion growth rate include review turnover constant exchange rate cer state calculation majority cns franchise impact generic underlie turnover describe sterling growth rate competition usa wellbutrin decline primarily find table pharmaceutical turnover reflect sale wellbutrin usa biovail therapeutic area geographic segment second quarter pharmaceutical turnover decline billion exclude cardiovascular urogenital pandemic product avandia valtrex underlie turnover cardiovascular urogenital sale increase billion increase reflect continue strong growth key product arixtra million avodart growth million lovaza million cer usa metabolic europe metabolic sale decrease billion emerge market avandia product sale decline million asia pacificjapan september european medicine agency suspend viiv healthcare marketing authorisation rosiglitazone contain product include avandia food drug administration announce additional measure ensure benefit avandia continue outweigh risk include risk evaluation sale usa decline billion primarily mitigation strategy rem programme generic competition valtrex significant reduction sale pandemic relate product low sale avandia new oncology emesis product exclude pandemic vaccine launch grow oncology emesis sale increase billion contribute sale tyverbtykerb million grow strongly europe pharmaceutical sale decline billion primarily segment newly launch oncology product votrient arzerra impact significant reduction sale pandemic promacta deliver sale million million relate product generic competition valtrex low sale million respectively avandia vaccine emerge market pharmaceutical sale grow billion strong growth product category total vaccine sale grow billion include billion help pandemic relate product sale million pandemic vaccine sale billion exclude flu million asia pacificjapan pharmaceuticals sales pandemic vaccine sale growth new vaccine grow billion contribute growth include synflorix double million boostrix million cervarix pharmaceutical turnover therapeutic area million sale hepatitis vaccine grow million infanrixpediarix grow million pharmaceutical turnover decline impact seasonal flu sale grow million rotarix sale generic competition valtrex low avandia pandemic million product continue recover product sale partly offset growth key product market share lose follow temporary suspension seretideadvair avamysveramyst avodart lovaza tyverbtykerb markets early year ventolin vaccine franchise dermatology respiratory dermatology sale billion include heritage gsk respiratory sale increase billion product acquire business acquisition seretideadvair sale grow billion strong growth principally stiefel july estimate sale growth japan million emerge market business proforma basis exclude acquisition million sale usa level billion approximately addition heritage consumer grow europe billion dermatology portfolio report consumer healthcare contribute sale million respiratory product deliver growth include avamysveramyst million ventolin million flovent million gsk annual report financial review financial review continue risk viiv healthcare hiv restructuring cost incur direct result acquisition stiefel laboratories inc july million sale hiv product viiv healthcare million restructuring cost incur direct result billion sale pfizer product selzentry acquisition reliant pharmaceuticals inc viracept combine sale million growth acquisition october meet criterion set epzicomkivexa million offset reduction charge pay sale hiv product include trizivir million combivir million epivir restructuring cost incur solely direct result million operational excellence programme restructuring programme follow reliant stiefel acquisition consumer healthcare turnover report major restructuring column income growth statement set note financial statement total cer major restructure programme asset impairment staff overthecounter redundancy account million medicine million restructuring cost incur report major restructuring column oral healthcare nutritional healthcare late position result major restructure total result result major restructure total result financial review cer represent growth constant exchange rate represent growth actual exchange rate operate profit profit taxation taxation profit year discuss term total result total consumer healthcare sale billion include major restructuring cost result significantly exceed market growth estimate gsk major restructuring approximately sale rest world grow profit tax total result billion drive strong growth india china grow respectively europe sale level total result include restructure cost relate operational year sale billion business excellence programme acquisition reliant stiefel usa grow billion growth otc medicine cer otc product sale grow billion drive turnover sale panadol nicotine replacement therapy product cost sale dermatology product partly offset low respiratory tract sell general product low sale alli administration research oral healthcare development sale oral healthcare product rise billion sensodyne operate perform strongly denture care sale grow sale income aquafresh decline slightly operate profit nutritional healthcare cost sale nutritional healthcare sale grow billion drive cost sale increase turnover strong performance horlick growth lucozade sale reflect impact generic competition high margin result major restructure total result product usa principally valtrex low avandia sale healthcare reform european austerity price cut inventory october announce significant new operational asset writedown partially offset saving excellence restructure programme second formal plan operational excellence programme low restructuring cost announce february expansion million million announce february sell general administration addition restructuring cost operational excellence programme major restructuring column income sga cost percentage turnover increase statement include restructuring cost incur solely direct percentage point exclude legal cost result restructure programme follow relate million million sga cost material acquisition operation acquire business turnover increase percentage point overlap extensively exist operation reflect sterling cer increase sga flat sterling turnover growth sga include restructuring cost restructuring activity follow relate million million investment growth market acquisition nature undertake year impact acquisition stiefel partly offset operational excellence programme consider appropriate operational excellence savings usa europe lower present cost restructuring activity manner exchange loss intercompany transaction advertising promotion decline sell distribution increase general administration exclude legal increase gsk annual report research development profit taxation total result expenditure total turnover take account net finance cost profit disposal reflect increase expenditure sterling cer interest associate share profit associate total flat sterling turnover growth include restructure profit taxation million compare cost million million viiv healthcare million cer decline investment low intangible asset impairment million sterling decline million saving operational excellence profit tax result major restructure programme addition comparison prior year unfavourably impact oneoff recognition recoverable result major restructuring set balance growth operating income cer operating income million million turnover primarily reflect royalty income million cost sale million income transfer genentech sell general exclusive promotion rights boniva usa asset disposal million million partially offset equity administration investment impairment million million research income include disposal wellbutrin asset development disposal aspen pharmacare royalty dispute settlement gain operating million accounting gain million creation income viiv healthcare operate profit operating profit total result cost sale operating profit restructuring charge million million million decrease cer cost sale increase turnover decrease sterle term compare reflect impact generic competition high margin exclude legal cost million million product usa principally valtrex low avandia sale operate profit million decline cer term healthcare reform european austerity price cut sterle term principally reflect decline inventory asset writedown partially offset saving turnover high cost sale high expenditure low operational excellence programme operating income sell general administration net finance cost sga cost percentage turnover increase percentage point primarily reflect high legal finance income charge million million interest finance income exclude legal cost sga cost turnover unwind discount asset decrease percentage point reflect fair value adjustment hedge sterling cer decline expenditure compare prior year flat sterling turnover growth decline expenditure finance cost reflect operational excellence savings usa europe interest cost low exchange loss intercompany transaction partially unwind discount liability offset investment growth market year impact fair value adjustment hedge acquisition stiefel finance expense advertising promotion decline sell distribution decline general administration exclude legal decline collectively item account decline profit disposal interest associate total sga profit disposal interest associate million research development million profit arise sale million quest share subsequent yearend expenditure total turnover group sell entire shareholding quest rise reflect flat expenditure flat sterling turnover growth pretax profit disposal associate approximately include saving operational excellence million million tax programme low intangible asset impairment million million high viiv healthcare share tax profit associate joint venture investment comparison prior year unfavourably share tax profit associate million impact oneoff recognition recoverable balance million arise principally group hold quest gsk annual report financial review financial review continue risk operating income taxation charge operating income million million primarily reflect royalty income million million income transfer genentech corporation tax statutory rate exclusive promotion rights boniva usa asset double taxation relief disposal million million partially offset equity investment impairment million overseas taxation million income include disposal wellbutrin current taxation asset disposal aspen pharmacare royalty dispute defer taxation settlement gain million accounting gain taxation total profit million creation viiv healthcare low tax charge reflect high legal charge operate profit result major restructuring billion billion operating profit major restructuring year end charge taxation total profit amount million december million decline cer term represent effective tax rate decrease sterle term exclude legal cost charge taxation profit major restructuring million million operating profit charge amount million represent effective million decline cer term decrease tax rate sterling term principally reflect decline turnover high cost sale high expenditure lower operate late position taxation taxation financial income partly offset reduce sga cost operating profit review margin exclude legal cost operate income profit year net finance cost growth cer total profit taxation finance income year interest income total profit attributable unwind discount asset shareholder fair value adjustment hedge basic earning share penny basic earning ad result major restructuring finance cost profit taxation year interest cost result major restructuring unwind discount liability profit attributable shareholder fair value adjustment hedge adjust earning share penny finance expense adjust earning ad weight average number net interest payable year million share million million company expect similar charge diluted total earning share penny diluted total earning ad profit disposal interest associate diluted weighted average number profit disposal interest associate million share millions million profit arise sale total result include restructuring cost produce basic eps million quest share subsequent yearend gsk compare decline sell entire shareholding quest rise cer term decline sterling term exclude major pretax profit disposal associate approximately restructure cost ep compare million million tax decline cer decrease sterling term share tax profit associate joint venture percentage point currency benefit arise weakness sterle major international currency compare share tax profit associate million year partly offset strengthen sterling million arise principally group hold euro quest diagnostics inc dividend profit taxation result major restructuring declare fourth interim dividend penny share take account net finance cost profit disposal result dividend year pence pence increase interest associate share profit associate profit penny share tax major restructuring million compare million cer decline decline sterling term gsk annual report property plant equipment provision total cost property plant equipment group carry defer tax provision shortterm december million net book value noncurrent provision million december million land building represent million respect estimate future liability million plant equipment million asset million million relate legal construction million gsk invest million dispute reach settlement new renewal property plant equipment agreement principle settle number significant legal december capital contractual commitment dispute settlement agreement principle settle future expenditure million operating lease include investigation government commitment million manufacturing facility cidra puerto rico product liability antitrust litigation relate paxil product liability case goodwill avandia paxil poligrip usa goodwill increase year million investigation government sale marketing december million increase primarily practice usa settlement process involve discussion reflect goodwill arise acquisition laboratorio plaintiff lawyer government prosecutor phoenix saicyf million impact strengthen matter facilitate ability update assessment overseas currency potential exposure face matter legal charge year increase million intangible asset result provision legal dispute billion net book value intangible asset december december include good estimate amount million million increase expect necessary resolve dispute base reflect addition million business know fact circumstance date approval combination currency movement partly offset financial statement director believe amortisation impairment exist intangible material additional legal charge necessary respect dispute investment net debt hold investment include associate joint venture carry value december million net debt decrease million million million market value december december free cash flow generate million million company exceed amount pay dividend shareholder invest new business derivative financial instrument asset total equity noncurrent current derivative financial instrument hold fair value million million december total equity decrease small decrease primarily reflect decrease net investment million december million hedging volume decrease arise principally increase provision legal charge year inventory cash flow inventory million decrease million year decrease reflect initiative reduce manufacture net cash inflow operating activity taxation pay cycle time reduce stockholde day efficient million decrease million use inventory supply chain reflect high legal settlement year partly offset net work capital reduction trade receivables net cash outflow investing activity million trade receivables million decrease decrease million primarily reflect lower reflect recovery significant level debt business purchase million business year specific action take reduce overdue purchase million primarily stiefel laboratory inc receivable initiative reduce work capital addition purchase property plant equipment low derivative financial instrument liability million hold current noncurrent derivative financial instrument capital expenditure financial investment hold fair value million million current cash payment tangible intangible fix asset amount relate primarily hedge exchange translation currency million million disposal realise asset consolidation small increase reflect marginally million million cash payment acquire high currency volatility euro dollar yen equity investment million million trade payable year sale equity investment realise trade payable amount million million million increase reflect work capital initiative extend supplier term day term objective strengthen yearend foreign exchange rate gsk annual report financial review risk factor risk risk factor new product candidate appear promise development significant investment group economic human risk uncertaintie relevant group business resource fail reach market limit financial condition result operation affect commercial success example result group performance ability achieve objective efficacy safety concern inability obtain necessary factor group believe cause regulatory approval difficulty manufacture excessive actual result differ materially expect historical manufacturing cost erosion patent coverage result result risk uncertainty affect lengthy development period infringement patent group performance ability achieve objective intellectual property right inability differentiate currently know group deem immaterial product adequately compete furthermore health authority food drug group review assess significant risk regular basis administration european medicines agency japan implement oversight programme help ensure pharmaceutical medicine device agency increase system internal control place system include focus safety product differentiation assess policy procedure communication training programme benefitrisk balance drug difficult supervision monitoring process escalate issue pharmaceutical vaccine product gain regulatory approval appropriate level senior management system help facilitate group ability respond appropriately risk increase pressure healthcare budget result achieve group objective help ensure compliance financial crisis increase average age applicable law regulation internal policy group population develop market increase absolute management risk discuss page population develop market payer increasingly corporate governance demand great incremental benefit pharmaceutical vaccine product agree reimburse drug possible group implement control manufacturer price manufacturer consider appropriate respond risk face failure develop commercially successful product develop assurance step group take address certain additional use exist product reason risk manage risk effectively principal materially adversely affect group financial result risk uncertainty affect gsk business break follow area intellectual property protection risk deliver commercially successful failure obtain effective intellectual property new product protection product group operate highly competitive market innovator pharmaceutical vaccine consumer healthcare pharmaceutical vaccine business face competition company group seek obtain appropriate intellectual proprietary product large international manufacturer property protection product ability obtain producer generic pharmaceutical pharmaceutical enforce patent proprietary right regard vaccine business face increase competition product critical group business strategy success manufacturer emerge market low cost number market group operate manufacture base group consumer intellectual property law patent office develop healthcare business group likewise face competition market unwilling extend intellectual property large international consumer healthcare company local protection innovative product fashion similar market consumer healthcare company significant product innovation develop region european union japan technical advance intensification price competition usa enforce previously grant intellectual property competitor materially adversely affect group right group inability obtain enforce effective financial result business group intellectual property protection product certain market predict timing impact competitive product material adverse result group financial result potential impact sale group product light country group operate patent competitive environment group operate continue protection significantly weak usa development commercially viable new product european union develop country reduce development additional use exist product critical threaten reduce effective patent protection group ability replace sale old product decline pharmaceutical product generally particular therapeutic expiration exclusive right increase overall sale area facilitate early competition market develop new pharmaceutical vaccine product costly generic manufacturer loss patent protection include lengthy uncertain process new product candidate fail reduce scope patent right compulsory licensing stage development process late stage government force manufacturer license intellectual product candidate fail receive regulatory approval property competitor materially adversely affect group financial result market absence adequate patent protection limit opportunity rely market future sale growth group product gsk annual report expiry intellectual property right protection potential change intellectual property law group product competitive product regulation competition generic manufacturer proposal change exist patent datum exclusivity law pharmaceutical vaccine product usually protect regulation major market group sell product copy generic manufacturer period continue feature political process country exclusivity provide issue patent relate intellectual include proposal effect make property right regulatory data protection orphan prosecution patent new product difficult time drug status follow expiry intellectual property right consuming adversely affect exclusivity period protection generic manufacturer produce generic version group product include biological product product proposal enact materially adversely affect group financial result example group face intense competition manufacturers comprehensive healthcare reform usa biologics price generic pharmaceutical product major market competition innovation act enact introduce introduction generic product particularly usa new regulations followon biologic allow sufficiently group high turnover margin typically lead similar biologic able rely innovator approval dramatic loss sale reduce group revenue follow year datum exclusivity period regulation outline margin proprietary product group requirement establish biosimilar interchangeable pharmaceutical vaccine product million product operation complicated patent litigation annual global sale certain product provision propose fda europe generic competition usa markets europe ema finalise guideline similar biological medicinal addition timing impact entry followon product contain mab monoclonal antibodie product seretideadvair contain active ingredient uncertain loss patent protection group product material adverse impact sale patent composition contain combination group product active substance seretideadvair expire outlook timing impact entry followon risk substantial adverse outcome litigation competition uncertain gsk notify government investigation acceptance fda application followon product note financial statement legal proceeding contain refer seretideadvair contain active discussion material proceeding governmental investigation ingredient expect precede introduction currently involve group prove rise product able predict occur civil andor criminal liability unfavourable resolution followon product enter market similar future proceeding investigation material generic drug manufacturer exhibit readiness adverse effect group financial condition result market generic version group important operation group provision prior year product prior expiration group patent effort relate legal proceeding investigation reduce involve challenge validity enforceability patent earning assertion generic product infringe group future group additional significant patent group successful defend attack provision relate legal proceeding investigation patent maintain exclusive right market reduce earning case group believe major product particularly usa europe group practice plaintiff bar claim damage amount financial result adversely affect expiration date bear reasonable relationship underlie harm allegedly patent group major product description cause group product action accordingly litigation settlement affect date generic potentially misleading group quantify base version group product introduce set damage claim potential exposure claim legal proceeding involve patent challenge set proceeding investigation type describe note note financial statement legal proceeding financial statement legal proceeding group experience impact sale recent insurance loss experience include pharmaceutical product product expiry loss patent protection liability exposure increase cost reduce capacity product market competitor similar product class insurer provide coverage pharmaceutical company treatment similar disease condition availability generic generally include group product similar product class group product compete material adverse impact order contain insurance cost recent year group sale group product continue adjust coverage profile accept great degree uninsured exposure area less degree order optimise value insurance market addition claim insurance policy insurer regularly reserve right deny cover ground gsk annual report financial review risk factor continue risk product liability litigation usa example group reach agreement principle resolve certain federal governmental investigation preclinical clinical trial conduct development pricing marketing reimbursement prescription potential pharmaceutical vaccine consumer healthcare drug product detail note financial statement product determine safety efficacy product legal proceeding relate state investigation use human follow approval regulatory authority initiate basis factual claim result notwithstanding effort group make determine restitution civil litigation behalf state government safety product regulate clinical trial unanticipate result relate proceeding initiate group effect evident drug vaccine behalf consumer private payer proceeding widely introduce marketplace result trebling damage award fine respect instance party perform analysis publish violation law conduct group result clinical trial result necessarily accurate additional investigation future federal state meaningful raise question safety government similar civil litigation consequence pharmaceutical vaccine consumer healthcare product materially adversely affect group financial result publicise medium result product liability governmental payer regulatory control claim group currently defendant substantial number product liability lawsuit include class action involve price significant claim damage relate group pharmaceutical vaccine product subject price control pharmaceutical consumer healthcare product litigation pressure restriction market include particularly usa inherently unpredictable class action limit france germany italy japan spain sweep person prescribe group government intervene directly set price addition product inflate potential liability force number market major purchaser pharmaceutical vaccine claim pain suffer punitive damage frequently product governmental agency private health care assert product liability action allow represent provider economic power exert substantial pressure potentially open ended exposure materially price term acces formulary difficult economic adversely affect group financial result condition particularly major market europe antitrust litigation increase pricing pressure group pharmaceutical vaccine product group accurately predict usa increasingly common patent exist control pressure restriction increase infringement action prompt claim antitrust law new control pressure restriction introduce violate prosecution patent measure materially adversely affect group ability litigation involve defence patent claim direct introduce new product profitably financial result indirect purchaser payer typically file class action relief seek include treble damage example usa group high margin restitution claim similarly antitrust claim bring sale country direct government government entity private party follow settlement price control private sector purchase federal law require patent litigation allege settlement anticompetitive pharmaceutical manufacturer pay prescribe rebate certain violation antitrust law group subject drug eligible reimbursement state antitrust litigation involve competition claim unrelated federal healthcare programme primarily medicare medicaid patent infringement prosecution successful antitrust pricing pressure likely increase government share claim private party government entity group national health spending continue increase additionally materially adversely affect group financial result passage comprehensive health care reform government role provide subsidise health insurance sale marketing regulation expect significantly expand indicate group operate globally complex legal regulatory grow role leverage government bring bear environment vary jurisdiction failure group rebate liability respect federal program comply applicable law rule regulation recent year number state propose jurisdiction result civil criminal legal proceeding implement scheme control pharmacy budget bring group governmental entity federal drug lowincome senior citizen program state level private plaintiff rule include increase rebate liability pharmaceutical regulation change governmental interpretation company importation country bulk purchase rule regulation evolve conduct group call drug give new state mandate contain health question care reform law increase number medicaid eligible participant economic pressure state government budget pricing pressure group pharmaceutical vaccine product likely increase trend materially adversely affect group financial result gsk annual report regulatory control material service provide thirdparty supplier necessary commercial production product group comply broad range regulatory control include speciality chemical commodity component manufacturing testing approval distribution marketing necessary manufacture package pharmaceutical vaccine consumer healthcare group pharmaceutical vaccine consumer healthcare product affect cost product development product thirdparty service procure example time require reach market uncertainty service provide clinical research organisation support successfully historically stringent development key product important operation regulatory requirement develop market recent group business group undertake year emerge market increase regulatory business continuity planning single source certain expectation base national interpretation component bulk active material finish product service standard detailed health authority create risk failure supply event regulatory develop market increase focus safety noncompliance physical disruption manufacturing site assess riskbenefit balance drug context failure small number singlesource thirdparty supplier initial product approval context approval service provider fulfil contractual obligation timely additional indication review information manner result regulatory noncompliance physical market product strict regulatory control heighten disruption manufacturing site result delay service risk change product profile withdrawal regulator interruption materially adversely affect basis postapproval concern product safety group financial result reduce revenue result product recall product liability lawsuit great regulatory scrutiny especially taxation treasury usa advertising promotion particular group effective tax rate drive rate tax directtoconsumer advertising jurisdiction higher lower apply addition case group voluntarily cease addition jurisdiction belgium marketing product face decline sale base concern usa currently offer regime encourage innovation new efficacy safety example decline sale scientific endeavour provide tax incentive example group product avandia begin follow publicity tax credit furthermore give scale international nature question risk associate product group business intragroup transfer price inherent tax scientifically justify absence risk international business change tax law regulatory action development postapproval adverse application respect matter transfer pricing event profile product product class materially foreign dividend control company tax credit adversely affect group financial result restriction tax relief allow interest intragroup debt increase group effective tax rate materially risk interruption product supply adversely affect financial result manufacture pharmaceutical vaccine product tax charge include financial statement group constituent material require compliance good manufacturing good estimate tax liability time audits tax practice regulation group manufacture site subject authority conclude degree uncertainty review approval fda regulatory agency final tax liability period group policy compliance failure group manufacture facility submit tax return statutory time limit engage supplier key service material lead product recall tax authority ensure group tax affair current seizure interruption production delay approval possible difference interpretation tax new product revoke license operate pende legislation regulation resolve quickly possible resolution manufacturing issue example noncompliance exceptional case matter settle agreement current good manufacturing practice cgmp requirement tax authority gsk resolve dispute supply ultimately result severe formal appeal proceeding example january circumstance fine disgorgement profit supreme court canada hear appeal respect interruption supply incur fine disgorgement group transfer pricing discuss note financial impact significant product market materially statement taxation adversely affect group financial result group deal high value transaction frequent basis result increase risk financial loss mismanagement cash enter high risk position hedge transaction materially adversely affect group financial result gsk annual report financial review risk factor continue risk number risk affect financial december group trade receivable condition result group follow wholesaler total million december million group expose concentration credit implement group strategic priority risk respect wholesaler group establish strategic priority grow affect financial difficulty materially adversely diversify business deliver product value simplify affect group financial result operating model group able implement global political economic condition strategic priority fully group able implement strategic priority deliver expect benefit describe world large economy include major market group operate example strategic priority grow diversified business financial institution recent past faced extreme financial involve expand group business emerge market difficulty include decline asset price liquidity problem group pharmaceutical sale emerge market grow limited availability credit economic uncertainty continue nearly billion represent group multiple downgrade sovereign credit rating pharmaceutical turnover guarantee particularly eurozone high level sovereign debt group sale emerge market continue grow negatively impact growth global economy uncertain market continue experience relatively high growth long effect economic financial rate emerge market especially vulnerable trend worsen improve ongoing debt crisis certain ongoing global financial crisis limit resource country europe increase pressure payer spend healthcare competition market staff country force healthcare company group skill train suitable employment enterprise decrease price product debt crisis give rise group intense emerge market concern country able pay group require rely party agent product current economic condition adversely affect group risk liability emerge market lack ability distributor customer supplier service sufficient protection crime counterfeit failure provider pay product buy necessary continue expand business emerge growth market inventory raw material perform obligation materially adversely affect group financial result agreement disrupt operation addition group undertake restructuring programme negatively impact business cash flow estimate cost approximately billion distributor customer supplier service provider expect deliver annual pretax saving approximately unable pay bill timely manner billion time substantially complete insolvent negatively impact business result group able execute fully transformation operation risk elevate respect business furthermore change group structure interaction party substantial operation operation revenue cost efficiency result country current economic condition severe restructuring activity strategic initiative result particularly party expose high expect cost difficulty failure realise risk business interaction directly fiscallychallenge expect cost saving end restructure programme government payer achieve maintain competitive cost base materially continue economic weakness uncertainty adversely affect group financial result materially adversely affect group revenue result antibribery corruption operation financial condition group business include pharmaceutical vaccine consumer healthcare group extensive increase international operation particularly sensitive decline consumer government rise possible claim bribery corruption failure spending addition renew decline asset price comply applicable legislation foreign corrupt result low return group financial investment practice act bribery act similar legislation cause value group investment pension country expose group senior officer civil plan decrease require group increase fund criminal sanction include fine prosecution potential debarment pension plan public procurement reputational damage materially adversely affect group financial result group conduct substantial portion operation outside compliance mechanism monitor programme group management foreign exchange rate group place adequately prevent detect possible discuss business review foreign exchange management violation applicable antibribery corruption legislation fluctuation exchange rate sterling currency especially dollar euro risk concentration sale wholesaler japanese yen materially adversely affect group usa similar pharmaceutical vaccine company financial result group sell product small number wholesaler group control change inflation interest addition hospital pharmacie physician group rate foreign currency exchange rate control sale large wholesaler amount approximately economic factor affect business possibility group pharmaceutical vaccine turnover political unrest legal regulatory change nationalisation jurisdiction group operate gsk annual report group operate number market experience failure implement appropriate safeguard adequately protect political social unrest event lead business unauthorised unintentional access acquisition use disruption liquidity problem adversely impact modification loss disclosure critical sensitive datum group result adversely impact group ability maintain patent right competitive advantage result regulatory noncompliance environmental liability result fine penalty inability sell product environmental law jurisdiction impose actual particular market potential obligation group remediate contaminate alliance acquisition site group identify potentially responsible party comprehensive environmental group strategy diversify new product area response compensation liability act number site market group grown expect continue remediation cost relate group use ownership grow acquisition business alliance site failure manage properly environmental risk intense competition alliance acquisition candidate result additional remedial cost materially adversely pharmaceutical industry group unable affect group financial result note financial deal acceptable term acquire statement legal proceeding discussion environmental forming alliance company group assume related proceeding group involve group significant debt subject unknown contingent routinely accrue amount relate liability matter liability fail realise benefit expect transaction example pharmaceutical company accounting standard include group consider acquire involve new revise accounting standard rule interpretation patent dispute product liability litigation government issue time time international accounting standard investigation legal proceeding outcome board result change recognition income subject considerable uncertainty assumption debt expense materially adversely affect group unknown contingent liability failure realise financial result expect benefit materially adversely affect group financial result international financial reporting standard change market valuation certain financial instrument require process integrate company group acquire reflect group report result gain result disruption ongoing business effort loss actually realise significant impact integrate organisation different location income statement give period accounting defer thing differ system corporate culture divert taxation intercompany inventory rise volatility attention resource result loss key employee depend group entity own inventory adverse consequence materially adversely affect group financial result regulator regularly review financial statement list company compliance account regulatory attraction retention requirement group believe complie group rely heavily recruit retain talented appropriate regulatory requirement concern financial employee range skill capability meet statement disclosure company objective group face intense competition qualified experienced investigation potential noncompliance individual supply people specific skill accounting disclosure requirement result significant leadership potential specific geographic region restatement previously report result limit particularly give group plan expand significant penalty investigation require operation emerge market vaccine restatement materially adversely affect group financial result inability attract staff specific technical leadership skill retain key employee ensure effective succession planning protection electronic information asset critical position materially adversely affect group group rely critical sensitive datum corporate ability implement key strategic objective ultimately impact strategic plan personally identifiable information trade secret financial result intellectual property drive planning operation security type datum expose escalate external threat increase sophistication change goal disruption financially politically motivated group subject standard protection personally identifiable information year submit application bind corporate rule status review information commissioner office gsk annual report governance remuneration board board responsible longterm success company corporate governance strategy risk management financial performance sir christopher gent committee memberships sir andrew witty audit risk professor sir roy anderson remuneration stephanie burn nominations stacey cartwright corporate responsibility larry culp sir crispin davis standing reelection agm simon dingemans judy lewent standing reelection agm sir deryck maughan james murdoch daniel podolsky moncef slaoui tom swaan sir robert wilson trakcorc niai dna skoorb egroeg gsk annual report sir christopher gent stacey cartwright sir deryck maughan chairman nonexecutive director nonexecutive director appoint board june appoint april stacey join burberry appoint june sir deryck partner chairman january sir christopher group plc chief financial officer kohlberg kravis roberts nonexecutive chairman nomination corporate appoint executive vice president chief financial director thomson reuters blackrock inc responsibility committees nonexecutive officer june previously hold role serve board director lincoln director ferrari spa member kpmgs chief financial officer egg plc center trustee new york university chairmans advisory group senior adviser work langone medical center chairman bain sir christopher chief executive financerelated position granada group plc chief executive officer citigroup international officer vodafone group plc retirement salomon brothers inc july nonexecutive larry culp director lehman brothers holdings inc nonexecutive director james murdoch nonexecutive director sir andrew witty appoint july larry president chief executive officer danaher corporation prior appoint james deputy chief chief executive officer join danaher hold position accenture operate officer chairman chief executive appoint october chief executive previously andersen consulting officer international news corporation officer designate chief nonexecutive chairman bskyb plc non executive officer ceo sir andrew join group sir crispin davis executive director sothebys previously serve hold senior position asia pacific nonexecutive director chief executive officer bskyb plc south africa usa immediately prior star appoint ceo president gsk pharmaceutical appoint july sir crispin chairman europe position hold january sir remuneration committee chairman daniel podolsky andrew serve numerous advisory role director starbev netherlands member nonexecutive director scientific expert government world include south africa citigroup global advisory board serve singapore guangzhou china currently council oxford university sir crispin previously appoint july daniel president member prime minister business advisory chief executive officer reed elsevi plc prior university texas southwestern medical center group lead nonexecutive board member appointment chief executive aegis group hold phillip obryan montgomery department business innovation skill plc join guinness plc distinguish presidential chair academic board member insead business member main board group manage administration doris bryan wildenthal school january sir andrew president director united distillers early career distinguish chair medical science european federation pharmaceutical industry work procter gamble president member institute medicine national association award knighthood north american food division academy sciences member board service economy pharmaceutical southwestern medical foundation director industry new year honour simon dingemans antibe therapeutics inc chief financial officer professor sir roy anderson moncef slaoui appoint january chief financial officer nonexecutive director scientific expert designate april chief financial officer chairman research development appoint october sir roy professor cfo simon join gsk goldman sachs appoint moncef join gsk infectious disease epidemiology faculty manage director partner biological engineer medicine imperial college london member year experience investment banking development robust vaccine pipeline international advisory board hakluyt goldman sachs simon work gsk subsequently lead worldwide business development ltd trustee natural history museum london decade closely involve number gsk pharmaceutical appointment lead fellow member science policy advisory strategic project include establishment moncef give overall responsibility gsk group royal society fellow viiv healthcare oncology business gsk vaccines academy medical sciences royal statistical phd molecular biology society sir roy member international judy lewent immunology universit libre bruxelles advisory board hiv monitor foundation nonexecutive director tom swaan honorary fellow institute actuary appoint april judy serve executive foreign associate member institute medicine nonexecutive director vice president chief financial officer merck national academy sciences french inc september director appoint january tom chairman academy sciences position include thermo fisher scientific inc motorola solutions audit risk committee chairman rector imperial college chief scientific adviser inc serve boards motorola inc supervisory board vanlanschot bankiers member ministry defence dell inc board directors zurich financial services stephanie burn previously serve board quaker oats nonexecutive member kpmg europe llp company judy serve board public interest committee tom vice chairman nonexecutive director purdue pharma inc napp pharmaceutical holdings supervisory board chairman audit appoint february stephanie limit certain mundipharma international limited committee royal ahold member chairman president chief executive company nonexecutive director supervisory board royal dsm previously officer dow corning corporation trustee chairperson audit committee member managing board chief financial retirement december stephanie rockefeller family trust life member officer abn amro appoint nonexecutive director corn inc massachusetts institute technology corporation january sit president export member american academy arts sir robert wilson council chairman american sciences nonexecutive director senior independent chemistry council officer society director chemical industry america section appoint november sir robert currently serve board michigan molecular nonexecutive chairman group plc institute society womens health research step previously executive chairman rio tinto plc retirement october chairman economist group gsk annual report governance remuneration corporate executive team corporate executive team support chief executive officer management business activity sir andrew witty david pulman simon bicknell david redfern john clarke moncef slaoui deirdre connelly jean stphenne simon dingemans claire thomas marc dunoyer phil thomson eddie gray dan troy abbas hussain patrick vallance bill louv emma walmsley sppihw mot dna neslin nairb nala trakcorc niai skoorb egroeg gsk annual report sir andrew witty bill louv phil thomson chief executive officer senior vice president core business service senior vice president global communications chief information officer phil appoint senior vice president global bill appoint chief information officer january communication august responsibility simon bicknell addition role appoint medium relation investor relation corporate senior vice president governance ethic create lead core business service global responsibility global community partnership assurance multifunction share service april prior internal product business communication current role bill senior vice president phil join glaxo wellcome commercial trainee simon appoint role january information technology bill join gsk responsible risk management compliance vice president medical data sciences internal auditing datum privacy security office dan troy product quality svp company david pulman senior vice president general counsel secretary corporate compliance officer simon president global manufacturing supply join corporate secretariat dan joined gsk senior vice president general appoint company secretary glaxosmithkline plc david responsible global manufacturing counsel september combined position role supply organisation global procurement partner washington law firm sidley austin llp corporate compliance officer april join glaxo broad experience chief counsel fda current appointment manufacturing operation previously lead chair american bar association section primary supply european manufacturing north administrative law previously adjunct john clarke american manufacturing global logistics scholar american enterprise institute president consumer healthcare worldwide manufacturing strategy organisation washington john appoint president consumer healthcare david redfern patrick vallance january october inline agree chief strategy officer president pharmaceutical succession planning hand responsibility emma walmsley john continue member david responsible proactive exploration appoint president pharmaceutical january corporate executive team march join new business opportunity strategic planning patrick joined gsk head drug beecham president future global leadership dermatology business discovery focus organisation science group current appointment january chairman board viiv healthcare good chance lead new medicine ltd begin career gsk corporate create small multidisciplinary team call discovery deirdre connelly development appoint finance director performance unit unite discovery president north america pharmaceuticals europe pharmaceuticals appoint development create therapy area unit group area director central europe northern lead recent appointment patrick clinician deirdre join gsk february working europe academic lead division medicine eli lilly company year hold variety university college london join gsk position include sale professional general moncef slaoui manager puerto rico senior vice president chairman research development emma walmsley human resource recently president president consumer healthcare worldwide operation emma assume role president consumer simon dingemans jean stphenne healthcare worldwide october join chief financial officer chairman president biologicals gsk president consumer healthcare europe join gsk loral work jean lead gsk global vaccine business year hold variety marketing general previously vice president human vaccine management role paris london new york marc dunoyer research development production join emma base shanghai general global head gsk rare disease chairman group head bacterial viral manager consumer product loral china gsk japan vaccines production jean name baron king join loral emma work strategic consultancy albert belgians recognition usa marc appoint chairman gsk japan january leading contribution industry belgium february lead gsk rare disease business commercialisation join claire thomas group previously president senior vice president human resources pharmaceutical japan january president pharmaceuticals asia pacific claire lead global human resource japan july function responsible gsk environmental sustainability strategy previously oversee eddie gray pharmaceuticals international pharmaceutical president pharmaceuticals europe europe claire join group appoint director human resource eddie responsible group operation pharmaceutical claire honour europe january join beecham outstanding european woman achievement prior current appointment senior vice president general manager pharmaceutical abbas hussain president emerge market asia pacific abbas join gsk june eli lilly company spend year oversee market europe africamiddle east australasia gsk annual report governance remuneration corporate governance dear shareholder good corporate governance provide structure deliver company strategy fundamental sound decisionmake process support executive management achieve maximum performance business chairman recognise leadership board critical encourage open transparent debate discussion constructive challenge support corporate governance code welcome introduction financial reporting council corporate governance code code report year structure report corporate governance arrangement practice section new provision code requirement director retire year annual general meeting agm wish continue office offer election reelection shareholder comply provision ahead time agm intend follow practice go forward conduct second external board evaluation year line code intend continue external evaluation year board composition year board review composition number change ensure membership continuously refresh provide leadership expect global business forward simon dingemans appoint board january succeed julian heslop cfo april james murdoch decide stand reelection year agm process refresh board continue nonexecutive director sir crispin davis sir robert wilson larry culp complete year service offer reelection agm year replace director priority give candidate knowledge emerge market chief executive officer global company support initiative increase diversity board public company view diversity wide context gender diversity reflect wide range background skill board member year please welcome judy lewent stacey cartwright bring particular experience global business finance nonexecutive director complete tailor induction programme active contributor board debate management risk current uncertain economic climate recognise important maintain increase focus risk spend significant time resource assessment monitor risk group lead audit risk committee oversee risk management internal control activity antibribery corruption programme enhance follow introduction bribery act gsk annual report communication shareholder value open constructive effective communication shareholder ceo sir andrew witty cfo simon dingemans continue regular dialogue major shareholder hold meeting shareholder year attend meeting chairman remuneration committee sir crispin davis discuss remuneration policy governance matter available meet shareholder anticipate continue programme meeting year corporate governance debate debate good corporate governance continue national international level seek contribute debate respond numerous consultation document issue subject feel strongly company adviser representative body contribute structure governance process go forward corporate governance report follow set comply code sir christopher gent chairman march gsk annual report governance corporate governance continue remuneration governance policy senior independent director sir robert wilson senior independent director section describe management structure governance role act sound board procedure remuneration report page chairman trust intermediary director include detail apply comply available additional point contact shareholder principle provision code legislation responsibility include evaluation performance regulation copy code available financial chairman request chairman evaluate reporting council website wwwfrcorguk board committee collaboration committee comply provision code larry chairmen year evaluation conduct internally culp unable attend agm press senior independent director work chairman business commitment process selection new chairman appropriate leadership chair nomination committee agree recommendation board chairmans successor board sir robert maintains understand issue concern board responsible longterm success company major shareholder meeting shareholder accountable shareholder ensure group report investor relation team appropriately manage achieve strategic objective sir deryck maughan succeed sir robert senior independent board responsible system corporate governance director effect end agm strategy risk management financial performance ceo sir christopher gent lead board chairman january board comprise executive director ceo sir andrew witty responsible management nonexecutive director include chairman executive business develop group strategic direction director ceo cfo chairman research consideration approval board implement development agree strategy ceo assist member cet biography director give board meet time year require page short biography member cet give corporate executive team page chairman company secretary role chairman lead manage business board provide direction focus ensure company secretary victoria whyte appoint clear structure effective operation board january solicitor fellow institute committee set agenda board discussion promote chartered secretary administrator victoria effective constructive debate support sound deputy secretary secretary remuneration committee decisionmake process ensure board receive act secretary board board accurate timely clear information particular committee appointment company secretary company performance victoria support chairman delivery corporate chairman work closely ceo ensure governance agenda particular planning agenda strategy action agree board effectively annual cycle board committee meeting ensure implement provide support advice ceo information available board member timely respect executive responsibility managing group fashion advise director board procedure division responsibility chairman ceo corporate governance matter arrange nonexecutive agree board set governance section director attend internal management meeting visit website business operation chairman responsible performance group example year larry culp visit gsk site shareholder lead discussion development shanghai china meet chairman general manager relations gsk india mumbai tom swaan attend internal compliance assurance meeting conference chairman consider independent character audit assurance team stacey cartwright visit gsk judgement appointment manufacturing site ware hertfordshire nonexecutive director nonexecutive director provide strong independent element board place constructively challenge support management help develop proposal strategy bring experience independent judgement gain senior level international business operation academia gsk annual report corporate governance framework board monitor performance group ngaging board meeting challenge ceo member cet appropriate financial operating performance group external issue material group prospect valuate progress achievement group financial business objective annual plan nonexecutiv director scrutinise performance management meeting objective plan onitore report receive committee significant risk face group board appraise approve major financing investment licensing decision excess define threshold ceo accountable report board performance business board discharge responsibility annual programme meeting include approval overall budgetary planning business strategy board chairman executive director independent nonexecutive director audit risk committee remuneration committee nomination committee independent independent nonexecutive independent nonexecutive chief executive nonexecutive director director chairman director chairman officer corporate responsibility finance committee corporate administration committee executive nonexecutive transaction committee cet independent nonexecutive director director cet member directors chairman company secretary key board committees management committee board ultimately responsible activity group strategy governance risk management financial performance follow matter specifically reserve board strategy approval strategic plan ensure strategic objective achieve major organisation change acquisition disposal license transaction merger joint venture governance composition board committee approval appointment succession plan executive director cet member senior management term employment corporate governance matter group code conduct risk management determination group risk appetite risk management policy monitor major risk exposure review approval internal control risk management policy process financial performance appropriation distribution profit capital investment regular review business performance objective gsk annual report governance corporate governance continue remuneration board meet time member attend board agenda follow agendas board meeting include number number follow business meeting hold whilst meeting board member attend january review board evaluation report sir christopher gent review investor relation strategy sir andrew witty review financial result simon dingemans review notice agm moncef slaoui consideration reappointment auditor professor sir roy anderson review commercial interface stephanie burn review risk internal control process stacey cartwright march annual review biological operation larry culp annual review gms sir crispin davis update investor relation strategy judy lewent sir deryck maughan review financial strategy james murdoch annual review european operation daniel podolsky annual review operation japan tom swaan agm preparation sir robert wilson review license capital project julian heslop july review change financial strategy simon dingemans appoint director january consideration funding strategy tacey cartwright judy lewent appoint nonexecutive consideration tax strategy director april julian heslop retire early director march annual review annual review talent leadership addition schedule meeting board meet development strategy quorate basis occasion october annual review project transaction approve director unable attend board committee meeting board receive paper material discussion annual review pharmaceuticals meeting review advise chairman vaccine operations committee chairman view comment annual review emerge market asia pacific matter discuss convey operation member meet december review board evaluation report approval plan consideration external economic environment impact pharmaceutical sector review strategy disease develop world oard agenda shape create time strategic discussion debate include deep dive review key issue business ensure focus consideration strategic priority item asterisk represent deep dive review take place addition meeting board receive regular update ceo group operation report cfo financial performance update development company compliance corporate governance requirement regulation company secretary cet member regular presentation board area responsibility director meet cet member annual basis discuss develop proposal collectively relation group strategy gsk annual report board committee meet good corporate governance practice audit risk remuneration nomination corporate responsibility committee long establish system corporate governance summary term reference board committee set table term reference available website report committee include activity year attendance meeting give page minimum number meeting committee committee role term reference membership year report page audit risk review financial internal reporting process independent integrity financial statement system internal nonexecutive director control identification management risk external internal audit process committee propose shareholder appointment external auditor directly responsible remuneration oversight work remuneration determine term service remuneration independent executive director member cet nonexecutive director assistance external independent adviser evaluate chairman make recommendation board overall executive remuneration policy chairman ceo responsible evaluating make recommendation board remuneration nonexecutive director nomination review structure size composition board independent appointment member board cet nonexecutive director make recommendation board appropriate chairman committee monitor plan succession board cet corporate provide boardlevel forum regular review independent responsibility external issue potential impact nonexecutive director group business reputation committee chairman responsible oversight gsk worldwide donation community support finance review approve behalf board annual executive necessary report form convene agm nonexecutive director preliminary quarterly statement trading result approve certain major licensing capital transaction change group investment instrument counterparty limit corporate review approve matter connection executive necessary administration administration group business certain corporate nonexecutive transaction transaction director cet members company secretary gsk annual report governance corporate governance continue background gender remuneration academia female pharmaceutical male healthcare general business effectiveness breakdown experience director different region world set board composition number director experience seek build effective complementary board capability appropriate scale complexity strategic positioning business process board appointment lead nomination committee describe page mindful need balance composition board committee refresh progressively time draw experience long serve director tap new external perspective insight recent appointee bring board deliberation europe emap global nonexecutive director draw wide range industry emerge market asia pacific background include pharmaceutical healthcare medical time allocation research academia medium retail financial service appropriate experience complex organisation global reach nonexecutive director letter appointment set considerable experience pharmaceutical industry term condition directorship recent appointee bring new approach group board discussion chairman nonexecutive director expect devote time necessary proper performance january simon dingemans appoint board duty precise timing give vary year year chief financial officer designate assume role cfo depend company activity director expect april succession julian heslop retire early attend board meeting additional meeting require board march april judy lewent expect attend meeting committee stacey cartwright appoint nonexecutive director member part audit risk board ongoing refreshment programme committee meeting open director strategy change board announce january session visit operational site addition board james murdoch offer reelection agm member invite attend cet meeting year agm follow year service attend certain research development executive sir crispin davis sir robert wilson larry culp stand operational meeting reelection board length tenure board diversity length tenure independence nonexecutive commit equal opportunity recruitment director show employee board member represent element consider society aspire create inclusive environment date year seek value draw differ knowledge perspective elect election independent experience style resident global community shareholder agm board sir christopher gent good representation woman management professor sir roy anderson position recognise need increase stephanie burn proportion female employee senior level stacey cartwright company board currently director larry culp female like increase sir crispin davis progress achieve judy lewent objective appointment judy lewent sir deryck maughan stacey cartwright james murdoch background gender mix director illustrate daniel podolsky tom swaan background gender sir robert wilson consider independent appointment academia female board consider nonexecutive director pharmaceutical male independent character judgement free healthcare business relationship materially interfere general exercise judgement business nonexecutive director exclude chairman independent nonexecutive director meet criterion independence set code number director experience date publication majority board member exclude chairman independent nonexecutive director europe emap global emerge market asia pacific gsk annual report board induction training company secretary assist chairman designing facilitate tailored induction programme new director ongoing training induction programme nonexecutive director include meeting member cet senior executive explain company business environment operate investor perspective guidance duty obligation director gsk visit business operation induction programme ensure nonexecutive director gain maintain great insight understanding business invite attend internal management meeting include meeting cet research development executive portfolio investment board scientific review board risk oversight compliance council meet employee visit company operation reception hold board meeting board keep date legal regulatory governance matter regular paper company secretary presentation internal external adviser year board brief boardroom diversity development narrative report executive remuneration risk management impact review audit market market abuse insider trading compliance new bribery act development corporate governance reporting include european commission review comply explain principle chairman meet director annually onetoone basis discuss individual performance contribution agree ongoing training development requirement board evaluation board carry evaluation performance performance committee year evaluation normally carry senior independent director year evaluation conduct external facilitator tracy long boardroom review carry evaluation conduct evaluation long connection company action point previous board evaluation set table date action progress utilise board committee time effectively board committee paper review appropriateness timeliness facilitate contribution nonexecutive circulation improve meeting structure create time director debate enhance continuous education process nonexecutive director encourage attend range internal nonexecutive director management meeting visit group site provide great visibility executive talent annual presentation board executive talent succession management succession planning process plan opportunity emerge talent meet board include annual board committee programme increase board time devote strategic discussion board increase focus activity please indicator success delivery progress year separately february remuneration pipeline committee grant incentive award link new product performance devote time focus consideration board seek assistance audit risk committee arc company key risk ongoing basis fully understand group key risk continue consider regular report arc provide board regular update board pleased operation nomination committee insight newly enhance management enhance succession planning process result appointment succession planning process chief financial officer designate positive progress recruitment new board members refresh board appointment stacey cartwright judy lewent nonexecutive director allocate time regular basis strategic board agenda revise create time strategic discussion issue significant challenge face debate fundamental review key issue introduce ensure industry enhance return shareholder focus consideration strategic priority enhance information flow provide board member provide external report review industry board member wide variety external company inform deliberation perspective company industry assess extent new policy board programme enhance inclusion deep dive implement recent year add value discussion aspect commercial interface disease develop world continue support executive management group compliance function review enhance provide ethical leadership group support management drive ethical leadership group gsk annual report governance corporate governance continue remuneration board evaluation summary conclusion committee evaluation include committee report board evaluation process include onetoone interview director company secretary topic discuss nonexecutive director lead senior independent director circulate director advance include meet separately chairman present discuss variety aspect associated board effectiveness include chairman performance consider leadership board committee information flow handle strategic performance overall contribution high standard issue collective effectiveness exploration way addition chairman meet nonexecutive director improve way board operate independently executive director key conclusion evaluation present reelection director discuss board agm entire board retire offer consistent long finding review conclude election reelection director elect reelect board highly effective way approach director receive vote cast work develop relationship time ceo agm director retire executive management welcome nonexecutive exception james murdoch offer reelection director quality debate high strong leadership chairman committee chairman use james murdoch decide stand reelection board board dinners board calendar agenda follow decision relocate united states focus effective previously review quality duty deputy chief operating officer chairman paper presentation improve chief executive officer international news corporation role nonexecutive chairman bskyb challenge give environment company operate build board contribution impact director stand reelection subject formal evaluation process believe continue board agree follow recommendation view effective demonstrate commitment respective increase ability add value role accordingly board recommend shareholder external landscape approve resolution propose agm relate reelection director board agenda dedicate time year consideration major external influence include sir crispin davis sir robert wilson larry culp tom swaan competitive business model market development gsk serve nonexecutive director relative strength weakness help expand board year performance subject rigorous review knowledge board conclude continue effective nonexecutive director board look increase understand knowledge individual nonexecutive director board director conflict interest site visit director duty company act avoid iven size board important nonexecutiv situation direct indirect director assist company secretary continue engage conflict interest possible conflict authorisation formally informally company draw company duty apply particular exploitation relevant personal experience inside outside board meeting property information opportunity gsk attend relevant internal executive meeting industry advantage article association provide general event abreast current development power board authorise conflict anagement demonstrate board nominations committee authorise board embed culture risk awareness emerge grant periodically event annually review market emerge risk capture potential actual conflict authorisation director assurance process count quorum authorisation actual potential conflict authorisation grant record board contribution composition company secretary register note board board opportunity build relevant skill meeting competency future composition change ongoing basis director responsible informing year helpful board plan company secretary new actual potential conflict composition year optimise arise change circumstance effectiveness affect authorisation previously give provide director identify significant gap board authorisation director absolve statutory current composition global ceo experience knowledge duty promote success company actual conflict experience emerge market aspect arise post authorisation board choose exclude address recruitment new board member director receipt relevant information participation nomination committee debate suspend director board resort require director resign gsk annual report nomination committee review register potential attach importance clear principle procedure conflict authorisation october report board design achieve appropriate accountability control conflict appropriately authorise group policy risk management legal compliance mandate process authorisation continue operate effectively business unit establish process manage monitoring risk significant business group independent advice business unit majority global support function board recognise occasion prepare report annually collaboration global compliance director feel necessary independent legal summarise risk management activity andor financial advice company expense report review relevant risk management agree procedure set website enable compliance board rmcb operation subsequently report risk oversight compliance council rocc indemnification director arc qualify party indemnity provision define risk oversight compliance council company act force benefit directors rocc council senior executive authorise board director hold office signing assist arc oversee risk management internal annual report control activity group membership comprise cet accountability member company secretary head department internal control risk management assurance internal control framework audit compliance responsibility board recognise responsibility present balanced rocc meet regular basis review assess significant understandable assessment group position prospect risks mitigation plan provide oversight internal control ensure compliance applicable law regulation board accountability review approve internal policy rocc respond group risk adequacy effectiveness internal control operate management legal compliance policy provide group include financial operational compliance control business unit framework risk management upward risk management board delegate responsibility report significant risk mitigation planning identification review audit risk committee arc receive regular individual overall responsibility management report align assurance programme give risk mandatory responsibility management cet risk management compliance board implement board policy risk control cet responsible identify approve monitoring enforce key policy rmcbs establish major business unit heart group conduct business comprise member senior executive team respective business unit augment specialist internal control framework include central direction resource appropriate rmcbs oversee management risk allocation oversight risk management key activity consider important respective business unit include manufacturing marketing sale legal human resource risk designate significant gsk information system financial practice increase number risk actively manage framework financial planning system annual group budget approve board result operating unit report monthly compare budget forecast business unit global support function periodically prepare regularly year review significant risk face operation review include identify operational risk legal compliance risk risk place establish procedure identify achievement strategic goal objective review consolidate report entity control activity include policy generally occur annually embed practice cover appropriate authorisation approval align annual planning process ensure significant transaction application financial reporting standard risk identify change management direction review significant judgment financial performance external environment extensive financial regulatory operational control procedure risk activity review group internal auditor responsibility risk management control clearly delegate local business unit support regional management structure principle design provide environment central leadership couple local operating autonomy framework exercise accountability control group gsk annual report governance corporate governance continue remuneration internal control framework interaction element set risk oversight audit risk compliance committee council risk global management quality compliance council board global business unit product audit assurance quality office independent external audit emerge business business internal review business regulatory incident risk control quality audit business unit monitor agency event management infrastructure head activity internal outcome audit activity gsk risk universe management quality internal assurance audit global compliance global compliance conduct review global strategy structure support process focus rocc rmcbs assist global compliance standardisation simplification intention provide department responsible support development consistent effective oversight increasingly implementation practice facilitate employee complex business model compliance law group policy year global compliance leadership team agree thrust compliance effort promotion ethical global strategy common role responsibilitie baseline behaviour corporate responsibility accordance expectation organisation hold accountable value diligence prevent detect misconduct new global compliance organisation comprise group noncompliance law regulation support effective compliance system lobal compliance business partner align business unit role proactively partner senior employee encourage seek help report concern leader drive value compliancebase culture suspect case misconduct fear retaliation improve risk identification management practice employee line management integrity confidential reporting line manage global lobal compliance operation centrally manage compliance compliance concern allegation fairly activity analytic report communication policy independently investigate disciplinary action applicable administration project management training focus commensurate issue present efficiency consistency continuous improvement global compliance department manage head lobal compliance investigation coordinate compliance governance ethic assurance cet member report related investigation ensure consistency efficiency directly ceo chair rocc provide summary investigation geography business unit report roccs activity group significant risk cet arc regular basis direct reporting line arc provide mechanism bypass executive management need arise gsk annual report global product quality office assurance excellence operation provide central oversight support drive integration holistic assurance delivery raise new central global product quality office standard assurance enhance talent development establish strengthen independence leadership continuous improvement benchmarke quality oversight governance good manufacturing practice gmp product enhance assurance reporting business unit arc quality activity company wide state control key risk organisation global product quality office provide common deliver assurance emerge risk gsk strategic governance framework risk area oversight risk evaluation sre responsibility develop common quality standard sre supplement internal audit programme examine system gsk manufacture consumer emerge risk face gsk sre conduct assurance pharmaceutical vaccine product accordance gmp team partnership business approach design chief product quality officer serve ultimate evaluate risk area enable development implementation independent central point contact escalation product andor evolution appropriate mitigation plan quality issue group need resolution additional attention antibribery corruption programme abac response risk bribery corruption build audit assurance value exist standard form comprehensive audit assurance responsibility independently assess practical approach compliance complex risk area adequacy effectiveness management significant abac programme oversee antibribery corruption risk area report outcomes arc line team provide advisory support routine audits risk agree assurance plan internal audit group comprise detail abac programme available website seven principal team focus follow area head audit assurance act global risk officer ommercial financial internal audit support director risk management risk management responsible maintaining gsk risk nformation technology internal audit management framework support business identify anufacture internal audit include environment health key risk management risk own business safety sustainability risk management internal audit arc ongoing oversight effectiveness audit assurance review assurance plan relate ssurance excellence operation delivery commitment periodic quality ntibribery corruption assessment review conduct external auditor isk management assurance report internal audit activity conduct single organisation assurance reporting arc follow structure programme leadership head audit assurance integrating reporting business unit audit assurance report head governance ethic assurance business unit majority global support function independent reporting line arc chairman prepare report annually detail risk management global audit function allow holistic assurance compliance approach provide balanced assessment consistency approach independence report status internal control key risk highlight help eliminate overlap gap potential significant compliance issue support function report audit biennially manager oversee risk consider internal audit undertake continuous process risk assessment important respective business unit include risk contribute evolution audit strategy designate significant group information compilation delivery audit schedule approach control place manage risk provide allow audit assurance respond expeditiously change assure arc risk adequately manage business risk environment ensure audit internal control framework strategy fitforpurpose addition significant compliance issue internal audit result issue control deficiency identify escalate rocc arc early opportunity audit engagement internal audit recommend process improvement manager develop corrective action plan address cause noncompliance gap internal control internal audit track plan completion report result executive management arc internal audit result compile report rocc arc detailed assurance reporting section gsk annual report governance corporate governance continue remuneration risk management relation shareholder risk management programme extend legal work engage effectively shareholder regulatory issue consider overall strategy change regular communication agm investor relation external environment furthermore risk management principle activity embed management practice business strategy objective setting process announce financial result quarterly basis annual result include annual report shareholder receive detail risk affect group risk factor annual summary leaflet advise annual page note financial statement report notice annual general meeting available legal proceeding website monitor risk effectiveness control ceo cfo live presentation institutional investor internal control framework operation analyst medium half year result year review continue operate date available webcast teleconference approval report system internal control design quarter result hold webcast teleconference manage eliminate risk achieve business audience result available website objective provide reasonable absolute investor relation department office london assurance material misstatement loss philadelphia act focal point communication arc receive report area significant risk group investors ceo cfo chairman maintain continuous relate internal control follow consideration dialogue institutional shareholder performance plan report receive assurance framework arc objective programme regular meeting report annually board effectiveness control year meeting hold major shareholder area business necessary risk company secretary act focal point communication achieve satisfactory return shareholder investment corporate governance matter small central acquire new product business corporate responsibility team coordinate strategy arc conjunction board consider review policy development report specifically respect nature extent risk risk associate communicate socially responsible investor achieve company strategic objective stakeholder case objective apply expertise prudent chairman meet regularly institutional shareholder management elimination risk board review hear view discuss issue mutual importance relate company subsidiary extend communicate view members board material associate undertaking joint venture senior independent director nonexecutive director investment consider risk participation available meet shareholder activity remuneration committee chairman chairman head board arc review assessment risk human resource company secretary hold annual internal control framework operate gsk meeting major shareholder discuss executive consider effectiveness system internal control remuneration governance matter operation group year cover report briefing process place manage chairman date approval board process follow nonexecutive director focus sector specific issue board review system internal control accord general shareholder preference guidance internal control issue turnbull committee agm accordance new provision corporate governance code provide board responsible agm hold london notice give shareholder determine nature extent significant risk willing month meeting agm include achieve strategic objective board provide presentation business director answer shareholder oversight ensure gsk maintain sound risk management question meet informally internal control system director attend agm exception larry culp unable attend press business remuneration commitment arise responsibility president chief executive officer danaher corporation sir deryck maughan remuneration report describe level participate meet telephone unable component remuneration director set travel page vote resolution agm poll result include vote withhold publish website gsk annual report total vote cast resolution range billion shareholder entitle appoint proxy attend share percentage vote show agm speak vote behalf provide table number vote withhold event single shareholder appoint multiple proxy resolution note vote withhold vote law proxy appoint exercise right attach different count calculation proportion vote share share hold member resolution share capital control total total vote vote vote detail issue share capital number share hold withhold treasury december find note million financial statement share capital share premium account adoption financial statement share list london stock exchange approval remuneration quote new york stock exchange nyse form report american depositary share ad ad represent election reelection ordinary share director reappointment auditor holder ordinary share entitle receive dividend remuneration auditor declare company annual report attend speak authorise company general meeting company appoint proxy donation political exercise voting right organisation incur political restriction transfer limitation expenditure hold ordinary share requirement obtain prior authority allot share approval transfer ordinary share carry special disapplication preemption right regard control company right restriction vote right major shareholder authority company voting right share shareholder purchase share exemption statement know arrangement financial right senior statutory auditor hold person holder share know reduce notice general agreement restriction share transfer voting right meeting agm share acquire share scheme plan rank equally nclude discretionary vote share issue special right indicate special resolution trustee employee share ownership plan trust waive right dividend share hold trust agm hold queen elizabeth conference centre broad sanctuary westminster london change control essential contract swp business propose meet contract arrangement individually explanatory note set separate notice fundamental ability business operate effectively meet ordinary business meeting include company party material agreement eceive adopt annual report effect altered terminate change control pprove remuneration report follow takeover bid retirement reelection director agreement director provide reappointment remuneration auditor compensation loss office employment result takeover provision company share plan special business seek authority cause option award grant plan vest ake donation political organisation incur takeover detail termination provision companys political expenditure framework contract executive director give llot ordinary share company interest vote right llow director disapply preemption right allotting state far aware new share connection right issue person significant direct indirect holding company maximum current issue share capital information provide company pursuant financial purchase company ordinary share maximum service authoritys fsa disclosure transparency rule dtrs current issue share capital publish regulatory information service xempt auditor state thei companys website senior statutory auditor company annual report educe notice require general meeting annual general meeting clear day enew glaxosmithkline sharesave plan glaxosmithkline sharereward plan gsk annual report governance corporate governance continue remuneration march company receive notification article association accordance fsas dtrs follow notifiable interest director power determine legislation voting right company issue share capital articles association available website percentage article amend special resolution member issue director exercise company power provide share capital article applicable legislation stipulate blackrock inc power exercise member legal general group plc board authorise issue allot ordinary share ercentage ordinary share issue exclude treasury share article power article authority bank new york mellon depositary company company purchase share subject ad list nyse ordinary share represent shareholder authority seek annual basis company adr program manage depositary agm share purchase company cancel register bny nominees limit detail hold treasury share number ordinary share hold depositary share buyback programme find acquire disposed interest february initiate new longterm share buyback share period review connection programme expect buyback billion share share buyback programme expect upper level billion band subsequently increase billion october director senior management million share purchase total cost interest director senior management million share purchase period january connect person issue share capital company february period february give remuneration report page march million share purchase cost million rule appointment replacement director contain article association programme cover purchase share cancellation hold treasury share accordance authority article provide director appoint renew shareholder agm ordinary resolution member resolution company authorise purchase maximum director provide instance director appoint million share detail share purchase cancel way retire agm follow appointment hold treasury share disclose note article provide director normally subject financial statement share capital share premium account reelection agm interval year annually exact time future purchase hold office continuous period year extent repurchase share hold treasury share board agree director wish cancel determine company continue member board seek reelection dependent market condition factor annually accordance code member remove donation political organisation political director pass ordinary resolution special notice give pass special resolution director expenditure automatically cease director effect january ensure consistent approach bankrupt compound political contribution group introduce global creditor generally policy stop voluntarily corporate political contribution cease director virtue company period january december articles group political donation noneu organisations suffer mental physical ill health notwithstanding introduction policy accordance miss director meeting continuous period federal election campaign act continue month permission board resolve support employeeoperate political action committee shall cease director pac facilitate voluntary political donation eligible prohibit director law gsk employee resign pac control gsk decision amount recipient contribution participate employee offer resign board accept offer exercise legal right pool resource political director number require contribution subject strict limitation total resign donate political organisation gsk employee pac gsk annual report agm shareholder authorise audit risk committee report company donation political organisation incur political expenditure provision political party election referendum act year authority renew annually company act require company continue obtain shareholder approval donation political organisation incur political expenditure intend donation political party independent election candidate dear shareholder donation political organisation incur political expenditure current global political economic environment create additional challenge business committee work definition political donation political expenditure audit assurance compliance model continue adapt political organisation legislation wide evolve help maintain improve integrity financial particular definition political organisation extend internal control effective identification body concern policy review law reform management risk response challenge representation business community special interest group concern environment committee agenda include usual review company subsidiary wish support result financial result control business operation definition cover legitimate business activity world management risk focus ordinary sense consider political donation political consideration matter include expenditure activity design support onclude government investigation sale political party independent election candidate authority marketing practice board seek annually precautionary measure verseee management sovereign debt ensure company subsidiary inadvertently rotecte security prevention cyber crime breach legislation nderstande nature problem corporate committee report governance failure occur olympus japanese camera manufacturer report audit risk nomination corporate responsibility committee describe activity onitore progress implementation globa committees year set enterprise resource planning system eviewe establishment enhance antibribery corruption programme meeting consider emerge risk impact group discussion provide opportunity committee member attendee raise issue warrant consideration investigation attention internal control framework strengthen establishment new global product quality office increase independence leadership governance good manufacturing practice product quality activity group addition consolidated compliance network new global compliance organisation provide consistent effective oversight group delight welcome stacey cartwright chief financial officer burberry judy lewent president chief financial officer merck inc members committee bring considerable financial experience expertise result board determine like designate audit committee financial expert year chairman audit risk committee remain member committee judy succeed chair committee effect january tom swaan audit risk committee chairman gsk annual report governance corporate governance continue remuneration membership main responsibility membership audit risk committee committee main responsibility committee set appointment date attendance meeting committee oversight role require address regularly set relationship management internal external auditor understand monitor report relationship attendance meeting tier accountability member committee member tom swaan committee receive regular report member cet chairman senior manager cover key risk management september january compliance activity group include cover professor sir roy anderson manufacture sale marketing corporate function stacey cartwright april details report framework committee judy lewent april set page accountability sir deryck maughan january committee review quarterly result group daniel podolsky january prepare management consider report key sir robert wilson december accounting issue committee meeting split part committee review term reference annual basis material change term reference art deal fundamental aspect interna financial control consider stand item receive qualification audit risk committee member report external auditor audit assurance committee member exception professor sir roy entire board invite attend committee anderson daniel podolsky bring considerable financial meeting usually consider development external accounting experience committee work member risk environment receive legal update new business unit past employment experience finance account corporate function report report outcome role comparable experience corporate activity sir roy strategic risk evaluation topical issue podolsky respectively worldrenowne medical addition schedule meeting committee meet scientist worldrenowne researcher enable quorate basis occasion bring scientific expertise committee deliberation attendee committee meeting include regular attend attendee attendee require chairman ceo cfo general counsel financial controller head audit assurance company secretary secretary committee chairman research development chief medical officer head governance ethic assurance chief product quality officer external auditor gsk annual report committee work structured programme financial accounting experience activity stand item committee require tom swaan hief financial officer abn amro unti consider meet matter time december coincide key event annual financial reporting cycle onexecutive director kpmg europe llp public interest committee external auditor report critical accounting policy significant judgement practice stacey cartwright xecutive vice president chief financial officer group alternative accounting treatments burberry group plc discuss management ormer chief financial officer egg plc resultant conclusion material write arious financerelated position granada communications management group plc restriction access information judy lewent ormer executive vice president chief cfo report financial performance financial officer merck inc group technical financial accounting matter sir deryck maughan partner kohlberg kravis roberts general counsel report material litigation ormer chairman chief executive officer citigroup international company secretary eported corporate governance ormer chairman chief executive officer salomon brothers inc head governance report activity undertake ethic rocc sir robert wilson hairman group plc assurance economist head audit majority head group ormer chairman economist group assurance report audit scope annual coverage ormer executive chairman rio tinto group compliance audit resource result audits audit group conduct year scientific expertise company secretary report matter affect quality chair timely disclosure financial professor sir roy worldrenowne medical scientist disclosure committee material information board public anderson advance knowledge infectious disease market shareholder enable epidemiology committee review clarity rofessor infectious disease epidemiology completeness disclosure publish faculty medicine imperial college london annual financial statement interim report ellow royal society quarterly preliminary result announcement oreign associate member institute formal announcement relate medicine national academy financial performance prior approval sciences board oreign associate member french academy sciences head audit report progress global assurance ormer chief scientific adviser ministry assurance plan review assurance significant defence risk group daniel podolsky worldrenowne researcher advance sarbanesoxley act knowledge underlie mechanism disease committee management internal auditor board new therapy gastrointestinal disorder work ensure quality company corporate resident university texas accounting financial reporting committee serve southwestern medical center primary link board external internal member institute medicine national academy science auditor facilitate necessary independence oris bryan wildenthal distinguish chair management encourage external internal auditor medical science communicate freely regularly committee mallinckrodt professor medicine committee meet collectively separately external harvard medical school auditor head audit assurance head ormer chief academic officer partner governance ethic assurance member healthcare management present board determine member audit committee financial chairman committee member expert purpose sarbanesoxley act addition remuneration committee provide input committee board satisfied member recent relevant financial experience purpose code review group performance oversight risk factor relevant remuneration matter gsk annual report governance corporate governance continue remuneration external auditor appointment fee consideration give committee need include risk withdrawal external auditor committee primary responsibility make market risk evaluation planning recommendation shareholder appointment reappointment removal external auditor assess external auditor require rotate audit engagement annual basis qualification expertise resource partner year current audit partner commence independence external auditor effectiveness engagement january subject rotation previous audit process audit gsk financial statement conclude evaluate effectiveness audit process prior make recommendation reappointment external auditor sarbanesoxley act prohibit engagement committee review effectiveness performance external auditor provision certain service legal criterion agree conjunction management actuarial internal audit outsource financial information begin year audit process system design external auditor permit committee consider feedback prior year external audit provide nonaudit services committee ensure auditor gather client satisfaction survey facilitate objectivity independence safeguard policy require auditor client service review team independent preapproval committee service total fee engagement team undertake audit work survey seek nonaudit work exceed audit fee feedback financial management team corporate special circumstance clear advantage business unit level review feedback provide company auditor undertake additional work committee satisfied effectiveness external audit service include audit auditrelated tax service process recommend reappointment auditor preapproval detailed particular service category forthcome agm service subject specific budget detail criterion judge effectiveness external guideline set group policy engage auditor set external auditor provide nonaudit service include scertaine skill experience externa eliver smoothrunne thorough efficiently execute auditor suitable supplier nonaudit service audit nsure adequate safeguard place objectivity rovide accurate date knowledge technical issue independence group audit threaten timely basis compromise erve industry resource communicate good practice nsure fee level relative annual audit fee industry trend report limit set committee dhere independence policy include gsk policy isa uki sec requirement external auditor management report regularly committee extent service provide accordance eliver focus consistent audit approach globally tha preapproval fee service perform reflect local risk materiality committee preapprove additional service caseby iaise audit assurance function avoid duplication case basis fee pay company auditor associate work set detail give note financial statement operating profit provide consistency advice level agree audit fee propose external auditor review management committee consider cost comparison ensure fair appropriate gsk contractual obligation restrict committee capacity recommend particular firm external auditor group pricewaterhousecooper llp remain place auditor group inception december performance audit assurance service review annually committee time service include tax regulatory compliance make assessment committee consider paper treasury relate service detail relevant legislative regulatory professional requirement relate external auditor evaluate report external auditor compliance requirement safeguard establish internal quality control procedure gsk annual report code conduct report line nomination committee report number establish policy include code conduct available website confidential reporting line report investigation unlawful conduct waivers code conduct committee review regular report arrangement available employee encourage seek help report concern suspect case misconduct fear sir christopher gent retaliation nominations committee chairman committee evaluation membership committee consider long evaluation board membership nominations committee committee committee particular conclude committee appointment date attendance meeting continue operate effectively respect long specific set observation agree committee ask management demonstrate embed culture attendance risk awareness emerge market emerge meeting risk capture assurance process member committee member sir christopher gent chairman january december larry culp march sir crispin davis july sir deryck maughan july sir robert wilson march addition schedule meeting committee meet quorate basis occasion attendee committee meeting regular attend attendee attendee require ceo head human resource company secretary secretary committee appropriate external adviser main responsibility main responsibility committee set work committee committee main focus search new nonexecutive director refresh board recruit nonexecutive director committee consider particular skill knowledge independence diversity experience benefit board significantly appointment broad selection criterion focus achieve balance representation continental european emerge market experience individual expertise develop sector speciality search process focus need candidate current recently retire ceo cfos audit partner significant financial expertise seek candidate increase diversity board composition gsk annual report governance corporate governance continue remuneration professional search agency engage specialise committee evaluation recruitment high calibre nonexecutive director dossier committee consider long evaluation board potential nonexecutive appointee consider committee particular conclude committee committee candidate shortlist interview continue operate effectively respect long specific objective criterion consider relevant qualification observation agree replace nonexecutive interview candidate committee please director retire agm priority recommend board stacey cartwright judy lewent give candidate global ceo experience knowledge nonexecutive director appoint board experience emerge market committee agree april recruit new nonexecutive director helpful plan composition board long time frame board consider experience global business finance respective knowledge consumer brand pharmaceutical industry bring fresh perspective board deliberation process refresh board continue number board member approach year service january announce james murdoch stand reelection agm sir crispin davis sir robert wilson larry culp serve nonexecutive director year stand reelection agm year committee recommend sir deryck maughan succeed sir robert senior independent director tom swaan succeed sir crispin chairman remuneration committee judy lewent succeed tom swaan chair audit risk committee term executive succession planning committee recommend appointment emma walmsley phil thomson cet president designate consumer healthcare worldwide senior vice president global communication respectively emma walmsley join gsk president consumer healthcare europe subsequently assume role president consumer healthcare worldwide october join gsk loral previously hold number marketing general management role phil thomson join glaxo wellcome hold senior position medium relation investor relation appoint role senior vice president global communication august responsibility medium relation investor relation corporate responsibility global community partnership internal product business communication ensure orderly succession global manufacturing supply gms committee recommend appointment roger connor vice president office ceo corporate strategy role president designate gms effect january roger succeed david pulman retire gsk join cet late detailed biographical information emma walmsley phil thomson give corporate executive team cet page gsk annual report corporate responsibility committee report main responsibility main responsibility corporate responsibility committee set committee rolling agenda receive report member cet senior manager ensure progress meeting gsk corporate responsibility principle review committee annually review progress follow principle sir christopher gent access medicine corporate responsibility committee chairman standard ethical conduct membership research innovation membership corporate responsibility committee employment practice committee appointment date attendance community investment meeting set gsk principle discuss attendance year committee review approve corporate meeting responsibility report member committee member sir christopher gent work committee chairman committee focus attention issue january december include stephanie burn december james murdoch gsk principle committee area focus daniel podolsky july access medicine access pricing medicine attendees committee meeting include middle income develop country regular attend standard ethical embed ethical value attendee attendee require conduct organisation ceo general counsel reinforce valuesbased decision make head global communication business head corporate responsibility research innovation replacement refinement reduction head governance ethic assurance use animal research company secretary secretary development committee research integrity transparency independent external corporate include medical governance ethical responsibility adviser standard human subject research employment practice inclusion diversity independent external corporate responsibility adviser lead develop employee augment gsk engagement stakeholder opinion march employee relation include consultation sophia tickell appoint independent external arrangement adviser committee tickell cofounder director employee health safety wellbee meteo direct pharma future series aim align well societal shareholder value community investment pulse volunteering programme sit expert review committee access medicine caring environment progress environmental foundation member european healthcare sustainability strategy innovation leadership network product customer adoption global principle tickell attend meeting committee provide practice ensure distinction independent advice guidance corporate social interaction exchange responsibility matter chairman ceo avoid scientific medical information product promotional activity conflict interest new role tickell decide retire adviser committee disclosure payment healthcare summer professional gsk annual report governance corporate governance continue remuneration corporate responsibility integrate management law regulation gsk business report read advance ensure gsk work efficiently effectively possible number provision law regulation apply gsk ensure act responsibly share quote new york stock exchange nyse form ad publish information approach performance annual corporate responsibility report report nyse rule find website publish march general nyse rules permit company follow committee evaluation corporate governance practice instead apply provide explain significant variation explanation committee consider long evaluation board contain form filing access committee particular conclude committee security exchange commission sec edgar database continue operate effectively committee website nyse rule come effect require review operation activity agree time file annual interim write affirmation concern allocate meeting discussion key audit risk committee statement significant subject risk area hot topic strategic thinking difference corporate governance emerge area concern sarbanesoxley act follow number corporate accounting scandal usa congress pass sarbanesoxley act sarbane oxley wideranging piece legislation concern largely financial report corporate governance recommend sec gsk establish disclosure committee committee report ceo cfo audit risk committee chair company secretary member consist senior manager finance legal corporate communication investor relation external legal counsel external auditor internal expert invite attend meeting periodically responsibility consider materiality information timely basis determine disclosure information responsibility timely filing report sec formal review annual report form committee meet time sarbanesoxley require annual report contain statement member audit risk committee arc audit committee financial expert define sarbanesoxley summary board judgement matter refer additional disclosure requirement arise section section sarbane oxley respect disclosure control procedure internal control financial reporting section corporate responsibility financial report sarbanesoxley introduce requirement ceo cfo complete formal certification confirm hey review annual report form ased knowledge contain material misstatement omission ase knowledge financial statement financial information fairly present material respect financial condition result operation cash flow date period present annual report form gsk annual report hey responsible establish maintain disclosure section management annual report internal control procedure ensure material information control financial reporting known evaluated effectiveness accordance requirement section sarbane control procedure yearend result oxley follow report provide management respect evaluation contain annual report company internal control financial reporting form define rule securities hey responsible establish maintain interna exchange act control financial reporting provide reasonable anagement responsible establish maintain assurance reliability financial report adequate internal control financial reporting group preparation financial statement external purpose internal control financial reporting design provide accordance generally accept accounting principle reasonable assurance reliability financial hey disclose annual report form report preparation financial statement change internal control financial report external purpose accordance ifrs period cover annual report form management conduct evaluation effectiveness materially affect reasonably likely affect materially internal control financial reporting base framework company internal control financial report internal control integrate framework issue committee hey disclose base recent evaluation sponsor organisation treadway commission internal control financial report external auditor change group internal control ove arc significant deficiency material weakness financial reporting materially affect design operation internal control financial reasonably likely affect materially group internal reporting reasonably likely affect adversely control financial reporting company ability record process summarise report financial information fraud regardless materiality anagement assess effectiveness internal contro involve person significant role company financial reporting december internal control financial reporting conclusion file group form carry evaluation supervision ricewaterhousecooper llp audit consolidated participation group management include financial statement group year end ceo cfo effectiveness design operation december assess effectiveness group disclosure control procedure group internal control financial reporting auditing december standard public company accounting oversight board united states audit report file inherent limitation effectiveness system group form disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective ceo cfo expect complete certification report conclusion effectiveness disclosure control procedure march follow certificate file sec group form gsk annual report governance remuneration remuneration report dear shareholder behalf board please present remuneration report seek approval agm recent change executive remuneration recent year remuneration committee implement number change executive remuneration extensive consultation good support major shareholder change include tailor benchmarking versus local market simplify align remuneration cet link reward longterm incentive plan closely performance company key strategic priority early day encourage increase motivation focus management team delivery priority promise year provide annual update performance longterm incentive target annual bonus structure year committee undertake review annual bonus structure place executive conclude measure remain sound continue focus annual delivery strong financial performance give change moncef role include overall responsibility vaccine amend measure weighting financial element bonus base performance vaccine performance group profit interest tax ceo remuneration committee mindful responsibility pay appropriately excessively apply rigorous datum drive process assess competitive positioning set remuneration determine performance target assess competitiveness remuneration executive director cet member satisfied instance remuneration appropriate identify significant competitiveness gap ceo particular concern committee sir andrew strong performance widely acknowledge appointment ceo set sir andrews remuneration conservatively significantly predecessor set primary benchmark crossindustry comparator group high benchmark global pharmaceutical company take account new ceo need demonstrate performance role increase remuneration year sir andrew appointment continual mark improvement group performance recently underlie sale profit perform group increase tsr upper quartile ftse corporate comparator group global pharmaceutical peer group group good tsr performance formation gsk gsk strategy momentum sir andrews vision leadership fundamental performance gsk annual report committee believe reward level offer ceo reflect achievement date increase level performance relate remuneration raising performance share award salary limit previously approve shareholder performance share continue vest base group performance year share vest grant retain year increase sir andrew base salary line average salary increase gsk employee change position competitively peer note adjustment remuneration quartile compare gsk pharmaceutical peer sir andrews total remuneration achieve increase significantly directly reflect pay performance policy gsk deliver good underlie financial performance pipeline progress strong cash generation upper quartile share price performance enable good annual total shareholder return sir andrew deserve credit reward detail give report follow governance committee aware sensitive environment surround executive pay time real economic challenge britain large company gsk recognise leadership role aware importance balanced approach year discuss proposal policy extensively major shareholder annual meeting autumn listen carefully feedback believe follow report reflect year substantial initiative government improve corporate communication executive pay proposal formative stage follow report attempt capture spirit government direction particularly regard simplification separation past pay future policy transparency year year chairman committee tom swaan member committee succeed chairman effect january like thank shareholder support tenure chairman committee welcome shareholder feedback report sir crispin davis remuneration committee chairman march gsk annual report governance remuneration report continue remuneration total remuneration value earn base salary benefit annual bonus longterm total remuneration incentive award pay performance total remuneration current executive director set table sir andrew witty simon dingemans moncef slaoui ceo cfo chairman total total total total total total salary benefit pay performance annual bonus include defer value earn lti award performance share plan share option plan sharesave total remuneration number number number share share ad deferral annual bonus defer number share ad purchase maximum matching award detail element total remuneration give follow page report fix pay detail pay performance detail base salary page annual bonus page benefit page investment bonus defer annual bonus plan table page value earn lti award performance share plan page share option plan page sharesave page note imon dingemans appoint board january performance period simon dingemans award performance share plan end december eligible receive remuneration respect plan early matching award subject performance target maximum number share ad show matching award include dividend reinveste performance period detail pension accrue date executive director give page gsk annual report pay performance annual bonus annual bonus base follow performance target executive director financial performance personal performance sir andrew witty group operating profit group profit simon dingemans individual objective interest tax moncef slaoui performance performance target financial roup operating profit group profit interest tax year exceed stretch target set performance committee performance reflect delivery underlie sale growth continue cost control context roll pandemic product avandia valtrex impact price reduction usa europe emerge market performance target year exceed datum receive phase iii asset highlight start sufficient datum receive house file product rate return spend estimate versus end new drug expect enter late stage development year personal group deliver continued underlie sale growth cer term compare growth performance pharmaceutical vaccine consumer healthcare business strong cash generation discipline allocation capital enable total billion return shareholder dividend billion share repurchase billion increase gsk achieve quartile share price performance ftse generate company well annual total shareholder return formation gsk reach agreement principle government resolve significant federal government investigation progress orderly succession key executive team role cfo establish financial architecture new year planning process enable business strategy translate optimise shareholder return identify saving ongoing operational excellence programme million initial progress deliver financial efficiency introduce core measure performance enable easy comparison peer hairman exceed pipeline development value target detailed establish new governance structure value earn longterm incentive award performance share plan share option plan structure award grant executive share option plan award grant executive performance level achieve year end december split element dependent set performance year period end december performance year period end vest december performance measure award performance achieve maximum award performance achieve vest adjust adjust free cash flow free cash year billion company eps decline compound cer basis flow include adjustment number year december material distort item threshold vest level growth rpi plus principally legal settlement award vest favourable exchange rate movement special pension vest remain assess contribution year performance period end december relative tsr gsk tsr rank position year median position comparator group pharmaceutical company gsk company total vested relative gsk tsr rank position tsr performance year maintain vest relative december tsr potential total vest award vest remain assess year performance period end december gsk annual report governance remuneration report continue remuneration remuneration policy table summarise committee set remuneration member cet executive key element remuneration include requirement hold minimum level share gsk principal pension arrangement committee review total remuneration executive executive comparable committee set company focus local global comparison committee aim ensure total remuneration remuneration level competitive set reference median appropriate comparator group balance fix element pay performance carefully consider overall package weight heavily fix pay base salary salary review annually datum relevant comparator group influence executive role experience performance average increase broad gsk workforce benefit principally healthcare car personal financial advice life assurance relevant cash lieu money purchase pension contribution secondment travel expense pay performance safeguard clawback mechanism incorporate annual bonus award process committee retain risk discretion reduce grant vest level performance awards appropriate management annual bonus target maximum target bonus opportunity majority bonus base achievement challenge financial executive director follow target groupbusiness unit operating profit group profit arget maximum interest tax agreed board committee salary salary individual performance predetermine personal objective ceo cfo rdspecific key performance indicator chairman vaccinesspecific key performance indicator defer annual individual choose invest award vest end threeyear performance period base bonus plan bonus earn equally weight performance measure dabp defer bonus business diversification performance match oneforone new product performance subject performance criterion adjust free cash flow relative tsr performance performance share share plan award executive director vest threshold rise stretching performance exceed psp follows set threshold specify margin comparator group comprise gsk pharmaceutical company salary ceo vest median vest upper quartile performance cfo chairman ceo retain share vest award year follow vest share ownership align interest executive shareholder executive require build maintain significant requirement holding shares gsk ceo base salary executive director base salary cet member base salary pension executive gsk operate define contribution plan executive participate define contribution plan benefit company contribution base salary plus match contribution base salary certain executive member legacy final salary plan close new entrant executive gsk operate cash balance pension plan plan executive participate plan benefit contribution base salary gsk annual report estimate total future potential remuneration remuneration package table provide estimate potential total future remuneration executive director respect remuneration opportunity grant range potential outcome provide executive director sir andrew witty ceo total annual total pay salary benefit fix pay bonus dabp psp performance total threshold threshold maximum simon dingemans cfo total annual total pay salary benefit fix pay bonus dabp psp performance total threshold threshold maximum moncef slaoui chairman total annual total pay salary benefit fix pay bonus dabp psp performance total threshold threshold maximum remuneration grant record follow earn award record remuneration respect annual report salary benefit annual bonus dabp bonus defer psp assumption underlie scenario outline scenario ther benefit estimate base actual amount receive respect ach executive director assume defer annual bonus maximum permit matching awar show dabp reflect show dabp reflect matching award bonus defer individual include annual bonus amount show dabp psp base bonus amount relevant multiple sala respectively include amount respect dividend reinveste performance period actual amount record remuneration dabp psp respectively calculate share ad price vest date include amount respect relate dividend reinveste relevant performance period dabp psp subject performance measure year period respectively threshold pay performance payable threshold minimum level pay performance payable assumed performance executive director result individual performance multiplier increase financial performance element bonus threshold level payment annual bonus vest award dabp psp discuss det ail maximum assume annual bonus payable maximum percentage set award dabp psp vest gsk annual report governance remuneration report continue remuneration committee set remuneration committee review ceo propose remuneration identify competitiveness gap highlight committee give consideration remuneration policy diagram address committee preference level wide employee population group increase level pay performance ceo ensure remuneration consistent industry broad remuneration package accordingly committee raise market norm committee set total remuneration psp award salary reference median level executive pay comparator group summary total package competitive positioning ceo benchmarke total remuneration follow principal element consider total remuneration base benchmarking criterion base salary nnual bonus comparison purpose assume company achieve target performance abp psp award assume awards vest maximum dabp assume executive choose defer maximum annual bonus committee consider pension arrangement significant proportion executive total remuneration crossindustry global pharmaceutical european crossin dustry group group group package base pay performance particular low quartile median median upper quartile emphasis longterm sharebase incentive closely align previous position new position executive interest shareholder balance fix pay pay performance element remuneration vary depend performance fix pay committee use primary pay comparator group base salary base salary set reference relevant comparator crossindustry global pharmaceutical comparator group comparator group group level consider appropriate secure retain anglo american france sanofi talent need deliver gsk strategic priority salary astrazeneca switzerland novartis level review annually influence barclay roche holding wide pay environment executive role experience group astrazeneca performance bhp billiton usa abbott laboratories amgen committee consider prevail economic condition british american tobacco bristolmyers squibb diageo eli lilly market competitiveness executive package hsbc johnson johnson position relativity pay broad gsk workforce reckitt benckiser merck average salary increase employee rio tinto pfizer royal dutch shell executive director approximately standard charter approximately usa tesco committee decide executive director salary unilever vodafone increase line average salary increase gsk employee usa sir andrew witty amgen include remuneration benchmarking include simon dingemans receive base salary increase tsr comparator group moncef slaoui primary comparator group executive director show table table set base salary executive director year appointment board primary comparator group salary salary increase typically effect global quarter year director crossindustry pharmaceutical sir andrew witty ceo base salary simon dingemans cfo change moncef slaoui chairman sir andrew witty reviewing ceo remuneration ceo primarily set reference crossindustry comparator simon dingemans cfo group committee reference pay group moncef slaoui european company select base size complexity chairman imon dingemans join board january gsk annual report benefit financial measure bonus threshold target maximum payable achievement executive receive benefit include healthcare car target bonus threshold reflect stretch nature personal financial advice life assurance matching share bonus target sharereward plan measure executive director set simon dingemans accumulate benefit gsk pension plan receive cash lieu money purchase personal pension contribution executive director financial performance performance sir andrew witty group moncef slaoui second year period november enable close simon dingemans operating profit group profit individual vaccine business assume operational responsibility moncef slaoui interest objective group receive appropriate performance tax secondment travel expense vaccine performance cash value benefit receive executive director show ure moncef slaoui assume responsibility group vaccine business financial element bonus pay performance adjust accordingly safeguard risk management ceo committee believe payment performance individual performance objective sir andrew witty set specifically committee want reward failure board january year board focus view important incentive payout strategic priority develop company circumstance performance outcome reflect set reason commercial sensitivity genuine achievement original target specific objective keep confidential follow end financial year board review performance generally give nature gsk business increase focus risk set objective determine appropriate bonus group committee take number step payable performance ensure performance relate pay underpin effective risk management chairman chairman audit risk committee member bonus measure employee include moncef slaoui committee provide input audit risk committee link pipeline performance robust governance structure review group performance oversight risk establish ensure bonus payable fairly reflect factor relevant remuneration decision productivity performance achievement committee review ongoing financial impact prio profit target performance target review year activity role individual executive bonus compensation review committee include activity continuity executive sir andrew witty companys designate scientific responsibility initiation adverse event expert nonexecutive director professor sir roy anderson emergence problem adverse event take daniel podolsky equivalently robust process account assess pay performance year problem implement review vaccine performance measure identify future period committee executive appropriate adjustment individual annual bonus amount executive ceo set individual objective grant vest level lti awards reflect line company strategy make recommendation circumstance clawback mechanism committee performance objective safeguard relate end year recommendation consider businessspecific performance measure longterm committee determine level bonus payable incentive plan set detail ontarget maximum bonus executive ongterm incentive award good leaver normally vest director give table end original vest period year departure ensure continued alignment shareholder ontarget bonus maximum interest follow cessation employment base salary base salary sir andrew witty ceo annual bonus simon dingemans cfo moncef slaoui chairman annual bonus design drive achievement gsk annual financial strategic business target delivery table set bonus earn executive personal objective director year appointment majority annual bonus opportunity base formal review performance stretch financial target sir andrew witty outcome adjust reflect individual performance simon dingemans apply individual performance multipli moncef slaoui imon dingemans appoint board january gsk annual report governance remuneration report continue remuneration longterm incentive plan performance measure longterm incentive form maximum number focus committee improve share award number share receive executive alignment executive remuneration arrangement depend performance performance period key strategic priority provide close link shareholder return payment consultation shareholder dabp psp executive notional dividend reinveste pay award executive comprise businessspecific proportion share earn performance measure business diversification performance new product performance adjust free defer annual bonus plan cash flow relative tsr defer annual bonus plan encourage longterm board recognise possibility company goal shareholde discourage excessive risk taking help evolve time committee intend review focus gsk key strategic priority performance measure periodically ensure annual bonus earn deferred remain appropriate share ad appropriate year company detail performance measure target performance match share ad oneforone depend threshold longterm incentive award give company performance measure outline table set threeyear performance period safeguard vest level participation year executive director show table addition set robust target committee maximum matching award grant respect implement number safeguard ensure target deferral bonus matching award vest meet sustainable way performance outcome subject continued employment achievement reflect genuine achievement original target performance measure represent delivery value shareholder performance measure impact acquisition total bonus defer matching divestment quantify adjust event executive director award major adjustment calculation performance measure sir andrew witty share disclose shareholder vest simon dingemans share moncef slaoui ad table set principal safeguard performance measure performance share plan performance measure safeguard vest performance share plan ensure focus delivery business diversification nclude impact revenue gsk strategic priority longterm shareholder performance opportunistic event pandemic return relative pharmaceutical company committee consider add shareholder value provide performance share plan award vest underlying performance sufficiently depend company performance year positive performance period measure outline djust major distort event limit time base salary maximum initial value espite reach target vest normally performance share grant individual reduce market growth achieve year new product esting reduce insufficient progress table show award level february performance period march executive director line policy gsk target return investment award level award level award level nclude impact revenue opportunistic event pandemic base salary base salary base salary award committee consider sir andrew witty add shareholder value provide ceo share underlying performance sufficiently positive simon dingemans cfo share adjust free cash flow djust materially distort item include exchange rate movement major moncef slaoui legal taxation settlement special chairman ad pension contribution gsk annual report performance target inevitably measure link directly strategy commercially sensitive particular committee consider appropriate disclose target business diversification performance new product performance grant result competitive harm target disclose fully remuneration report end performance period detail extent meet committee undertake provide update achievement date target performance period performance target set table longterm incentive measure awards award vest schedule award business diversification performance incentivise growth global diversified business design focus turnover major growth area vaccine consumer healthcare emerge market asia pacific proportion japan pharmaceutical business exclude vaccines award dermatology dermatology business achievement available threshold aggregate revenue target business division threshold threeyear performance period reflect strong growth maximum previous period market growth new product performance maximum recognise importance future business growth express measure threshold revenue target base new product sale incentivise well business diversification performance new product define product launch performance performance period precede year performance period product launch new product year include measurement performance aggregate threeyear revenue target award new product sale reflect growth historic performance adjust free cash flow year adjust free recognise importance effective work capital cash flow target vest cash management threshold threshold billion billion billion maximum billion relative tsr proportion vest focus delivery value shareholder relative tsr comparator group comprise gsk global pharmaceutical company relative tsr measure year twelvemonth averaging period tsr measure local currency tsr rank position median upper quartile performance performance gsk annual report governance remuneration report continue remuneration historical vest gsk ltis share ownership requirement follow table show vest level gsk performance align interest executive share share option award executive tsr shareholder executive require build vest percentage indicate gsk relative tsr maintain significant holding share gsk time performance median comparator group current share ownership requirement sor set performance period table share option performance share plan plan share ownership requirement vest ceo base salary adjust executive director base salary vest free total vest performance tsr cash flow vest eps cet member base salary period measure measure measure shareholding purpose sor march achievement sor base average share price working day precede date hold ordinary share sor purpose december march increase achievement award include respect relative tsr shareholding sor respect adjust free cash flow year performance sir andrew witty period remain respect relative tsr year simon dingemans performance period assess year moncef slaoui allemployee share plan executive require continue satisfy shareholde executive participate allemployee share plan requirement minimum month follow retirement usa include sharereward sharesave company sharereward plan revenue customs approve pension plan open employee term participant pension provide important tool create longterm contribute month gross salary purchase culture loyalty gsk share company match number gsk share buy month arrangement sir andrew witty executive participate group senior executive pension simon dingemans contribute month buy share plan pension arrangement structure accordance sharereward plan plan operate executive country likely retire detail individual arrangement executive sharesave plan revenue customs approve plan director set page open employee participant save month net salary fix term year new executive eligible participate define end saving period option buy gsk contribution scheme depend personal share discount market price set circumstance relevant tax restriction cash balance launch saving contract pension plan usa dilution limit exist obligation legacy define benefit scheme continue honour award plan incorporate dilution limit consistent guideline provide association british insurers current estimate dilution exist award year set table issue share capital abi dilution december december share plan limit gsk employee share plan executive share plan gsk annual report pension arrangement company currently operate define contribution plan legacy final salary plan close new entrant executive participate define contribution plan receive company contribution base salary opportunity receive match contribution line policy member pension plan government announce series change taxation pension continue impact pension employee gsk taxation change significant negative consequence effectiveness pension reduce pension continue important tool create longterm culture promote employee retention committee decide exist pension promise honoured employee pension impact change opportunity pension new limit deliver gsk exist unfunded scheme legacy final salary plan provide twothird final salary age employee subject cap benefit excess cap currently provide unfunded arrangement legacy final salary plan actuarial reduction factor apply participant leave employment accord age pension arrangement usa gsk operate cash balance plan provide annual contribution interest sum accumulate cash balance plan contractual promise provide specific level retirement income plan incorporate executive pension credit senior executive contribution rate plan range base salary depend grade current senior executive eligible executive pension credit cap employee usa benefit cap provide unfunded nonqualified plan update performance ongoing awards committee undertake provide update performance outstanding lti award note actual vest level determine base performance year performance period interim position provide regard indication management perform date regard prediction final vest level award performance period december december committee review performance criterion defer annual bonus plan performance share plan award grant executive director performance achieve year january december follow dabp award subject performance relative tsr year estimate likely vest base performance date maximum total performance measure award performance achieve date vest award adjust free cash flow target year period december billion threshold vest billion maximum vest base performance measure adjust free cash flow year period december billion relative tsr year gsk tsr rank position year period december pharmaceutical comparator relative tsr year group gsk company potential total vest psp award vest schedule performance criterion give page report level performance measure maintain end performance period december vest award show performance measure end performance period performance date necessarily indication final vest level gsk annual report governance remuneration report continue remuneration award performance period december committee review performance defer annual bonus plan performance share plan award grant executive director performance achieve year december follow estimate likely vest base performance date performance maximum total measure award performance achieve date vest award business vaccine diversification lack flu pandemic vaccine sale year result decline report vaccine performance sale million flu pandemic vaccine sale million year compare million cervarix sale double million primarily reflect national hpv vaccination programme japan start end synflorix grow million reflect continued growth relate tender emerge market strong report growth rotarix million primarily reflect impact product market exclude pandemic vaccine sale cer growth estimate market growth exclude pandemic vaccine sale consumer healthcare consumer healthcare sale grow year million sale usa europe decline slightly largely result reduction sale alli decline offset strong growth rest world oral healthcare nutritional healthcare sale grow strongly overthecounter sale flat estimate market growth market gsk compete emerge market asia pacific japan exclude vaccine dermatology emerge market asia pacific japan pharmaceutical business exclude vaccine dermatology report combine sale million year represent growth compare region respiratory product provide strong growth support antibacterial product emerge market avodart lamictal japan estimate market growth dermatology dermatology sale grow year million growth emerge market benefit ongoing launch stiefel product new market offset impact price cut europe generic competition evoclin usa report growth year benefit addition sale business acquire late early offset effect disposal zovirax north america quarter estimate market growth market gsk compete new new product sale product sale product launch total million year grow performance large product group synflorix million return investment increase approximately end end adjust free award aggregate threeyear adjust free cash flow target threshold cash flow vest billion billion maximum vest base performance measure adjust free cash flow year billion relative tsr period january december companys tsr rank pharmaceutical comparator group gsk company potential total vest award vest schedule performance criterion give page report level performance measure maintain end performance period december vest award show performance measure end year period performance date necessarily indication final vest level committee review performance year remain view target award new measure remain suitably robust stretch actual target detail extent met disclose time vest gsk annual report remuneration committee committee meeting usually begin closed session member committee company role committee secretary external adviser present individual invite attend committee meeting year role committee set company remuneration executive committee attendee involve policy gsk able recruit retain motivate decision present discussion executive policy regularly review ensure remuneration consistent company scale scope operation support business strategy growth plan help drive attendee committee meeting include creation shareholder value regular attend term reference attendee attendee require ceo committee term reference available cfo company website term reference review head human resource minimum annual basis revise december head reward light good practice corporate governance company secretary secretary developments committee governance committee adviser deloitte llp board consider member committee adviser committee independent nonexecutive director accordance committee access external advice require deloitte corporate governance code exception sir christopher llp deloitte appoint committee provide gent chairman company independent independent advice executive remuneration appointment year deloitte provide independent commentary matter committee meet time member consideration committee update good practice attend follow legislative requirement market practice attendance deloitte provide consult tax assurance service committee gsk year provide advice executive member meeting remuneration matter committee member sir crispin davis committee conduct formal review deloitte chairman july performance july establish set criterion larry culp january enable consideration committee need sir christopher gent january deloitte member remuneration consultant group james murdoch october voluntarily operate code conduct relation tom swaan executive remuneration consulting code conduct ames murdoch tom swaan unable attend find wwwremunerationconsultantsgroupcom meet personal reason meeting unable attend review paper provide view matter tower watson pay governance provide additional market consideration committee chairman advance data committee swaan chairman audit risk committee commitment shareholder committee engage regular dialogue shareholder addition schedule meeting committee meet hold annual meeting gsk large investor discuss quorate basis occasion principally approve feedback remuneration policy governance matter formal grant base performance vest longterm particular committee discuss significant change incentive award accordance gsk remuneration policy policy measure assess performance annual meeting hold november sir crispin davis committee chairman share progress remuneration matter month proposal sir christopher gent chairman update attendee corporate governance development gsk annual report governance remuneration report continue remuneration principal activity matter address committee principal activity matter address set remuneration item specific month overall annual bonus ltis governance matter january approve executive review approve review lti measure review shareholder voting remuneration include executive target policy guideline salary ceo cfo bonus remuneration chairman set ceo bonus review draft remuneration objective report overview bonus annual committee employee cet evaluation result february review lti performance review feedback target outcome shareholder approve lti award remuneration policy vest approve remuneration set lti award report target grant lti awards executive approve defer annual bonus plan election matching awards march review pay comparator initiate review annual initiate review currency review shareholder vote strategic overview wide bonus plan calculation tsr policy guideline remuneration environment remuneration july approve remuneration complete review complete review tsr review committee new cet appointee annual bonus plan currency calculation adviser review general market grant interim lti review vote outcome development award executive remuneration initiate review ceo report agm remuneration feedback october agree salary review review bonus review lti performance review government process executive approval process report meet remuneration consultation review ceo remuneration executive commitment proposal shareholder tsr currency update november annual meeting investor december review executive review propose consider feedback remuneration market datum annual bonus target annual meeting competitiveness investor annual committee evaluation result gsk annual report executive director term condition follow table set detail executive director service contract executive director contract current director date contract effective date expiry date policy set provide framework contract sir andrew witty june august executive director simon dingemans september january april moncef slaoui december december august policy andrew wittys contract renew june follow appointment ceo amend february remove notice period calendar month entitlement bonus severance term termination moncef slaouis previous contract date replace employ company new contract december reflect change severance executive term outline termination payment annual salary termination payment respect payable termination company notice period extend contract expiry date vest ltis rule relevant incentive plan entitlement approve shareholder addition contractual provision outline pension base exist arrangement event moncef slaouis service agreement terminate term relevant pension plan employ company follow apply noncompete clause month termination case outstanding award notice date glaxosmithkline annual investment plan close ability impose month noncompete period nonsolicitation new deferral effect quarter restriction executive consider important company provide agreement terminate cause ability protect group intellectual property staff light moncef slaoui exercise bonus investment right committee believe appropriate provide month termination receive defer mitigation contract amount income gain contract new executive normally include bonus line policy applicable senior executive element termination payment moncef slaoui eligible future date receive continue medical dental insurance retirement term contract seek balance commercial imperative good practice company consider important outside appointment executive individual work notice board encourage executive hold external directorship period compensatory payment respect bonus establish role broaden period restraint experience development help increase pool julian heslop retire early company march candidate nonexecutive director term contract enter prior outside appointment consider nomination framework introduce entitle receive committee ensure cause conflict interest year notice termination payment include year approve chairman behalf board annual salary month ontarget bonus company policy remuneration earn simon dingemans join board january appointment keep individual executive appoint cfo april follow julian heslops early retirement line company policy simon dingemans contract provide termination payment base year base salary gsk annual report governance remuneration report continue remuneration chairman nonexecutive director share ad notionally award non executive director allocate interest account set nonexecutive director fee set table include director interest table accumulate balance company aim provide chairman non share ad notional dividend subsequently executive director fee competitive pay reinveste pay nonexecutive director company equivalent size complexity subject retirement board retirement nonexecutive limit contain gsk article association director receive share ad cash chairman ceo responsible evaluate equal value share ad date retirement make recommendation board fee payable date payment later nonexecutive director letter appointment fee term engagement nonexecutive director chairman fee currently annum plus set letter appointment available inspection allocation share value annum company register office agm nonexecutive director initial appointment nonexecutive director fee apply december subsequent reappointment subject election follow periodic reelection shareholder annum nonexecutive director letter appointment standard annual cash retainer fee contain provision notice period compensation supplemental fee appointment terminate chairman audit risk committee follow table show date initial letter appointment nonexecutive director senior independent director scientificmedical expert nonexecutive director date letter appointment chairman remuneration corporate sir christopher gent responsibility committee professor sir roy anderson september stephanie burns february nonexecutive director undertaking stacey cartwright march intercontinental travel meeting meet larry culp june fee chairman audit risk committee reflect increase sir crispin davis june focus group compliance risk time commitment judy lewent march require committee chairman approximately day annum sir deryck maughan detail operation audit risk committee give james murdoch february pages daniel podolsky july christopher gent chairman corporate responsibility tom swaan december committee receive additional fee list sir robert wilson june recent year increase time sir christopher gents letter appointment agree commitment demand responsibility place role serve company deputy chairman nonexecutive director generally lead increase december january chairman fee result development market conclusion agm follow anniversary nonexecutive director fee gsk independently review appointment extend term year review highlight scope mutual agreement effect reelection director increase nonexecutive director fee light agm hold extend current environment decide increase fee period year effect january subject time continue keep review annual reelection agms nonexecutive director share allocation plan exchange rate enhance link director shareholder gsk fee pay dollar convert follow require nonexecutive director receive significant exchange rate fee form share nonexecutive director total fee exclude chairman pay exchange rate form share ad allocate share account period rate apply january december nonexecutive director opportunity invest january december balance fee share january december ad account exchange rate set annually base average daily rate quarter year prior payment rate review move significantly year gsk annual report tsr performance graph follow graph set performance company relative ftse index company constituent pharmaceutical performance comparator group year period december graph prepare accordance regulation define basis preparation indication likely vest award grant company incentive plan tsr performance glaxosmithkline total return glaxosmithkline pharma peer return index ftse total return index index include abbott laboratories astrazeneca bristolmyers squibb eli lilly johnson johnson merck novartis pfizer roche holding sanofi gsk annual report governance remuneration report continue remuneration director emolument total remuneration addition statutory disclosure total emolument year provide total remuneration include value ltis earn relevant performance period end year compen sation total value total total value total fee annual loss emolu ltis remune fee annual emolu ltis remune footnote salary benefit bonus office ment earn ration salary benefit bonus ment earn ration executive director sir andrew witty abcdh simon dingemans bceh julian heslop abdg moncef slaoui acfh total executive director nonexecutive director professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom swaan sir robert wilson stephanie burn larry culp judy lewent sir deryck maughan daniel podolsky total nonexecutive director director jeanpierre garnier total director total remuneration director payroll report dollar average exchange rate year director receive reimbursement expense year require separate disclosure regulation define basis preparation analysis value ltis earn sir andrew witty julian heslop moncef slaoui set andrew witty simon dingemans participate salary sacrifice scheme include sharereward julian heslop participate early retirement march andrew witty simon dingemans moncef slaoui elect participate gsk defer annual bonus plan respect bonus sir andrew witty defer bonus simon dingemans defer bonus moncef slaoui deferred bonus ollowe merger glaxo wellcome smithkline beecham encourage employee convert holding nonsaving relate option legacy share ad option glaxosmithkline share ad employee grant additional cash benefit equal grant price original option additional benefit know exchange offer incentive eoi payable new option exercise lapse underwater qualify additional cash benefit participant retain option second anniversary effective date merger sir andrew witty receive julian heslop receive amount include benefit award eligible eoi imon dingemans join board january remuneration record date participate gsk pension plan instead receive respect lieu money purchase pension contribution respect life assurance contribution include benefit moncef slaoui step nonexecutive director agency science technology research astar january receive nil include ulian heslop retire early march receive year annual salary month ontarget bonus compensation loss office set term contract total remuneration executive director office december year date appointment later follow sir andrew witty simon dingeman moncef slaoui andrew witty appointed board january simon dingemans appoint january tacey cartwright judy lewent join board april fee record date gsk annual report nonexecutive director fee cash sharesad total cash sharesad total fee nonexecutive director professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom swaan sir robert wilson stephanie burn larry culp judy lewent sir deryck maughan daniel podolsky total fee nonexecutive director require total fee form share ad allocate sharead account pay retirement board detail share allocation plan nonexecutive director total value share ad date award cash payment form total fee include table fee salary table set value fee receive form cash share ad table set accumulate number share ad hold nonexecutive director share allocation plan relation fee receive board member december movement account year number share ad december allocate dividend december share allocation plan elect reinveste nonexecutive director share professor sir roy anderson stacey cartwright sir crispin davis sir christopher gent james murdoch tom swaan sir robert wilson ads stephanie burns larry culp judy lewent sir deryck maughan daniel podolsky gsk annual report governance remuneration report continue remuneration director interest follow interest director company office december connect person show accordance fsa listing rule share ad march december january march december january footnote executive director sir andrew witty simon dingemans moncef slaoui nonexecutive director professor sir roy anderson stephanie burn stacey cartwright larry culp sir crispin davis sir christopher gent judy lewent sir deryck maughan james murdoch daniel podolsky tom swaan sir robert wilson glaxosmithkline ad represent glaxosmithkline share interest abovementione director march reflect change yearend date include share purchase glaxosmithkline sharereward plan sir andrew witty totalling share december december share march simon dingemans totalling share december december nil share march total march include share ad vest element award performance share plan sell satisfy tax liability plan award page detail imon dingemans join board january holding disclose date nclude ad purchase glaxosmithkline stock fund retirement saving plan executive supplemental saving plan nclude share ad receive fee describe nonexecutive director share allocation plan dividend receive share ad convert share ad december tacey cartwright judy lewent joined board april holdings disclose date longterm incentive plan value ltis earn value ltis earn current executive director include amount vest gsk lti plan share option plan performance share plan relevant performance period end reporting year amount vest sharesave plan contract end year total analyse follow sir andrew witty moncef slaoui julian heslop total vest performance share plan award performance share plan award sharesave total gsk annual report share option plan award respect option grant share option plan sop remuneration receivable executive director calculate date option vest remuneration difference executive director require pay buy share ad total value share ad vest date executive director choose exercise option vest date exercise option time seven year subsequent increase decrease realise movement share ad price initial vest date date exercise increase decrease value result investment decision executive director record remuneration option outstanding december march movement period show table december december march option share exercise lapsed exercise lapsed sir andrew witty moncef slaoui julian heslop exercise option share market date number price gain date grant exercise share grant price exercise sir andrew witty moncef slaoui julian heslop sir andrew witty december december march option ad footnote exercised lapsed exercise lapsed moncef slaoui total ad slaoui include interest connect person employee gsk follow table show gain exercise option set analysed remuneration executive director subsequent gainslosse result investment decision market remuneration investment net date vest price date gainloss gain plan grant date vest exercise year sir andrew witty sop moncef slaoui sop julian heslop sharesave sop sop sir andrew witty sharesave gsk annual report governance remuneration report continue remuneration share option plan award continue option outstanding december early late vesting lapse date option market price glaxosmithkline share ad yearend give table weight average vest date lapse date sir andrew witty grant price number early latest early late total share option share option market price december vest weight average vest date lapse date moncef slaoui grant price number early latest early late share total share option share option market price december vest ad option market price yearend vest option market price yearend vest unvested total ad option december include ad option hold moncef slaouis connect person employee gsk weight average vest date lapse date julian heslop grant price number early latest early late total share option option market price december vest gsk grant share option executive director annual basis director hold option share option plan refer note financial statement employee share scheme nonexecutive director interest option company share highest low closing price year end december glaxosmithkline share ad respectively market price glaxosmithkline share december december glaxosmithkline ad december table set share option grant performance period performance target option vest december march performance target vest status annualise growth percentage grant footnote performance period december eps award vest february lapse rpi rpi rpi rpi rpi performance target vest status annualise growth percentage grant footnote performance period march december eps award vest february award lapse unvested rpi february award unveste unvested rpi rpi rpi rpi performance target share option meet result lapse anniversary date grant gsk annual report defer annual bonus plan award defer annual bonus plan dabp award executive director annually base individual voluntary bonus deferral election company match share ad oneforone depend company performance year performance period remuneration receivable respect matching share ad calculate share ad price date relevant dabp award vest sir andrew witty share performance period market price grant unvested december grant dividend reinveste unvested december grant dividend reinveste unvested march simon dingemans share performance period market price grant unvested december grant unvested march moncef slaoui ad performance period market price grant unvested december grant dividend reinveste unvested december grant dividend reinveste unvested march follow vest schedule apply dabp award award vest year subject relative tsr vest schedule give psp award award performance period vest criterion psp award give gsk annual report governance remuneration report continue remuneration performance share plan award performance share plan psp award executive director annual basis director hold award psp plan refer note financial statement employee share scheme remuneration receivable respect performance share calculate share ad price date relevant psp award vest sir andrew witty share performance period market price grant unvested december grant dividend reinveste vested lapse unvested december grant dividend reinveste vested lapse unvested march sir andrew witty vested share number share market price vest gain remuneration remuneration simon dingemans share performance period market price grant unvested december grant dividend reinveste unvested december grant dividend reinveste unvested march julian heslop share performance period market price grant unvested december dividend reinveste vested lapse unvested december dividend reinveste vested lapse unvested march julian heslop vested share number share market price vest gain remuneration remuneration gsk annual report performance share plan award continue moncef slaoui ad performance period market price grant unvested december grant dividend reinveste vested lapse unvested december grant dividend reinveste vested lapse unvested march moncef slaoui vested ad number ad market price vest gain remuneration remuneration term psp number share ad actually vest determined following end relevant performance period dependent gsk performance period committee adjust comparator group relative tsr remove scheringplough wyeth follow delisting revise vest schedule accordingly outstanding future awards relative tsr performance measure revise comparator group set dividend reinveste performance share ad award executive performance period date final award term psp participant defer receipt vested award follow vest schedule apply psp award business diversification performance vest schedule maximum performance express award award performance period percentage award vest percentage threshold new product performance vest schedule maximum performance express award award performance period percentage award vest percentage threshold adjust free cash flow vest schedule cash flow target award award performance period percentage award vest relative tsr vest schedule award award performance period tsr rank company percentage award vest median median commercial sensitivity target business diversification performance new product performance measure disclose outcome remuneration report gsk annual report governance remuneration report continue remuneration share value plan awards moncef slaoui ad market price unvested unvested unvested date december december march plan year grant grant vested vested executive director moncef slaoui eligible receive award share value plan award show reflect holding moncef slaouis connect person employee gsk award subject threeyear vest period vest contingent continue employment gsk gain arise vest include total remuneration moncef slaoui set pension benefit accrue annual pension benefit transfer value retirement executive director office year set company act require disclosure accrue benefit end year change accrue benefit year transfer value beginning end year change transfer value year fsa list rule require additional disclosure change accrue benefit net inflation transfer value change pension executive director disclose currency pension payable change transfer value accrue accrue change personal transfer transfer accrue change benefit benefit accrue contribution value value change benefit accrue december december benefit december december transfer year net benefit net executive director year year value inflation inflation sir andrew witty moncef slaoui moncef slaoui julian heslop show net contribution individual change accrue benefit show julian heslop exclude impact inflation sir andrew witty julian heslop participate glaxo wellcome final salary plan accrual rate final pensionable salary annum benefit accrue glaxo wellcome pension arrangement augment trustee plan reflect distribution surplus augmentation apply element sir andrew wittys julian heslop pension earning march transfer value sir andrew witty julian heslop calculate accordance pension regulation represent present value potential payment pension plan condition underlie calculation change particular yield indexlinke gilt change increase transfer value increase sir andrew witty increase julian heslop remain increase transfer value result increase valuation pension benefit accrue period sir andrew witty reduce period service assume retirement age julian heslop early retirement march simon dingemans join gsk january accumulate benefit gsk pension plan receive cash contribution lieu money purchase pension contribution moncef slaoui member executive cash balance pension plan plan provide executive pension credit gsk make annual contribution calculate percentage executive base salary gsk make contribution base pay fund increase interest rate set annually advance base year treasury bond rate provide cash sum retirement plan entitlement spouse pension pension increase transfer value cash sum increase moncef slaoui year result accumulation interest contribution pay company moncef slaoui active participant belgium fortis plan plan define benefit plan lump sum payable normal retirement age plan transfer value cash sum moncef slaouis plan increase year result accumulation interest gsk annual report moncef slaoui member retirement saving plan basis preparation saving scheme open employee executive supplemental saving plan saving scheme open executive remuneration report prepare accordance accrue benefit government limit impose company act large mediumsize retirement saving plan contribution plan invest company group account report regulation range fund value accumulate fund pay regulation meet relevant requirement fsa retirement listing rule accordance regulation follow section remuneration report subject audit director contribution pay emolument total remuneration nonexecutive director fee scheme gsk respect moncef slaoui longterm incentive plan include share option plan award director interest contract defer annual bonus plan award performance share plan awards share value plan award pension benefit describe note financial statement relate opinion thereon express party transaction end financial year remain section subject audit page director connected person material interest refer audit section remuneration contract significance group company report approve board director sign behalf director senior management information provide compensation interest director senior management group group purpose group define nonexecutive executive director members cet company secretary financial year total compensation sir crispin davis pay members group periods remuneration committee chairman serve capacity aggregate increase march accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad defer annual bonus plan share ad performance share plan share ad share value plan option grant member group share option plan notional share ad grant defer investment award plan member group award reinvestment dividend share ad performance share plan share ad defer annual bonus plan notional share defer investment award plan march group comprise person own share ad constitute issue share capital company group hold date option purchase share ad share ad award performance share plan include share ad vest defer vested defer ad legacy smithkline beecham midterm incentive plan share ad award share value plan share ad defer annual bonus plan notional share award deferred investment award plan holding issue executive share plan describe note financial statement employee share scheme gsk annual report financial statement statement director statement responsibility director statement responsibility relation business review page include fair review group financial statement development performance business position group description director responsible prepare annual report principal risk uncertainty face remuneration report group financial statement accordance applicable law regulation disclosure information auditor company law require director prepare financial director office date report statement financial year law director confirm require prepare group financial statement far aware relevant audit accordance international financial reporting standard ifrs information company auditor unaware adopt european union prepare group take step ought financial statement director elect comply take director aware ifrs issue international accounting standard relevant audit information establish company board iasb company law director approve auditor aware information group financial statement satisfied true fair view state affair group confirmation give interpret accordance profit loss group period provision section company act prepare financial statement director require go concern basis elect suitable accounting policy apply business review page contain information consistently performance group financial position cash flow net debt ake judgement accounting estimate position borrowing facility information include reasonable prudent treasury risk management policy exposure market credit risk hedging activity give note financial tate group financial statement comply ifrs statement financial instrument relate disclosure adopt european union ifrs issue iasb make enquiry director reasonable expectation subject material departure disclose explain group adequate resource continue operational group financial statement existence foreseeable future reason continue director responsible keep adequate accounting adopt go concern basis prepare financial statement record sufficient explain company internal control transaction disclose reasonable accuracy time financial position group enable ensure board audit risk committee review group financial statement remuneration report assessment risk internal control framework operate comply company act article ias gsk consider effectiveness system internal regulation responsible safeguard asset control operation group year cover report group take reasonable step date approval board directors prevention detection fraud irregularity corporate governance code group financial statement year end december board consider glaxosmithkline plc apply comprise principal statement support note set principle provision corporate governance code financial statement page report maintain financial reporting council describe responsibility auditor relation group financial corporate governance section page statement set independent auditor report comply provision disclose group financial statement year end december require financial service authoritys list rule include annual report publish hardcopy auditor consider director statement compliance print form available website director relation point corporate governance code responsible maintenance integrity annual report specify review website accordance legislation govern annual report preparation dissemination financial statement access website available outside comparable annual report year end december legislation different comprising report director remuneration report financial statement additional information investor current director name function approve board director sign list corporate governance section annual report behalf confirm good knowledge group financial statement prepare accordance ifrs adopt ifrs issue sir christopher gent iasb true fair view asset liability chairman financial position profit group march gsk annual report independent auditor report separate opinion relation ifrs issue iasb members glaxosmithkline plc explain note group financial statement audit group financial statement group addition comply legal obligation apply glaxosmithkline plc year end december ifrs adopt european union apply ifrs comprise consolidated income statement consolidate issue international accounting standard board iasb statement comprehensive income consolidate balance sheet consolidate statement change equity opinion group financial statement comply ifrs consolidated cash flow statement relate note issue iasb financial reporting framework apply opinion matter prescribe company preparation applicable law international financial reporting act standard ifrs adopt european union opinion information give director report respective responsibility director auditor financial year group financial statement explain fully director statement prepare consistent group financial statement responsibility set director responsible matter require report preparation group financial statement exception satisfied true fair view responsibility audit express opinion group report respect follow financial statement accordance applicable law company act require report international standard audit ireland opinion standard require comply auditing practice board ethical standard auditor ertain disclosure director remuneration specify law report include opinion prepare company member body accordance chapter receive information explanation company act purpose require audit give opinion accept assume list rule require review responsibility purpose person report show hand come save director statement set relation expressly agree prior consent write go concern scope audit financial statement corporate governance statement relate company compliance provision audit involve obtain evidence amount corporate governance code specify review disclosure financial statement sufficient reasonable assurance financial statement free material ertain element report shareholder board misstatement cause fraud error include director remuneration assessment accounting policy appropriate matter group circumstance consistently apply report separately parent company financial adequately disclose reasonableness significant statement glaxosmithkline plc year end accounting estimate director overall december information director presentation financial statement addition read remuneration report describe audit financial nonfinancial information annual report identify material inconsistency audit financial company pass resolution accordance section statement aware apparent material company act senior statutory misstatement inconsistency consider implication auditor state report opinion financial statement pricewaterhousecooper llp opinion group financial statement charter accountant statutory auditor true fair view state group affair london december profit cash flow year march end ave properly prepare accordance ifrs adopt european union prepare accordance requirement company act article las regulation gsk annual report financial statement financial statement consolidate income statement year end december result result result major major major major major major restructuring restructure total restructuring restructure total restructure restructure total note turnover cost sale gross profit sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny calculation result major restructuring describe note presentation financial statement consolidate statement comprehensive income year end december profit year exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement fair value movement subsidiary acquisition cash flow hedge reclassify goodwill actuarial loss define benefit plan defer tax actuarial movement define benefit plan share comprehensive expense associate joint ventures comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report result result result major major major major major major restructuring restructure total restructuring restructure total restructure restructure total note turnover cost sale gross profit sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny calculation result major restructuring describe note presentation financial statement consolidate statement comprehensive income year end december profit year exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement fair value movement subsidiary acquisition cash flow hedge reclassify goodwill actuarial loss define benefit plan defer tax actuarial movement define benefit plan share comprehensive expense associate joint ventures comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report financial financial statement continue statement consolidate balance sheet december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision derivative financial instrument noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity approve board march sir christopher gent chairman gsk annual report consolidate statement change equity year end december shareholder equity non share share retain control total capital premium earning reserve total interest equity january profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest change noncontrolle interest option noncontrolle interest dividend shareholder ordinary share issue ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive income year total comprehensive income year distribution noncontrolle interest dividend shareholder ordinary share issue ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expense year total comprehensive income year distribution noncontrolle interest dividend shareholder change noncontrolle interest forward contract relate noncontrolle interest ordinary share issue ordinary share purchase cancel hold treasury share ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report financial financial statement continue statement consolidated cash flow statement year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment purchase business net cash acquire investment associate joint venture proceeds disposal subsidiary interest associate decrease liquid investment interest receive dividend associate joint venture net cash outflow investing activity cash flow financing activity proceed share employee share option share acquire esop trust issue share capital purchase share cancellation hold treasury share increase longterm loan increase shortterm loan repayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder distribution noncontrolle interest finance cash flow net cash outflow financing activity decreaseincrease cash bank overdraft exchange adjustment cash bank overdraft begin year cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report note financial statement presentation financial presentation restructuring cost statement october board approve implementation detail formal plan gsk announce significant new description business operational excellence restructure programme glaxosmithkline major global healthcare group second formal plan represent significant expansion engage creation discovery development manufacture operational excellence programme approve board marketing pharmaceutical product include vaccine announce february expansion overthecounter otc medicine healthrelate consumer approve board announce february product gsk principal pharmaceutical product include restructure programme comprise detailed formal plan medicine follow therapeutic area respiratory cover area gsk business include manufacturing antiviral include hiv central nervous system cardiovascular sell infrastructure saving urogenital metabolic antibacterial oncology emesis identify year estimate total cost vaccine dermatological increase approximately billion expand compliance applicable law ifrs programme expect deliver annual pretax saving approximately billion time substantially complete financial statement prepare accordance give extent cost operational excellence company act article ias regulation programme management believe material impact international accounting standard ias international gsk operating result manner gsk financial reporting standard ifrs relate interpretation business conduct gsk present restructure cost adopt european union incur solely direct result operational excellence financial statement compliance ifrs issue programme separate column income statement title international accounting standard board major restructuring composition financial statement addition restructuring cost operational excellence programme major restructuring column income consolidate financial statement draw sterling statement include restructuring cost incur solely direct functional currency glaxosmithkline plc accordance result restructure programme follow relate ifrs accounting presentation financial statement material acquisition operation acquire comprise business overlap extensively gsk exist operation consolidated income statement restructuring activity follow relate consolidate statement comprehensive income acquisition nature undertake operational excellence programme carry consolidated balance sheet follow detailed formal plan management consider consolidated statement change equity appropriate present cost restructuring activity consolidate cash flow statement manner billion million acquisition reliant pharmaceutical december billion note financial statement billion acquisition stiefel laboratory july accounting convention acquisition october meet criterion set financial statement prepare historical acquisition cost incur cost convention modify revaluation certain item direct result related restructuring programme state accounting policy include major restructure column financial period group result cost operational excellence programme acquisitionrelate restructuring programme financial statement cover financial year january meeting criterion describe present december comparative figure financial separate column income statement describe year january december appropriate result major restructure presentation january december adopt clearly group result composition group cost restructure programme management believe presentation assist investor gain clear list subsidiary associate undertaking understand group financial performance opinion director principally affect profit making projection future financial performance result net asset group give note principal include cost virtue size nature limited group company comparative value presentation consistent way management assess group financial performance gsk annual report financial note financial statement continue statement presentation financial accounting principle policy statement continue consolidation restructuring cost arise solely direct result consolidated financial statement include operational excellence programme restructure asset liability result cash flow programme follow relate acquisition meeting company subsidiary include esop trust criterion describe continue report operating expense result major restructuring group share result net asset associate joint venture accounting principle policy preparation financial statement conformity financial statement entity consolidate generally accept accounting principle require management december year estimate assumption affect report entity group power govern amount asset liability disclosure contingent financial operating policy account subsidiary asset liability date financial statement group ability exercise joint control report amount revenue expense entity account joint venture group report period actual result differ estimate ability exercise significant influence account financial statement prepare accordance associate result asset liability group accounting policy approve board associate joint venture incorporate describe note accounting principle policy consolidate financial statement equity method information application accounting policy account include area estimation judgement give note interest acquire entity consolidate date key accounting judgement estimate appropriate group acquire control interest sell deconsolidate comparative figure reclassify ensure consistent date control cease presentation current year information transaction balance subsidiary eliminate implementation new accounting standard profit tax take sale subsidiary effect january gsk implement product sell customer outside group amendment ia financial instrument presentation relevant proportion profit transaction joint classification right issue ias revise relate party venture associate defer product disclosure minor amendment number sell party transaction noncontrolle interest accounting standard revision material impact record directly equity defer tax relief unrealise current period intragroup profit account extent consider recoverable parent company financial statement goodwill capitalise separate item case financial statement parent company glaxosmithkline subsidiary cost investment case plc prepare accordance gaap joint ventures associate goodwill denominate accounting presentation company balance sheet currency operation acquire present accounting policy give cost acquisition fair value net asset acquire difference recognise directly income statement business combination business combination account acquisition accounting method identifiable asset liability contingent liability acquire measure fair value acquisition date consideration transfer measure fair value include fair value contingent consideration cost acquisition charge income statement period incur equity subsidiary acquire noncontrolle interest recognise fair value noncontrolle interest share net asset subsidiary casebycase basis change group ownership percentage subsidiary account equity gsk annual report accounting principle policy expenditure continue expenditure recognise respect good service receive supply accordance contractual term foreign currency translation provision obligation exist future liability foreign currency transaction book functional respect past event obligation currency group company exchange rate ruling reliably estimate manufacturing startup cost date transaction foreign currency monetary asset validation achievement normal production liability retranslate functional currency rate expense incurred advertising promotion expenditure exchange rule balance sheet date exchange difference charge income statement incur shipment cost include income statement intercompany transfer charge cost sale distribution cost sale customer include sell general consolidation asset liability include related goodwill administrative expenditure overseas subsidiary associate joint venture translate sterling rate exchange rule balance restructuring cost recognise provide sheet date result cash flow overseas subsidiary appropriate respect direct expenditure business associate joint venture translate sterling reorganisation plan sufficiently detail average rate exchange advance appropriate communication affect undertaken exchange adjustment arise open net asset profit year retain overseas subsidiary research development associate joint venture translate sterling research development expenditure charge income exchange difference arise related foreign currency statement period incur development borrowing hedge group net investment expenditure capitalise criterion recognise operation take separate component equity asset meet usually regulatory filing translate sterling asset liability result major market approval consider highly probable cash flow overseas subsidiary associate joint venture property plant equipment research report currency hyperinflationary economy development capitalise depreciated accordance adjustment material reflect current price group policy level loss net monetary asset charge environmental expenditure consolidate income statement environmental expenditure relate exist condition result revenue past current operation current revenue recognise income statement good future benefit discernible charge income statement service supply available external customer group recognise liability sitebysite basis order receive title risk loss pass reliably estimate liability include group customer reliable estimate relevant deduction portion total cost portion potentially relevant obligation fulfil responsible party cost probable earning process regard complete able satisfy respective share cleanup obligation recovery reimbursement record asset turnover represent net invoice value deduction virtually certain discount allowance give accrual estimate future rebate return methodology assumption legal dispute estimate rebate return monitor adjust provision anticipate settlement cost legal regularly light contractual legal obligation dispute group outflow resource historical trend past experience project market consider probable reliable estimate condition market condition evaluate wholesaler likely outcome addition provision legal thirdparty analysis market research datum internally expense arise claim receive dispute generate information value add tax sale taxis respect product liability claim relate certain product exclude revenue sufficient history claim settlement group copromote product party enable management reliable estimate provision record sale group record share revenue require cover unasserted claim certain case incur copromotion income turnover nature report ibnr actuarial technique determine promotion activity group record cost estimate sale pharmaceutical turnover include copromotion revenue group involved legal proceeding respect million million million possible reliable estimate royalty income recognise operating income expect financial effect result ultimate accrual basis accordance term relevant resolution proceeding case appropriate licensing agreement disclosure case include provision cost associate claim group party charge income statement incur gsk annual report financial note financial statement continue statement accounting principle policy disposal ppe cost relate accumulate continue depreciation impairment remove financial statement net proceed take pension postemployment benefit income statement cost provide pension define benefit scheme lease calculate project unit credit method spread leasing agreement transfer group substantially period benefit expect derive benefit risk ownership asset treat employee service consistent advice finance lease asset purchase outright qualified actuary pension obligation measure asset include ppe computer software capital present value estimate future cash flow discount rate element leasing commitment show obligation reflect yield high quality corporate bond finance lease asset hold finance lease pension scheme asset measure fair value balance depreciate basis consistent similar own asset sheet date actuarial gain loss difference lease term short interest element lease rental expect actual return asset effect change include income statement lease operate actuarial assumption recognise statement lease rental cost charge income statement comprehensive income year arise straightline basis lease term group contribution define contribution plan goodwill charge income statement incur cost goodwill state cost impairment goodwill deem postemployment liability calculate similar way indefinite useful life test impairment annually define benefit pension scheme spread period benefit expect derive fair value interest acquire entitys asset employee service accordance advice qualified liability contingent liability exceed consideration pay actuary excess recognise immediately gain income statement employee share plan intangible asset incentive form share provide employee share option share award scheme intangible asset state cost provision amortisation impairment fair value option award calculate grant date blackschole option pricing model licence patent knowhow marketing right separately charge income statement relevant vest acquire acquire business combination period amortise estimate useful life generally exceed year straightline basis time group provide finance esop trust purchase company available use estimate useful life share open market meet obligation provide determine amortisation charge account patent share employee exercise option award cost life applicable value obtain run esop trust charge income statement period nonexclusivity asset life review share hold esop trust deduct reserve appropriate adjust annually contingent milestone payment transfer reserve retain earning recognise point contingent event vest period relate share option award certain development cost incur group reflect ultimate proceed receivable employee associate acquire licence patent knowhow exercise marketing right write income statement property plant equipment incur criterion recognition internally generate intangible asset meet usually regulatory property plant equipment ppe state cost filing major market approval purchase construction provision depreciation consider highly probable impairment financing cost capitalise cost qualifying asset construction acquire brand value independently fair value business acquire party brand depreciation calculate write cost residual value value substantial longterm brand ppe exclude freehold land straightline basis contractual legal nature sell separately expect useful life residual value life review rest business acquire brand amortise appropriate adjust annually normal expect estimate useful life year useful life major category ppe consider useful economic life indefinite freehold building year cost acquire develop computer software internal leasehold land use internet site external use capitalise intangible building lease term year fix asset software site support significant business plant machinery year system expenditure lead creation durable asset fixture equipment year erp system software amortise seven year computer software year gsk annual report accounting principle policy trade receivable continue trade receivables carry original invoice provision doubtful debt provision impairment noncurrent asset evidence risk nonpayment take account age carry value noncurrent asset review previous experience general economic condition impairment standalone basis large trade receivable determine uncollectable write cash generating unit indication asset firstly provision available income impair additionally goodwill intangible asset statement indefinite useful life intangible asset subsequent recovery amounts previously provide available use test impairment annually provision credit income statement longterm receivables impairment charge income statement year discount effect material concern trade payable impairment goodwill reverse impairment loss noncurrent asset reverse trade payable initially recognise fair value hold change estimate determine recoverable amount amortise cost equate nominal value longterm extent revise recoverable amount payable discount effect material exceed carry value exist net cash cash equivalent depreciation amortisation impairment cash cash equivalent comprise cash hand current recognise balance bank similar institution highly liquid investment associate joint venture investment generally maturitie month investment associate joint venture carry readily convertible know amount cash consolidate balance sheet group share net asset insignificant risk change value date acquisition postacquisition retain profit borrowing loss goodwill arise acquisition borrowing initially record proceed availableforsale investment receive net transaction cost borrowing subsequently liquid investment investment classify carry amortise cost difference availableforsale investment initially record fair proceed net transaction cost value plus transaction cost remeasure subsequent redemption recognise charge income reporting date fair value unrealised gain loss statement period relevant borrowing availableforsale investment recognise directly taxation comprehensive income impairment arise significant current tax provide amount expect pay prolong decline fair value equity investment reduce apply tax rate enact substantively carry asset directly charge enact balance sheet date income statement defer tax provide liability method disposal impairment investment gain temporary difference arise tax basis asset loss defer comprehensive income liability carry amount financial statement reclassify income statement dividend equity defer tax asset recognise extent probable investment recognise income statement future taxable profit available group right receive payment establish equity temporary difference utilise defer tax provide investment record noncurrent asset temporary difference arise investment subsidiary expect sell year associate joint venture time purchase sale equity investment account reversal temporary difference control trade date purchase sale availableforsale probable temporary difference reverse investment account settlement date foreseeable future defer tax provide rate tax inventory enact substantively enact balance sheet date defer tax liability asset discount inventory include financial statement low cost include raw material direct labour direct cost relate production overhead net realisable value cost generally determine basis prelaunch inventory hold asset high probability regulatory approval product point provision carry value recoverable provision reverse point high probability regulatory approval determined gsk annual report financial note financial statement continue statement accounting principle policy amount estimate fully reflect continue final outcome amount subject change dependent thing type buy group derivative financial instrument hedge product sale mix derivative financial instrument manage exposure level accrual review adjust regularly market risk principal derivative instrument gsk light contractual legal obligation historical trend past foreign currency swap interest rate swap forward foreign experience project market condition market condition exchange contract group hold issue derivative evaluate wholesaler thirdparty analysis financial instrument trade speculative purpose market research datum internally generate information future event cause assumption derivative financial instrument classify heldfortrading accrual base change affect future carry balance sheet fair value derivative result group designate hedge instrument classify inception cash flow hedge net investment hedge fair value hedge taxation change fair value derivative designate cash flow current tax provide amount expect pay hedge recognise comprehensive income defer tax provide temporary difference extent hedge effective ineffective portion tax basis asset liability carry amount recognise profit loss immediately amount defer rate enact substantively enact comprehensive income reclassify income balance sheet date statement hedge item affect profit loss defer tax asset recognise extent probable net investment hedge account similar way future taxable profit available cash flow hedge temporary difference utilise base management assumption relate amount time future taxable change fair value derivative designate fair value profit factor affect tax charge future year set hedge record income statement note taxation change group effective tax change fair value hedge asset liability rate change total tax charge year change fair value derivative instrument approximately million qualify hedge accounting recognise immediately group open tax issue number revenue income statement authority outflow fund believe probable discount reliable estimate outcome dispute management provide good estimate liability time effect money material balance estimate account specific circumstance discount current value appropriate rate interest dispute relevant external advice inherently unwind discount record finance income judgemental change substantially time new finance cost fact emerge dispute progress detail relate key accounting judgement significant unresolved dispute set note taxation gsk continue believe adequate provision estimate liability likely arise open assessment open prepare financial statement management require issue exist ultimate liability matter vary estimate assumption affect amount amount provide dependent outcome asset liability revenue expense report financial negotiation relevant tax authority necessary statement actual amount result differ litigation proceeding estimate follow consider key account legal dispute judgement estimate gsk provide anticipate settlement cost outflow turnover resource consider probable reliable estimate revenue recognise title risk loss pass likely outcome dispute legal customer reliable estimate relevant deduction expense arise claim group estimate relevant obligation fulfil account specific circumstance dispute earning process regard complete relevant external advice inherently judgmental change substantially time new fact emerge gross turnover reduce rebate discount allowance dispute progress detail status uncertainty product return give expect give vary involve significant unresolved dispute set note product arrangement buy group arrangement legal proceeding purchase organisation dependent submission claim time initial recognition sale accrual time sale estimate rebate discount allowance payable return base available market information historical experience gsk annual report key accounting judgement case valuation indicate sufficient headroom estimate continue reasonably possible change key assumption unlikely result impairment relate goodwill assumption company director take legal advice relate future cash flow discount rate base established provision take account relevant fact business forecast inherently judgemental circumstance matter accordance future event cause assumption accounting requirement respect product liability claim impairment test change consequent adverse effect relate certain product sufficient history claim future result group settlement enable management reliable intangible asset estimate provision require cover unasserted claim certain case incur report ibnr actuarial intangible asset acquire gsk party technique determine estimate group cost acquisition capitalise licence compound involved legal proceeding respect development amortise point possible reliable estimate expect financial available use estimate useful life effect result ultimate resolution include period nonexclusivity estimate useful life proceeding case appropriate disclosure review annually impairment test undertake event case include provision occur question carry value asset contingent liability quantify december brand acquire business capitalise independently provision legal dispute amount billion separable expect life billion year brand amortise straightline basis estimate useful life exceed year ultimate liability legal claim vary amount end useful economic life foresee brand provide dependent outcome litigation amortise subject annual impairment test proceeding investigation possible settlement negotiation position change time initial valuation valuation subsequent impairment assurance loss result outcome test base established market multiple riskadjuste legal proceeding exceed provision future cash flow estimate useful life asset report group financial statement material limited discount appropriate interest rate set note intangible asset assumption relate future cash flow estimate useful life discount rate property plant equipment base business forecast inherently set note property plant equipment judgemental future event cause assumption carry value property plant equipment test impairment review change consequent adverse impairment indication value effect future result group asset impaired impairment determine reference pension postemployment benefit high fair value cost sell value use measure assess riskadjuste future cash flow cost provide pension postemployment estimate useful life asset discount appropriate benefit charge income statement accordance interest rate ranges estimate useful life apply ias employee benefit period benefit category property plant equipment set derive employee service cost assess note accounting principle policy assumption basis assumption select management relate future cash flow estimate useful life discount assumption include future earning pension increase rate base business forecast inherently discount rate expect long term rate return asset judgemental give large number individual item mortality rate disclose note pension property plant equipment consider likely postemployment benefit reasonably possible change assumption apply expect long term rate return bond determine impairment test item lead material adverse base portfolio mix indexlinke government effect future result group future event corporate bond equity risk premium add cause assumption impairment test equity change consequent adverse effect future result discount rate derive rate corporate bond yield group country deep market corporate goodwill bond government bond yield sensitivity goodwill arise business combination capitalise analysis provide note pension post allocate appropriate cash generating unit deem employment benefit reduction discount indefinite life amortise rate lead increase net pension deficit approximately million increase annual pension annual impairment test relevant cash generating unit cost selection different assumption affect perform impairment test base established market future result group multiple riskadjuste future cash flow discount appropriate interest rate assumption impairment test set note goodwill gsk annual report financial note financial statement continue statement new accounting requirement amendment ias employee benefit issue june implement gsk january follow new amend accounting standard ifric amendment eliminate ability defer recognition gain interpretation issue iasb likely loss corridor method require remeasurement affect future annual report current form present comprehensive income require fund expect material impact result cost calculate net define benefit liability financial position group make minor accounting disclosure change amendment ifrs disclosure transfer financial amendment ifrs disclosure offset financial asset asset issue october implement financial liability issue december gsk january amendment require additional implement gsk january amendment disclosure risk exposure relate transfer require additional disclosure financial asset financial financial asset liability offset balance sheet iasbs annual improvement project publish amendment ia offset financial asset financial change effective january liability issue december implement project make minor amendment number standard gsk january amendment provide additional area include consolidation business combination guidance financial asset financial liability financial instrument offset follow new standard interpretation ifrs financial instrument issue november endorse amend october implement gsk january standard eventually amendment ias defer tax recovery underlie replace ias cover classification measurement asset issue december implement derecognition financial asset financial liability iasb gsk january amendment require intend expand ifrs add new requirement impairment defer tax nondepreciable asset measure hedge accounting complete revaluation model calculate sale basis replacement ia course ifrs consolidated financial statement issue exchange rate replace part ias separate financial statement previously deal consolidated financial group use average exchange rate prevail statement sic consolidation special purpose entity period translate result cash flow overseas implement gsk january standard subsidiary joint venture associate undertaking use control single basis determine sterling period end rate translate net asset entity consolidated undertaking currency influence ifrs joint arrangement issue translation relevant exchange rate implement gsk january standard require entity report share asset liabilitie revenue average rate expense joint operation financial statement apply equity method accounting joint venture euro consolidated financial statement yen ifrs disclosure interest entity issue implement gsk january period end rate standard require disclosure relate financial effect risk associate entitys investment subsidiary euro joint arrangement associate unconsolidate structured yen entity ifrs fair value measurement issue implement gsk january standard provide guidance fair value measurement introduce consistent disclosure requirement situation standard permit require fair value measurement amendment ia presentation item comprehensive income issue june implement gsk january amendment change require disclosure financial statement particularly respect statement comprehensive income gsk annual report segment information gsk revise segmental information disclosure reflect change internal reporting structure effect january pharmaceutical vaccines business japan show separate segment comparative information restate consistent basis gsk operating segment report base financial information provide chief executive officer responsibilitie corporate executive team cet individual member cet responsible geographic segment pharmaceutical vaccine business viiv healthcare consumer healthcare business respectively investment essential sustainability pharmaceutical business segment report usa europe emerge markets asia pacific japan pharmaceutical vaccine operating profit exclude allocation globally fund central cost principally corporate function unallocate manufacturing cost gsk management reporting process allocate intragroup profit product sale market sale record profit analysis present basis trading unallocated pharmaceutical vaccine include canada puerto rico central vaccine tender sale contract manufacturing sale cost vaccine central dermatology cost central manufacturing cost attribute segment pharmaceutical segment responsibility chairman research development report separate segment corporate unallocated cost disposal profit include corporate function cost legal matter fair value movement financial instrument investment profit global asset disposal restate restate turnover segment pharmaceutical vaccines usa europe emerge markets asia pacific japan viiv healthcare trading unallocated pharmaceutical vaccine turnover consumer healthcare turnover restate restate pharmaceutical vaccine turnover therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine dermatological viiv healthcare hiv consumer healthcare turnover category otc medicine oral healthcare nutritional healthcare gsk annual report financial note financial statement continue statement segment information continue pharmaceutical viiv healthcare sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler segment profit restate restate pharmaceutical vaccines usa europe emerge markets asia pacific japan viiv healthcare pharmaceutical trading unallocated cost pharmaceutical vaccine operate profit consumer healthcare operate profit segment profit corporate unallocated cost disposal profit operate profit major restructure major restructuring total operating profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year depreciation amortisation segment restate restate pharmaceutical vaccines usa europe emerge markets asia pacific japan viiv healthcare pharmaceutical trading unallocated pharmaceutical vaccine depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation depreciation amortisation major restructure major restructure total depreciation amortisation gsk annual report segment information continue ppe intangible asset goodwill impairment segment restate restate pharmaceutical vaccines usa europe emerge markets asia pacific japan viiv healthcare pharmaceutical trading unallocated pharmaceutical vaccine impairment consumer healthcare impairment segment impairment corporate unallocated impairment impairment major restructure major restructure total impairment ppe intangible asset impairment reversal segment restate restate pharmaceutical vaccines usa europe emerge markets asia pacific japan viiv healthcare pharmaceutical trading unallocated pharmaceutical vaccine impairment reversal consumer healthcare impairment reversal segment impairment reversal corporate unallocated impairment reversal impairment reversal major restructure major restructure total impairment reversal gsk annual report financial note financial statement continue statement segment information continue restate net asset segment pharmaceutical vaccines usa europe emerge markets asia pacific japan viiv healthcare pharmaceutical trading unallocated pharmaceutical vaccine net operating asset consumer healthcare net operating asset segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale net asset trade unallocated pharmaceutical segment include asset centrally manage pharmaceutical vaccine manufacture operation depreciation total million million million recover standard cost product charge business geographical information regard group country domicile restate restate turnover location customer usa rest world external turnover turnover location subsidiary usa rest world turnover include intersegment turnover usa rest world intersegment turnover usa rest world external turnover gsk annual report segment information continue operate profit location usa rest world total operating profit restate net operating asset location usa rest world net operating asset restate noncurrent asset location usa rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables major restructure programme october board approve implementation detail formal plan gsk announce significant new operational excellence restructure programme improve effectiveness productivity operation second formal plan represent significant expansion operational excellence programme approve board announce february expansion approve board announce february restructure programme comprise detailed formal plan cover area gsk business include manufacturing sell infrastructure saving identify year estimate total cost increase approximately billion expand programme expect deliver annual pretax saving approximately billion time substantially complete approximately programme cost incur december approximately expect incur majority balance incur total approximately cost expect cash expenditure expect asset writedown uncertainty exist exact time cash outflow result potential future exchange rate fluctuation element restructure programme subject employee consultation procedure make difficult predict precision procedure complete majority remain cash payment expect total restructuring cost million incur million incur operational excellence programme follow area cost saving project focus primarily simplification streamline support infrastructure include site rationalisation principally clinical imaging centre hammersmith harlow verona italy adoption customise sale approach lead staff reduction number sale force principally italy closure number manufacture site principally usa ireland give rise asset writedown staf reduction rationalisation consumer healthcare business project simplify eliminate process lead staff reduction administrative support function remain cost million incur year restructure programme relate integration stiefel laboratories inc business usa follow acquisition july gsk annual report financial note financial statement continue statement major restructuring programme continue analysis cost incur programme follow asset staff impairment reduction cost total cost sale sell general administration research development operating income effect operating profit net finance expense effect profit taxation effect taxation effect earning asset staff impairment reduction cost total cost sale sell general administration research development effect operate profit net finance expense effect profit taxation effect taxation effect earning asset staff impairment reduction cost total cost sale sell general administration research development effect operate profit net finance expense effect profit taxation effect taxation effect earning cost major restructuring programme arise follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise foreign exchange gain recognise liquidation subsidiary noncash charge cash cost net finance expense effect profit taxation asset impairment million million million noncash charge total million million million noncash item principally accelerate depreciation asset life shorten result major restructuring programme charge settle cash include termination lease site closure cost consultancy project management fee restructuring cost report major restructuring column income statement cost result minor restructuring activity initiate prior october amount million million income million cost amount report result major restructure gsk annual report operate income royalty income milestone income impairment equity investment disposal equity investment disposal business asset legal settlement gain recognise creation viiv healthcare fair value adjustment derivative financial instrument income royalty milestone income principally core recur income outlicense intellectual property disposal business asset legal settlement include cost million associate propose divestment noncore consumer healthcare brand cost report consolidated income statement major restructure programme operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal amortisation intangible asset impairment intangible asset goodwill net reversal net foreign exchange loss inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration fee payable company auditor associate audit parent company consolidated financial statement audit account group overseas subsidiary pursuant legislation assurance service pursuant legislation include attestation sarbanesoxley act audit assurance service tax service service include regulatory compliance treasury relate service december pricewaterhousecooper llp associate fee invoice million comprise statutory audit million taxation service million addition fee pay respect gsk pension scheme audit service gsk annual report financial note financial statement continue statement employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance cost sharebase incentive plan analyse follow share value plan performance share plan share option plan plan average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan finance income interest income arise cash cash equivalent availableforsale investment derivative fair value profit loss loan receivables realise gain liquid investment fair value movement derivative fair value profit loss derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest income arise derivative fair value profit loss relate swap interest income gsk annual report finance cost interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value movement derivative designate hedge instrument fair value adjustment hedge item fair value movement derivative fair value profit loss reclassification cash flow hedge comprehensive income unwind discount provision movement amount owe noncontrolle interest finance expense derivative fair value profit loss designate effective hedging instrument classify heldfor trade financial instrument ia interest expense arise derivative fair value profit loss relate swap interest expense associate joint ventures associate share tax profit quest diagnostic inc share tax profit aspen pharmacare holding limit share tax loss associate share tax loss joint venture share turnover joint venture sale joint ventures associate summarise income statement information respect group associate set total turnover quest diagnostic inc aspen pharmacare holding limit total profit quest diagnostic inc aspen pharmacare holding limited result aspen pharmacare holding limit include summarise income statement information represent estimate earning aspen group year result quest diagnostic inc summarise income statement represent estimate earning quest diagnostics inc february february gsk sell entire shareholding quest diagnostic inc gsk annual report financial note financial statement continue statement taxation taxation charge base profit year corporation tax statutory rate double taxation relief overseas taxation current taxation defer taxation reconciliation taxation rate group profit statutory rate taxation difference overseas taxation rate benefit special tax status credit intercompany stock profit impact share base payment tax profit associate reductionincrease tax rate recognisedunrecognise loss permanent difference prior year item disposal associate tax unremitte earning restructure tax rate disposal associate undertaking reflect impact disposal shareholde quest diagnostic inc high tax rate year end december reflect impact relatively low tax relief arise billion legal provision charge year nondeductability cost associate certain site closure partly offset settlement certain historical tax matter percentage reconciliation exacerbate relatively low report profit group operate country tax rate differ tax rate impact overseas taxis overall rate tax show profit arise certain operation singapore accord special status tax reduce rate compare normal rate tax territory effect reduction taxation charge increase earning share group require ifrs create defer tax asset respect unrealise intercompany profit arise inventory hold group yearend apply tax rate country inventory hold tax rate country profit originally tax pay practice gaap result difference accounting treatment group tax rate current period intercompany profit ifrs decrease increase increase arise change location workinprogress finished good tax item charge equity statement comprehensive income current taxation share base payment foreign exchange movement defer taxation share base payment define benefit plan fair value movement cash flow hedge fair value movement availableforsale investment total creditcharge equity statement comprehensive income item charge statement comprehensive income tax share base payment gsk annual report taxation continue issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax resolution issue continue fact life gsk year gsk agree settle open year major tax authority include january supreme court canada hear appeal gsk canadian revenue agency federal court appeal judgement respect gsk transfer pricing early judgement await gsk continue believe adequate provision liability likely arise period open agree tax authority ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate provision defer tax liability million respect taxation arise distribution profit retain certain overseas subsidiary provision ground group able control timing reversal remain temporary difference probable reverse forseeable future aggregate unremitte profit balance sheet date approximately billion billion unprovided defer tax unremitted earning december estimate million million relate taxis payable repatriation dividend withholding taxis levy overseas tax jurisdiction legislation relate company distribution provide exemption tax repatriate profit subject certain exception movement defer tax asset liability pension manu share accelerate intra post legal facture stock option net offset capital group employment tax restruct valuation award temporary allowance intangible profit benefit loss dispute ure adjustment scheme difference country total defer tax asset january defer tax liability january january exchange adjustment chargecredit income statement credit equity credit statement comprehensive income acquisition december defer tax asset december defer tax liability december defer tax credit income relate change tax rate million million million defer tax movement arise origination reversal temporary difference net temporary difference mainly include accrue expense tax deduction available pay basis gsk annual report financial note financial statement continue statement taxation continue tax loss recognise unrecognised trading loss expire year year available indefinitely december defer tax asset addition group capital loss december approximately billion billion respect defer tax asset recognise defer tax asset recognise probable future taxable profit available utilise loss factor affect tax charge future year global organisation factor affect future effective tax rate group mix profit different territory transfer pricing dispute tax authority location research development activity significant impact group effective tax rate change tax legislation territory gsk business operation impact group effective tax rate government propose significant change taxation system march government announce phase reduction main rate corporation tax year april defer tax movement reflect reduction tax rate effect april effect april substantively enact december government publish draft legislation introduce patent box regime enact apply reduce rate corporation tax income patent effect april government continue consult business draft legislation relate control foreign company expect affect gsk january earning share pence pence pence basic earning share adjustment major restructure basic earning share major restructuring dilute earning share adjustment major restructuring dilute earning share major restructure basic adjust earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust adjust earning share calculate result major restructure earning calculation result major restructuring describe note presentation financial statement dilute earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award diluted gsk annual report dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable pence paidpayable pence paidpayable penny interim july july july second interim october october october interim january january january fourth interim april april april annual total supplemental april total supplemental dividend board declare supplemental dividend penny share relate disposal certain noncore otc brand north america complete january pay time fourth interim dividend ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition addition business combination capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition addition business combination capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december gsk annual report financial note financial statement continue statement property plant equipment continue plant land equipment asset building vehicle construction total depreciation january exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december net book value december group land building comprise freehold property million million property lease year million million property lease year million million include land building december lease asset cost million million accumulate depreciation million million impairment million nil net book value million million include plant equipment vehicle december lease asset cost million million accumulate depreciation million million impairment million nil net book value million million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost sell value use value use calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate relevant specific risk impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately impairment loss charge cost sale million million million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale gsk annual report goodwill cost january exchange adjustment addition business combination note impairment loss cost december net book value january net book value december impairment loss year carry value goodwill translate yearend exchange rate balance arise acquisition follow business cash generating unit stiefel laboratories inc europe emerge market asia pacific pharmaceuticals vaccine biomedical corporation europe emerge markets asia pacific japan pharmaceutical vaccines reliant pharmaceuticals inc pharmaceuticals vaccines sirtris pharmaceuticals inc europe emerge markets asia pacific japan pharmaceuticals vaccines glaxosmithkline japan pharmaceutical vaccine pfizer hiv business viiv healthcare domantis limit europe emerge markets asia pacific japan pharmaceuticals vaccines cns inc consumer healthcare maxinutrition group holdings limited consumer healthcare polfa poznan europe pharmaceutical vaccine certain business ucb emerge market asia pacific pharmaceuticals vaccine laboratorios phoenix saicyf emerge market pharmaceutical vaccine novamin technology inc consumer healthcare goodwill arise acquisition stiefel allocate europe emerge market asia pacific pharmaceutical vaccine cash generating unit impairment testing purpose benefit acquire business expect arise business goodwill arise acquisition biomedical sirtris pharmaceuticals domantis split europe emerge markets asia pacific japan pharmaceutical vaccine cash generating unit impairment testing purpose benefit acquire business split cash generating unit acquire business generate independent cash flow gsk annual report financial note financial statement continue statement goodwill continue recoverable amount cash generating unit assess fair value cost sell basis group acquisition valuation model fair value cost sell cash generating unit goodwill allocate calculate net present value project riskadjuste posttax cash flow plus terminal value posttax discount rate apply calculate net present value cash flow discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific country currency risk detail relate discount cash flow model impairment test pharmaceutical vaccine consumer healthcare cash generating unit follow valuation basis fair value cost sell key assumption sale growth rate advertising promotion investment profit margin terminal growth rate discount rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change advertising promotion investment base historical level adjust management view support need innovation expansion terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate pharmaceutical vaccines europe pharmaceutical vaccines emerge market pharmaceutical vaccine asia pacific pharmaceuticals vaccines japan pharmaceuticals vaccines viiv healthcare pharmaceuticals vaccines consumer healthcare terminal growth rate exceed longterm project growth rate relevant market terminal growth rate fair value cost sell calculation cash generating unit reflect impact future generic competition account new product launch pharmaceutical vaccine cash generating unit comprise collection small cash generating unit include asset indefinite live carry value million million consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill gsk annual report intangible asset computer licence amortise indefinite life software patent etc brand brand total cost january exchange adjustment capitalise internal development cost addition business combination capitalise borrowing cost addition disposal asset writeoff reclassification cost december exchange adjustment capitalise internal development cost addition business combination capitalise borrowing cost addition disposal asset writeoff reclassification transfer asset hold sale cost december amortisation january exchange adjustment charge year disposal asset writeoff amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss disposal asset writeoff impairment december exchange adjustment impairment loss reversal impairment disposal asset writeoff transfer asset hold sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december gsk annual report financial note financial statement continue statement intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development include impairment nil million million arise major restructuring programme net book value computer software include million million internally generate cost licence patent etc include large number acquire licence patent knowhow agreement marketing right market use development net book value include million million internally generate cost impairment loss million million principally arise asset development long actively pursue note acquisition disposal give detail addition business combination year book value large individual item follow flulavalfluviral lovaza selzentry arzerra duac fraxiparine indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc number pharmaceutical brand acquisition stiefel laboratories inc book value major brand follow panadol sensodyne stiefel trade breathe right physiogel polident corega biotene poligrip solpadeine brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment apply fair value cost sell methodology generally year posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate country currency specific risk main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply nil management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment brand gsk annual report investment associate joint venture joint associate joint associated venture undertaking total venture undertakings total january exchange adjustment addition disposal transfer investment distribution receive movement lossprofit tax recognise consolidated income statement december group hold significant associate undertaking december december group own million share aspen pharmacare holding limit aspen list johannesburg stock exchange africa large pharmaceutical manufacturer major supplier brand generic pharmaceutical healthcare nutritional product southern african select international market investment book value december million million market value million million group hold ownership interest voting control aspen group ability exercise significant influence shareholding nominate director active participation aspen board director february gsk dispose entire shareholding quest diagnostic inc clinical laboratory business list new york stock exchange sale comprise secondary public offering accompany repurchase share quest diagnostic generate profit disposal million tax transfer investment relate group hold longwood founder fund previously classify investment summarise balance sheet information respect group associate set total asset quest diagnostic inc aspen pharmacare holding limit total liability quest diagnostic inc aspen pharmacare holding limit net asset summarise balance sheet information respect aspen pharmacare holding limit base preliminary result information analyst forecast available december investment joint venture comprise million share gross asset million million share gross liability million principally arise interest joint venture shionogiviiv healthcare holding develop specify chemical compound viiv healthcare shire canada primarily comarket combivir trizivir epivir certain territory viiv healthcare business investment joint venture include interest pharmaceutical insurance limit mutual insurance company cover pharmaceutical business risk gsk additional capital contribution million shionogiviiv healthcare holding million gsk annual report financial note financial statement continue statement investment january exchange adjustment addition net fair value movement impairment loss transfer investment associate joint venture disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument discount cash flow underlie net asset group hold number equity investment entity group enter research collaboration investment include list investment million million decrease primarily arise fair value adjustment impairment disposal investment fair value movement reclassify equity income statement base average cost share acquire different time impairment loss record table recognise income statement year operate income amount reclassify fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement investment include asset impaired follow original cost cumulative impairment recognise income statement subsequent fair value increase carry value december noncurrent asset amount receivable insurance contract pension scheme surplus receivables inventory raw material consumable work progress finish good gsk annual report trade receivable trade receivables net provision bad doubtful debt prepay pension contribution prepayment accrue income interest receivable employee loan advance receivables trade receivable include million million provision bad doubtful debt million provision million state hospital authority greece ireland italy portugal spain trade receivables include million million associate joint venture bad doubtful debt provision january exchange adjustment charge year subsequent recovery amount provide utilise december cash cash equivalent cash bank hand shortterm deposit asset hold sale land building plant equipment vehicle asset construction intangible asset inventory noncurrent asset transfer asset hold sale expect carry amount recover principally disposal sale consider likely hold low carrying fair value cost sell increase asset hold sale primarily arises transfer certain noncore consumer healthcare otc product group divesting impairment carrying value recognise transfer divestment design realise value shareholder simplify gsk consumer healthcare business allow focus priority brand market disposal north american otc brand complete january proceed million net profit disposal estimate approximately million tax net cash proceed expect million process divest remain noncore otc brand continue gsk annual report financial note financial statement continue statement trade payable trade payable wage salary social security payable defer income customer return rebate accrual accrual customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer principally usa accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption accrual base change affect future result group trade payable include million million associate joint venture pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service hybrid define benefit scheme include define contribution section gsk annual report pension postemployment benefit continue pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment expect rate return bond reflect portfolio mix indexlinke government corporate bond expect rate return equity represent group long term view include high risk premium bond past reflect current low bond yield project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust pca standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line medium cohort improvement recently observe high level assume continue minimum improvement year male females usa mortality rate calculate fully generational table project scale white collar adjustment average life expectancy assume individual age project apply individual age follow usa male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment group review investment strategy plan anticipate asset allocation plan adjust approximately return seek asset liability match asset target asset allocation plan currently return seek asset liability match asset define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme usa glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal usa group apply follow financial assumption assess define benefit liability usa rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate gsk annual report financial note financial statement continue statement pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial loss record statement comprehensive income postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial gainslosse record statement comprehensive income postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial lossesgain record statement comprehensive income amount include settlement curtailment include million million million augmentation cost arise major restructuring programme note provision total actuarial loss record statement comprehensive income january million gsk annual report pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise pension postemployment benefit pension scheme deficit postretirement benefit fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow usa rest world group average expect rate fair expect rate fair expect rate fair fair december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset december scheme purchase insurance contract guarantee payment specify pensioner liability include asset present value scheme obligation table value million million usa rest world group average expect rate fair expect rate fair expect rate fair fair december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report financial note financial statement continue statement pension postemployment benefit continue usa rest world group average expect rate fair expect rate fair expect rate fair fair december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset postretirement pension benefit usa rest world group group movement fair value asset asset january exchange adjustment expect return asset settlement curtailment actuarial gain employer contribution scheme participant contribution benefit pay acquisition asset december exchange adjustment expect return asset actuarial gain employer contribution scheme participant contribution benefit pay asset december exchange adjustment expect return asset actuarial lossesgain employer contribution scheme participant contribution benefit pay asset december define benefit scheme include define contribution section account balance total million december million million group special funding contribution pension scheme total million million million million million million scheme gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation additional contribution expect million year contribution base discount rate inflation assumption review contribution level progress base actuarial valuation december employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report pension postemployment benefit continue postretirement pension benefit movement define benefit obligation usa rest world group group obligation january exchange adjustment service cost interest cost settlement curtailment actuarial lossesgain scheme participant contribution benefit pay transfer provision obligation december exchange adjustment service cost interest cost settlement curtailment actuarial loss scheme participant contribution benefit pay obligation december exchange adjustment service cost interest cost settlement curtailment actuarial loss scheme participant contribution benefit pay obligation december unrecognised past service cost recognise balance sheet december define benefit scheme include define contribution section obligation total million december million million liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade pension postretirement healthcare scheme amend change result oneoff gain million recognise income statement december postretirement healthcare scheme obligation million million million accordance ias unvested benefit improvement recognise immediately balance sheet recognise gradually income statement december group unrecognise past service cost million million million primarily relate effect change postretirement healthcare scheme amount million million million define benefit pension obligation analyse follow fund unfunded postretirement benefit unfunded gsk annual report financial note financial statement continue statement pension postemployment benefit continue postretirement pension benefit history experience gain loss usa rest world group group experience lossesgain scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience gainslosse scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience gain scheme asset percentage scheme asset december experience gainslosse scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience loss scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience gain scheme asset percentage scheme asset december experience gainslosse scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficitssurpluse scheme gsk annual report pension postemployment benefit continue sensitivity analysis effect change assumption annual define benefit pension postretirement cost benefit obligation decrease discount rate follow approximate effect increase annual pension cost decrease annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation decrease expect rate return asset follow approximate effect increase annual pension cost increase rate future healthcare inflation follow approximate effect decrease annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation provision integration legal major employee restructuring relate manufacturing dispute programme provision reorganisation provision total january exchange adjustment charge year reverse unused unwind discount utilise transfer pension obligation reclassification movement december settle year settle year december gsk annual report financial note financial statement continue statement provision continue legal dispute group involve substantial number legal dispute include notification possible claim set note legal proceeding provision legal dispute include amount relate product liability principally relate avandia paxil poligrip antitrust principally relate wellbutrin flonase government investigation principally relate colorado investigation avandiarelate investigation awp nominal price investigation cidra puerto rico manufacturing settlement contract termination selfinsurance environmental cleanup property rental charge year million million net reversal estimate insurance recovery primarily relate provision relation product liability case paxil poligrip product government investigation discount provision decrease million million calculate riskadjuste project cash flow riskfree rate return movement include decrease million million arise change discount rate year respect product liability claim relate certain product sufficient history claim settlement enable management reliable estimate provision require cover unasserted claim certain case ibnr incur report actuarial technique determine estimate ultimate liability matter vary amount provide dependent outcome litigation proceeding investigation possible settlement negotiation nature group business number matter include provide ibnr actuarial technique subject negotiation litigation year litigation proceeding include appeal procedure year reach resolution outofcourt settlement discussion protract group potential settlement discussion number dispute amount provide base current assessment progress dispute estimate billion provide december settle year december expect million million provision legal dispute reimburse party insurer include receivables balance note noncurrent asset note trade receivables discussion legal issue note legal proceeding major restructuring programme october group announce significant new operational excellence programme improve effectiveness productivity operation note major restructure programme significant expansion operational excellence programme approve board announce february expansion approve board announce february saving identify year estimate total cost increase approximately billion expand programme expect deliver annual pretax saving approximately billion time substantially complete provision staff severance payment management formal decision eliminate certain position communicate group employee affect provision staff severance payment immediately pension augmentation arise staff redundancie million million charge year transfer pension obligation provision show note pension postemployment benefit asset write down recognise impairment property plant equipment note property plant equipment majority amount provide expect utilise year employee relate provision employee relate provision include certain medical benefit disabled employee spouse usa december provision benefit amount million million employee benefit reflect variety provision severance cost jubilee awards longservice benefit integration manufacture reorganisation provision integration manufacturing reorganisation reflect cost relate ongoing restructure programme include cost disclose note major restructuring programme provision include provision contingent consideration respect business acquisition principally stiefel laboratory inc contingent consideration payable certain criterion meet certain specified date future aggregate provision item amount million december million gsk annual report noncurrent liability accrual defer income payable contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december million million financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible reliable estimate potential outflow fund require settle dispute possibility outflow remote description significant tax legal dispute group party set note taxation note legal proceeding net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing bank loan overdraft obligation finance lease european medium term note london stock exchange european medium term note london stock exchange longterm borrowing european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange bank loan obligation finance lease net debt gsk annual report financial note financial statement continue statement net debt continue current asset liquid investment classify availableforsale investment december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float fix rate million million respectively million million effective interest rate cash cash equivalent december approximately approximately cash cash equivalent balance december earn interest float fix rate million million respectively million million gsk policy credit quality cash cash equivalent refer note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme billion billion issue december commit facility day duration billion billion billion billion renewable annually liquid investment cash cash equivalent show table weight average interest rate current bank loan overdraft december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year average effective preswap interest rate note december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range secure liability gsk loan secure charge noncurrent current asset year nil group pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation finance lease obligation december bear interest float fix rate million million respectively million million gsk annual report share capital share premium account share ordinary share premium number share capital authorise december december december share capital issue fully pay january issue employee share scheme december issue employee share scheme december issue employee share scheme share capital purchase cancel december december december number share issuable employee share scheme note number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme total million share purchase company cost million year million share cancel million share add treasury share monthly purchase share follow average share price exclude number share commission stamp duty february march april june july august september october november december total company expect share repurchase billion exact time purchase share hold treasury share cancel determined company dependent market condition factor share purchase period january february period february march million share purchase cost million detail substantial shareholding refer gsk annual report financial note financial statement continue statement movement equity retain earning reserve amount million december million million million million million relate joint venture associate undertaking cumulative translation exchange equity show follow table net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset reclassification exchange liquidation overseas subsidiary december exchange movement overseas net asset reclassification exchange liquidation overseas subsidiary december exchange movement overseas net asset reclassification exchange liquidation disposal overseas subsidiary december analysis comprehensive income equity category follows retain noncontrolle earning reserve interest total exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment reclassification cash flow hedge income statement actuarial loss define benefit plan defer tax actuarial movement define benefit plan share comprehensive expense associate joint ventures comprehensive expense year retain noncontrolle earning reserve interest total exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement cash flow hedge reclassify goodwill actuarial loss define benefit plan defer tax actuarial movement define benefit plan comprehensive income year gsk annual report movement equity continue retain noncontrolle earning reserve interest total exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement fair value movement subsidiary acquisition actuarial loss define benefit plan defer tax actuarial movement define benefit plan comprehensive expenseincome year analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total january transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust option noncontrolle interest december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust forward contract noncontrolle interest december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report financial note financial statement continue statement relate party transaction february gsk sell entire shareholding quest diagnostic inc sale comprise secondary public offering accompany repurchase share quest diagnostic generate profit disposal million gsk hold interest aspen pharmacare holding limit december gsk distribute million million product aspen extensive distribution network december balance gsk aspen million million balance payable gsk aspen million million gsk subsidiary viiv healthcare company shionogi ltd enter transaction joint venture company support research development activity conduct joint venture company viiv healthcare company provide service joint venture million million december balance viiv healthcare company joint venture million million december gsk hold interest viiv healthcare shire canada subsidiary viiv healthcare ulc primarily comarket combivir trizivir epivir certain territory december balance payable viiv healthcare shire canada million million aggregate compensation director cet give note employee cost adjustment reconcile profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance income net finance cost depreciation amortisation intangible asset impairment asset write profit sale intangible asset profit sale investment associate profit sale equity investment change work capital increasedecrease inventory decreaseincrease trade receivables increasedecrease receivables increase trade payable increasedecrease payable decreaseincrease pension provision sharebase incentive plan cash generate operation decrease pension provision primarily reflect legal settlement billion contribution define benefit pension scheme gsk annual report reconciliation net cash flow movement net debt net debt begin year decreaseincrease cash bank overdraft cash inflow liquid investment net increase longterm loan net increaserepayment shortterm loan net repayment obligation finance lease debt subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year analysis change net debt exchange reclassification acquisition cash flow liquid investment cash cash equivalent overdraft debt year eurobond mediumterm note debt year eurobond mediumterm note private financing net debt information significant change net debt note net debt gsk annual report financial note financial statement continue statement acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give acquisition year gsk complete subsidiary acquisition cash total purchase price million include million cash acquire fair value book value adjustment fair value net asset acquire intangible asset property plant equipment trade receivables asset include cash cash equivalent defer tax provision liability goodwill investment associate convert subsidiary total consideration acquisition beginning year estimate group turnover increase million year subsidiary fully integrate gsk business practicable separately identify impact acquisition group profit year goodwill arise acquisition reflect potential business synergy sale growth increase gsk market presence follow acquisition business addition goodwill million recognise respect fair value adjustment prior year acquisition goodwill recognise expect deductible income tax purpose result acquisition report consumer healthcare emerge market reportable operating segment group recognise loss million result remeasure fair value associate hold prior acquisition date loss report loss disposal interest associate income statement acquisition cost expense arise acquisition total million investment joint venture gsk cash contribution million joint venture group share cash investment associate total million transfer million equity investment associate group increase share disposal gsk dispose subsidiary cash outflow disposal million net cash dispose february gsk dispose entire shareholding quest diagnostic inc clinical laboratory business list new york stock exchange sale comprise secondary public offering accompany repurchase share quest diagnostic generate profit disposal million tax associate joint cash flow acquisition venture total total cash consideration cash cash equivalent acquire cash consideration net cash acquire net cash consideration pay deferred consideration cash consideration net cash acquire net cash outflowproceed disposal net cash dispose gsk annual report acquisition disposal continue acquisition laboratorios phoenix sacyf june gsk acquire issue share capital laboratorios phoenix sacyf leading pharmaceutical business focus development marketing sale brand generic overthecounter product latin america cash purchase price million include million net cash million intangible asset million goodwill million net liability goodwill arise acquisition business reflect potential business synergy sale growth increase gsk market presence follow acquisition establish market participant goodwill recognise expect deductible income tax purpose result phoenix report emerge market operating segment transaction account purchase method accounting proforma result laboratorios phoenix cyf year turnover million loss tax major restructuring million acquisition gsk record turnover million tax loss major restructuring million business transaction cost expense arise acquisition laboratorio phoenix sacyf amount million fair value book value adjustment fair value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration acquisition year gsk complete small subsidiary acquisition cash total purchase price million include million net cash fair value book value adjustment fair value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill fair value gain recognise conversion associate subsidiary total consideration acquisition beginning year estimate group turnover increase million year subsidiary fully integrate gsk business practicable separately identify impact acquisition group profit year gsk annual report financial note financial statement continue statement acquisition disposal continue acquisition continue goodwill arise acquisition reflect potential business synergy sale growth increase gsk market presence follow acquisition establish market participant addition goodwill million recognise respect consideration prior year acquisition goodwill recognise expect deductible income tax purpose result acquisition report primarily emerge market reportable operating segment group recognise gain million result measure fair value associate hold prior acquisition date gain report profit disposal interest associate income statement acquisition cost expense arise acquisition total million investment joint venture gsk cash noncash contribution million joint venture group share million joint venture group share investment associate million increase group share investment associate total million associate joint phoenix acquisition venture total cash flow total cash consideration cash cash equivalent acquire cash consideration net cash acquire net cash consideration pay deferred consideration cash consideration net cash acquire acquisition certain business ucb march group acquire ucb market product portfolio certain territory africa middle east asia pacific latin america include lead pharmaceutical brand number disease area subsequent date group complete country acquisition form original transaction purchase price million include million net cash million intangible asset million goodwill million net liability goodwill arise acquisition business reflect potential product growth region expect synergies group transaction account purchase method accounting transaction include acquisition number legal entity product right previously market outside entity product portfolio acquire integrate gsk business acquisition practicable identify result tax arise result transaction period acquisition prior acquisition estimate product portfolio record turnover million acquisition gsk record turnover million product acquire book fair value fair value adjustment value net asset acquire intangible asset property plant equipment cash cash equivalent defer tax provision liability goodwill total consideration gsk annual report acquisition disposal continue acquisition continue stiefel laboratories inc july group acquire share capital stiefel laboratory inc world large private dermatological company cash consideration million net cash acquire include million debt repay acquisition purchase price million include contingent cash consideration million payable certain criterion meet specify date future include million cash cash equivalent million intangible asset million goodwill represent potential additional growth combination stiefel business gsk exist dermatology portfolio million net liability purchase price include potential obligation additional payment million million depend future performance certain product stiefel laboratory inc turnover million loss tax include restructuring cost million year end december million turnover million loss tax include restructuring cost relate period acquisition include group account acquisition stiefel operating profit million restructuring cost intangible asset amortisation business provide significant opportunity sale cost synergy stiefel product benefit gsk global distribution commercial organisation particularly market brazil russia india china japan gsk product benefit stiefel speciality sale force relationship experience management dermatology cost synergies business expect primarily combine manufacture administrative function previously report gsk expect deliver annual pretax cost saving million restructuring cost approximately million exclude restructuring cost stiefel acquisition result dilution gsk earning share book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration viiv healthcare limited october gsk acquire pfizer inc hiv business combine hiv business form viiv healthcare limited subgroup own gsk pfizer consideration give gsk represent net value gsk hiv business contingent consideration transaction cost value million represent million intangible asset million defer tax liability million net asset million increase noncontrolle interest million goodwill represent economy scale gain combination business potential growth partner hiv product viiv healthcare noncontrolle interest represent pfizer interest viiv healthcare include right preferential dividend base sale performance certain product gsk recognise accounting gain million transaction arise disposal interest gsk hiv business pfizer record book value return pfizer hiv business record fair value gsk annual report financial note financial statement continue statement acquisition disposal continue acquisition continue acquire pfizer hiv business turnover million loss tax million take account transition status territory million turnover million loss tax include restructuring cost recognise group account book fair value fair value adjustment value net asset acquire intangible asset asset include cash cash equivalent defer tax provision noncontrolle interest goodwill total consideration consideration fair value asset contribute gsk fair value contingent equity contribute gsk direct cost total consideration acquisition investment year include million subsidiary million joint venture group share million associate group initial share certain stiefel business laboratorie cash flow ucb inc total cash consideration cash cash equivalent acquire net cash consideration contingent consideration net purchase consideration acquisition subsidiary beginning year estimate group turnover increase million year acquisition fully integrate gsk business practicable separately identify impact acquisition group profit year gsk annual report commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment business combination pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount number commitment licensing agreement include arrangement theravance inc janssen biologics ireland new arrangement offset reduced commitment prior year transaction include amendment agreement anacor pharmaceuticals inc concert pharmaceuticals inc chroma therapeutics inc oncome pharmaceuticals inc tolerx inc mpex pharmaceuticals inc terminate year gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation table show commitment exclude normal ongoing annual funding requirement approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease post balance sheet event january gsk complete disposal noncore north american otc brand proceed million january gsk copromotion agreement vesicare astellas pharma inc terminate result gsk recording cumulative income attributable performance brand quarter approximately million million turnover gsk annual report financial note financial statement continue statement financial instrument relate expect deliver continue dividend growth disclosure longterm share buy programme target share repurchase billion depend market condition glaxosmithkline plc report sterling pay dividend net debt increase year billion sterling profit role corporate treasury manage billion december billion december monitor external internal funding requirement group positive cash generation cash holding financial risk support strategic objective treasury largely sufficient finance group acquisition activity govern policy procedure approve dividend share buyback payment legal cost year board director recently july gsk operate global basis primarily subsidiary treasury management group tmg meeting chair company establish market trade chief financial officer take place monthly basis review manage capital ensure subsidiary able treasury activity member receive management information operate go concern optimise return shareholder relate treasury activity internal audit review treasury appropriate balance debt equity internal control environment regularly liquidity risk gsk use variety financial instrument finance operation derivative financial instrument manage risk gsk policy borrow centrally order meet anticipate operation derivative principally comprise forward funding requirement cash flow forecast fund foreign currency contract interest rate currency swap requirement monitor tmg monthly basis swap borrowing liquid asset currency require european medium term note programme billion group purpose manage exposure funding risk december billion note issue change foreign exchange rate interest rate programme shelf registration statement gsk hold issue derivative speculative purpose december billion billion note treasury policy specifically prohibit activity issue programme transaction financial instrument undertake manage december gsk borrowing billion risk arise underlie business activity speculation repayable year gsk longterm borrowing mature capital management date longterm debt rating remain unchanged february currently gsk rate gsk financial strategy regularly review board gsk stable outlook standard poor stable outlook manage capital structure group appropriate moodys investor service moodys shortterm debt rating mix debt equity deliver good return shareholder standard poor moodys respectively whilst maintain credit rating maximise flexibility access debt capital market attractive term gsk access shortterm finance billion commercial paper programme billion commit capital structure group consist net debt facility facility renew october billion note net debt shareholder equity increase billion billion time consider billion consolidated statement change equity level commit facility adequate give current total capital include provide non liquidity requirement information facility control interest billion billion refer note net debt allocate capital deliver good return commit facility gsk substantial cash shareholder commitment use free cash flow support cash equivalent liquid investment amount dividend undertake share repurchase return billion december review cash attractive invest bolton acquisition investment opportunity balance relative debt portfolio source debt continue assess strict financial criterion access order improve efficiency balance significant level patent trademark protection sheet result intend reduce effective net funding pharmaceutical product compete largely product efficacy cost maintain low level cash diversify differentiation sell margin sufficient cover normal source funding give current low interest rate environment operating cost operation continue highly cash market risk generative net cash inflow operating activity billion free cash flow billion interest rate risk management return free cash flow asset disposal gsk objective reduce effective net interest cost proceed shareholder balance dividend share rebalance mix debt fix float interest rate time buyback pay billion dividend complete policy interest rate risk management limit billion share repurchase longterm float interest payment prescribe percentage trading profit programme alongside elect use series interest rate swap redenominate return net proceed sale noncore north bond float interest rate duration swap american otc brands shareholder payment match duration principal instrument interest rate supplemental dividend derivative instrument account fair value cash flow hedge relevant asset liability gsk annual report financial instrument relate disclosure continue foreign exchange risk management foreign currency transaction exposure arise internal external trade flow hedge exposure overseas operating subsidiary transaction risk minimised match local currency income local currency cost purpose internal trading transaction match centrally manage intercompany payment term reduce foreign currency risk exceptional foreign currency cash flow hedge selectively management corporate treasury tmg possible manage cash surplus borrowing requirement subsidiary company centrally forward contract hedge future repayment originate currency order reduce foreign currency translation exposure seek denominate borrowing currency principal asset cash flow primarily denominate dollar euro sterle certain borrowing swap currency require borrowing denominate swap foreign currency match investment overseas group asset treat hedge relevant asset forward contract major currency reduce exposure investment overseas group asset net investment hedge section note detail tmg review ratio borrowing asset major currency monthly credit risk group consider maximum credit risk million million total group financial asset exception investment bear credit risk detail group total financial asset gsk great concentration credit risk billion investment treasury treasury repo money market fund fund aaaaaa rate moodys standard poor respectively bear credit exposure government aaa rate moodys standard poor respectively great concentration credit risk billion morgan chase aaaa rate time moodys standard poor respectively comprise billion invest deposit billion derivative treasuryrelate credit risk gsk manage exposure credit risk actively recent financial crisis reduce surplus cash balance particular middle east africa europe treasury strategy regionalise cash management concentrate cash centrally possible gsk continue maintain conservative approach counterparty risk period report relationship bank credit rating present annually tmg approval aggregate credit risk respect financial instrument group counterparty limited reference longterm credit rating assign counterparty moodys standard poor table set credit rating counterpartie liquid investment cash cash equivalent derivative gross asset position derivative contract consider purpose table isda contract risk net position counterparty million invest baabbb rate investment include proportion gsk indian asset bank deposit hdfc bank state bank india indian government bond counterpartie local cash management purpose local investment purpose gsk sole shareholder million invest babb rate counterpartie comprise bank balance hold operating company overseas credit rating counterparty aaaaaa aaaa aaaa aaaa aabaabbb baabbb baabbb babb babb total bank balance deposit treasury treasury repo money market fund corporate debt instrument government security party financial derivative total credit rating counterparty aaaaaa aaaa aaaa aaaa aabaabbb baabbbbaabbb babb babb total bank balance deposit treasury treasury repo money market fund corporate debt instrument government security party financial derivative total credit rating table assign moodys standard poor respectively opinion rating agency differ gsk assign low rating counterparty local rating agency datum source available rating convert global rating equivalent moodys investor service standard poor publish conversion table gsk annual report financial note financial statement continue statement financial instrument relate follow method assumption estimate disclosure continue fair value cash cash equivalent approximate centrally manage cash reserve amount billion carrying december available month exclude billion centrally manage cash hold viiv healthcare iquid investment base quote market price own subsidiary group invest centrally manage calculate base observable input case marketable liquid asset bank deposit aaaaaa rate treasury security base principal amount case non treasury repo money market fund note bear marketable security short repricing period credit exposure government aaaaa rate ther investment investment trade active market global counterparty limit assign gsk banking determine reference relevant stock exchange quote investment counterpartie base longterm credit rating bid price investment determine reference moodys standard poor corporate treasury usage current market value similar instrument reference limit monitor daily corporate compliance officer discount cash flow underlie net asset cco operate independently corporate treasury hortterm loan overdraft approximate carry breach limit report cfo immediately short maturity instrument cco monitor credit rating counterpartie change rating occur notifie corporate treasury ongterm loan base quote market price case change investment level authority eurobond fix rate borrowing approximate limit appropriate carrying case float rate bank loan loan wholesale retail credit risk orward exchange contract base market data usa line pharmaceutical company exchange rate balance sheet date group sell product small number wholesaler addition hospital pharmacie physician group currency swap base market datum balance sale large wholesaler approximately sheet date group pharmaceutical vaccine turnover nter rate swap base net present value december group trade receivable discount cash flow wholesaler total million million group expose concentration credit eceivable payable approximate risk respect wholesaler carrying encounter financial difficulty materially ompanyowne life insurance policy base cash adversely affect group financial result surrender value group credit risk monitoring activity relate ease obligation approximate carry wholesaler include review quarterly financial information standard poor credit rating development gsk internal fair value investment gsk share risk rating establishment periodic review credit limit december employee share ownership plan group believe credit risk provision esop trust held gsk share carry value million require excess normal provision bad doubtful million fair value million debt note trade receivables outside million base quote market price share usa customer account group represent purchase esop trust satisfy future exercise trade receivable balance option award employee incentive scheme fair value financial asset liability carry value low cost expect proceed share recognise deduction table present carry amount reserve december gsk hold treasury fair value group financial asset liability share cost million million december december deduct retain earning fair value financial asset liability include commit facility instrument exchange current transaction willing party force group commit facility billion billion liquidation sale billion billion renewable annually facility renew october december undrawn gsk annual report financial instrument relate disclosure continue carry fair carry fair value value value value cash cash equivalent availableforsale investment liquid investment government bond total liquid investment investment loan receivables trade receivables certain noncurrent asset scope ia financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia total financial asset financial liability measure amortise cost borrowing bond designate hedge relationship bond bank loan overdraft obligation finance lease total borrowing trade payable provision noncurrent liability scope ia financial liability fair value profit loss derivative designate fair value profit loss derivative classify hold trading ia total financial liability net financial asset financial liability trade receivable certain noncurrent asset trade payable provision noncurrent liability reconcile relevant note financial asset liability classify measure fair value balance sheet valuation methodology describe categorise derivative balance analyse instrument type hedge programme gsk annual report financial note financial statement continue statement financial instrument relate disclosure continue follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss derivative designate fair value profit loss derivative classify held trading ias level level level total december financial asset fair value availableforsale financial asset liquid investment investment financial asset fair value profit loss noncurrent asset derivative designate fair value profit loss derivative classify hold trading ia financial liability fair value financial liability fair value profit loss derivative designate fair value profit loss derivative classify hold trading ia movement year financial instrument measure level valuation method present january loss recognise income statement gainslosse recognise comprehensive income addition disposal transfer level exchange december net loss million million attributable level financial instrument hold end year report operate income transfer level million million relate equity investment list stock exchange transfer investment associate year reasonably possible change assumption unlikely result material change fair value level instrument gsk annual report financial instrument relate disclosure continue trade receivables noncurrent asset scope ias follow table reconcile financial asset trade receivables noncurrent asset fall scope ia relevant balance sheet amount financial asset predominantly noninterest earn financial instrument noncurrent asset balance include companyowne life insurance policy asset include tax receivables pension surplus balance prepayment outside scope ias financial financial asset asset fair value fair value loan financial loan financial profit loss receivables instrument total profit loss receivables instrument total trade receivable note noncurrent asset note follow table show age financial asset past provision bad doubtful debt past day past day past day past day past day amount past great day provision bad doubtful debt total million million balance million million relate receivable state hospital authority greece ireland italy portugal spain total receivable state hospital authority country current past net provision million million trade payable provision noncurrent liability scope ias follow table reconcile financial liability trade payable provision noncurrent liability fall scope ia relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability liability include payment account tax social security payable provision constitute contractual obligation deliver cash financial asset outside scope ia financial financial instrument total instrument total trade payable note provision note noncurrent liability note gsk annual report financial note financial statement continue statement financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt effect interest rate swap maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease effect effect interest interest debt rate swap total debt rate swap total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bearing group hold interest rate swap designate fair value hedge convert million fix rate debt maturity year million maturity year float rate exposure sensitivity analysis sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation place december financial instrument affect market risk include borrowing deposit derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change relevant foreign exchange interest rate foreign exchange sensitivity table group sensitivity foreign exchange rate dollar euro yen financial instrument exclude obligation finance lease certain nonderivative financial instrument net debt present material exposure currency major foreign currency gsk financial instrument denominate gsk consider movement currency year conclude cent yen movement rate gbp reasonable benchmark table financial instrument consider sensitive foreign exchange rate functional currency entity hold intercompany loan fully hedge maturity currency swap exclude analysis increase reduction increase reduction nonfunctional currency foreign exchange exposure income equity income equity cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation state currency equal opposite effect movement income statement relate primarily hedge instrument legal provision trade payable trade receivables whilst hedge instrument provide economic hedge relate provision financial instrument include table combine sensitivity hedge instrument provision insignificant provision include movement equity relate foreign exchange position hedge group asset denominate euro movement value currency swap largely offset correspond opposite movement group asset foreign exchange sensitivity group asset financial instrument include gsk annual report financial instrument relate disclosure continue table present group sensitivity foreign exchange rate base composition net debt increasedecrease increasedecrease impact foreign exchange movement net debt net debt net debt cent appreciation dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation state currency equal opposite effect interest rate sensitivity table show group sensitivity interest rate float rate sterling dollar euro financial instrument currency gsk historically issue debt hold investment gsk consider movement interest rate year conclude basis point increase reasonable benchmark debt maturity year float rate calculation interest rate movement derivative financial instrument designate fair value hedge deem immaterial effect group income statement compensating amount carry value debt basis point movement interest rate deem material effect equity increasedecrease increasedecrease income income basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate interest rate decrease currently maximum increasedecrease income limit million million million sterling dollar euro interest rate respectively million million million contractual cash flow nonderivative financial liability derivative instrument follow analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis impact interest rate swap exclude purpose table debt define class borrowing obligation finance lease interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december finance charge trade payable obligation obligation interest finance finance liability december debt debt lease lease net debt total year year year year year year great year gross contractual cash flow finance charge trade payable obligation obligation interest finance finance liability december debt debt lease lease net debt total year year year year year year great year gross contractual cash flow gsk annual report financial note financial statement continue statement financial instrument relate disclosure continue follow table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument amount receivable payable year increase compare high level hedge inter company loan deposit legal provision indicate increase principal amount show table receivables payable receivables payable year year year year gross contractual cash flow derivative financial instrument hedge programme follow table set fair value derivative hold gsk fair value fair value asset liability asset liabilitie fair value hedge interest rate swap principal million million net investment hedge foreign exchange contract principal million million derivative designate fair value profit loss foreign exchange contract principal million million embed derivative derivative classify hold trading ia total derivative instrument analyse current noncurrent total derivative financial instrument principal foreign exchange contract absolute total outstanding position balance sheet date majority contract period month december group hold outstanding foreign exchange contract consist primarily currency swap net credit fair value million million credit represent hedge intercompany loan deposit legal provision designate accounting hedge change fair value take income statement period offset exchange gain loss relate intercompany lending borrowing cash flow hedge group designate cash flow hedge group carry balance reserve arise prehedge interest rate exposure euro sterling bond issue balance reclassify finance cost life bond gsk annual report financial instrument relate disclosure continue fair value hedge group designate series interest rate swap fair value hedge risk hedge variability fair value bond arise interest rate fluctuation gain loss fair value hedge disclose note finance cost net investment hedge year certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment euro foreign operation foreign exchange contract designate net investment hedge group net investment dollar yen foreign operation december december group hold net investment hedge respect euro foreign operation addition euro loan capital billion issue previous year designate net investment hedge respect foreign currency translation risk arise consolidation group net investment euro operation employee share scheme group operate share option scheme option grant employee acquire share ad glaxosmithkline plc grant price savingsrelate share option scheme share award scheme addition gsk operate performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period grant restrict share award replace grant option employee cost scheme readily equate potential gain employee onwards grant savingsrelated share option scheme grant share option scheme normally exercisable year date grant grant restrict share share award normally exercisable end year vestingperformance period grant savingsrelate share option scheme normally exercisable year save grant share option scheme award performance share plan normally grant employee acquire share ad gsk plc circumstance settle cash option share option scheme grant market price ruling date grant accordance practice majority option savingsrelate share option scheme grant price market price ruling date grant share option award director effect grant cet subject performance criterion option pricing purpose value option award arrive share base payment charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year year savingsrelate share option share award scheme year year year weight average share price grant year share ad plan dividend reinveste volatility determine base year share price history appropriate fair value performance share plan grant account market condition expect life option determine base weighted average historic exercise option gsk annual report financial note financial statement continue statement employee share scheme continue share option share option savingsrelate option outstanding scheme share scheme ad share option scheme weight weight weight weight weight weight number exercise fair number exercise fair number exercise fair price value price value price value january option grant option exercise option lapse december option grant option exercise option lapse december option grant option exercise option lapse december range exercise price weight average market price exercise weight average remain contractual life year year year share option share option savingsrelate option outstanding scheme share scheme ad share option scheme december weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option normally exercisable year date grant certain circumstance vest early set scheme rule change effective exercise price outstanding option year share option share option savingsrelate option exercisable scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december december december gsk annual report employee share scheme continue glaxosmithkline share award scheme performance share plan group operate performance share plan award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant onwards director member cet performance condition base equally weight measure year performance period measure base achievement adjust free cash flow target second measure base relative tsr performance comparator group remain measure base businessspecific performance measure business diversification new product performance detail calculation measure remuneration report page award grant director member cet award base achievement adjust free cash flow target year measurement period remain award base relative tsr performance comparator group describe page half tsr element award measure year half year award grant director member cet prior subject single performance condition compare gsk tsr period tsr company comparator group period award eligible employee prior performance condition consist part apply award performance condition compare gsk ep growth increase retail price index year measurement period second performance condition compare gsk tsr period tsr company comparator group period award grant onwards performance condition continue base eps second performance condition base strategic operational business measure year measurement period specific employee business area share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december year additional share additional ad award dividend reinveste share value plan group operate share value plan award grant form share certain employee cost award vest year performance criterion attach share weight ad weight number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december gsk annual report financial note financial statement continue statement employee share scheme continue defer investment award plan group operate defer investment award plan award grant form notional share certain senior executive cost award typically vest threeyear period commence fourth anniversary date grant award initially vest subsequent year performance criterion attach share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december year additional share additional ad award dividend reinveste employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share open market finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve hold value proceed receivable employee exercise deem permanent diminution value reflect transfer retain earning trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group december detail give principal country operation location headquarters business sector business activity equity share capital undertaking wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch brentford glaxosmithkline holding limited phch brentford glaxosmithkline service unlimited phch brentford glaxosmithkline mercury limit brentford glaxosmithkline finance plc phch brentford glaxosmithkline capital plc phch brentford smithkline beecham limited phch brentford wellcome limited phch brentford glaxo group limit brentford glaxo operation limit brentford glaxosmithkline export limit brentford glaxosmithkline research development limit brentford glaxosmithkline limit brentford glaxochem pte ltd brentford setfirst limited phch brentford wellcome foundation limit cambridge domantis limit brentford viiv healthcare limit brentford viiv healthcare limit brentford viiv healthcare trading service limit austria vienna glaxosmithkline pharma gmbh belgium wavre glaxosmithkline pharmaceuticals rixensart glaxosmithkline biological czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare brndby glaxosmithkline pharma finland espoo glaxosmithkline france marly roi groupe glaxosmithkline sas marly roi laboratoire glaxosmithkline sas marly roi glaxo wellcome production sas marly roi glaxosmithkline sante grand public sas marly roi viiv healthcare sas amand les eaux glaxosmithkline biological sas germany buehl glaxosmithkline consumer healthcare gmbh munich glaxosmithkline gmbh greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare product limited phch italy verona glaxosmithkline spa milan glaxosmithkline consumer healthcare spa verona glaxosmithkline manufacturing spa luxembourg mamer glaxosmithkline international luxembourg sarl phch netherlands zeist glaxosmithkline zeist glaxosmithkline consumer healthcare norway oslo glaxosmithkline poland poznan glaxosmithkline pharmaceuticals poznan gsk service spz warsaw glaxosmithkline consumer healthcare spz portugal alge glaxosmithklineprodutos farmaceuticos limitada gsk annual report financial note financial statement continue statement principal group company continue europe location subsidiary sector activity republic carrigaline smithkline beecham cork limited ireland cork glaxosmithkline trading services limited dublin glaxosmithkline consumer healthcare ireland limited dublin glaxosmithkline ireland limited dungarvan stafford miller ireland limited dungarvan glaxosmithkline dungarvan limited sligo stiefel laboratory ireland limited romania brasov europharm hold phch buchar glaxosmithkline gsk srl russian moscow glaxosmithkline trading zao federation moscow glaxosmithkline healthcare zao spain madrid glaxosmithkline madrid glaxosmithkline consumer healthcare aranda duero glaxo wellcome sweden solna glaxosmithkline switzerland muenchenbuchsee glaxosmithkline usa usa research triangle park stiefel laboratory inc marietta corixa corporation philadelphia glaxosmithkline llc phch pittsburgh glaxosmithkline consumer healthcare pittsburgh block drug company inc wilmington glaxosmithkline holdings americas inc phch wilmington glaxosmithkline capital inc cambridge sirtris pharmaceuticals inc research triangle park viiv healthcare company americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc mississauga glaxosmithkline consumer healthcare inc laval biomedical corporation quebec mexico delegacion tlalpan glaxosmithkline mexico phch asia pacific australia boronia glaxosmithkline australia pty ltd phch china beijing glaxosmithkline china investment ltd phch hong kong glaxosmithkline limited phch shanghai glaxosmithkline biological shanghai ltd tianjin sinoamerican tianjin smith kline french laboratories ltd india mumbai glaxosmithkline pharmaceutical limit new delhi glaxosmithkline consumer healthcare limited iii malaysia petale jaya glaxosmithkline pharmaceutical sdn bhd selangor glaxosmithkline consumer healthcare sdn bhd new zealand auckland glaxosmithkline limited phch pakistan karachi glaxosmithkline pakistan limited phch philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited thailand bangkok glaxosmithkline thailand limited phch gsk annual report principal group company continue japan location subsidiary sector activity japan tokyo glaxosmithkline phch latin america argentina buenos aires glaxosmithkline argentina phch buenos aire laboratorios phoenix sociedad anonima industrial comercial financiera brazil rio janeiro glaxosmithkline brasil limitada phch colombia bogota glaxosmithkline colombia phch venezuela caracas glaxosmithkline venezuela phch middle east africa egypt cairo glaxosmithkline sae phch south africa johannesburg glaxosmithkline south africa pty limited phch turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch middle east africa associate south africa johannesburg aspen pharmacare holding limit phch incorporate singapore exempt provision section company amendment act ireland iii onsolidate subsidiary undertaking accordance section company act ground dominant influence quity account ground significant influence directly hold wholly own subsidiary glaxosmithkline plc key business sector pharmaceutical consumer healthcare business activity development export finance hold company insurance marketing production research service detail group subsidiary associate undertaking attach company annual return file registrar company glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report financial note financial statement continue statement legal proceeding intellectual property advairseretide group involve significant legal administrative proceeding principally product liability intellectual property number company challenge group patent tax antitrust governmental investigation cover advairseretide salmeterolfluticasone propionate relate private litigation group make provision certain european jurisdiction include belgium proceeding regular basis summarise note france germany ireland netherlands february accounting principle policy note action bring mylan pharmaceuticals inc hexal provision group involved significant legal pharmaceutical hexal neolab ltd ivax international proceeding respect possible federal court munich revoke group german seretide reliable estimate expect financial effect combination patent lack inventive step group result ultimate resolution proceeding appeal decision netherlands action bring case appropriate disclosure case sandoz pharmaceutical sandoz hexal district include provision court hague january revoke supplementary protection certificate spc extend respect legal proceeding describe protection product september provision group unable reliable estimate expect financial revocation action basic patent cover seretide effect stage group believe information combination ireland file high court dublin seek plaintiff know behalf ivax july high court hand meaningful respect legal proceeding decision june find patent invalid number factor include limited obviousness group file appeal decision stage proceeding entitlement party appeal october trial date set appeal decision clarity theory liability damage currently generic salmeterolfluticasone govern law intellectual property claim include challenge proportionate product market validity enforceability group patent product process assertion noninfringement july group enter settlement agreement patent loss case result loss sandoz pursuant party resolve pende patent protection product issue consequence litigation relate group combination patent seretide loss significant decrease sales europe settlement agreement provide group product materially affect future result operation pursue legal action combination patent group sandoz block launch generic salmeterolfluticasone propionate product european country sandoz legal expense incur provision relate legal claim receive regulatory approval salmeterolfluticasone charge sell general administration cost provision proportionate product european country date take appropriate legal specialist advice outflow resource consider probable argatroban reliable estimate likely outcome december encysive pharmaceuticals inc mitsubishi kasei dispute respect product liability claim relate certain corporation group file action united states product sufficient history claim district court southern district new york barr settlement enable management reliable estimate laboratories inc infringement mitsubishis pharmaceutical provision require cover unasserted claim certain composition patent cover argatroban pursuant licence case incur report ibnr estimate actuarial mitsubishi encysive develop argatroban treatment technique appropriate determine estimate heparininduced thrombocytopenia hold new drug group exposure describe note provision application approve food drug administration december group aggregate provision legal fda encysive license marketing right argatroban dispute include tax matter describe group mitsubishi patent expire june barr note taxation billion ultimate liability teva pharmaceuticals inc file abbreviate new drug legal claim vary amount provide application anda fda certification dependent outcome litigation proceeding invalidity unenforceability noninfringement mitsubishi investigation possible settlement negotiation patent june group partner prevail group position change time teva trial judge rule mitsubishis patent assurance loss result cover formulation injectable argatroban infringe outcome legal proceeding exceed material invalid august united states court provision report group appeal federal circuit affirm decision result financial account happen material court decision teva preclude launch generic adverse impact result operation group product june reporting period judgment incur settlement enter significant matter describe gsk annual report legal proceeding continue group subsequently receive similar notice anchen pharmaceutical anchen roxane laboratories roxanne arzerrabenlystacabilly patents watson laboratories inc watson mylan pharmaceuticals inc mylan variously challenge patent february group file declaratory action patent united states district court northern district california declaration patent know group file suit banner anchen united cabilly patent own jointly genentech inc states district court district delaware january city hope invalid unenforceable infringe infringement avodart patent consequence group product arzerra ofatumumab approve stay fda approval banner anchen product fda refractory chronic lymphocytic leukaemia cll effect early decision adverse genentech city hope counterclaimed infringement group separate complaint file roxane suit subsequently transfer united states district watson court june september court middle district california group file suit mylan thirtymonth stay fda approval subsequent generic product april obtain cabilly patent extend past anchenbanner stay case cabilly iii patent genentech file suit group avodart consolidated original case united states district court middle district california anchen banner twoweek trial schedule commence allege group lonza manufacturer arzerra october infringe cabilly iii patent making sell arzerra group contractually require defend indemnify lonza group settle early patent challenge claim relate arzerra cabilly patent genentech avodart teva pharmaceuticals inc teva sue group human genome sciences inc hgs term settlement teva permit launch claim infringement make sell benlysta generic dutasteride product fourth quarter cabilly iii patent hgs group licensor early certain condition tevas generic dutasteride benlysta product approve fda december september district court decide stay december anchen notify group cabilly iii case group hgs notice file anda jalyn paragraph certification alleging decide consolidate arzerra benlysta case patent expire invalid relate cabilly patent december district unenforceable infringe jalyn combination court stay benlystacabilly case resolution dutasteride tamsulosin cover patent summary judgment motion file arzerracabilly case cover avodart subsequently group receive similar discovery complete arzerracabilly case notice impax laboratories inc watson challenging summary judgment motion pende patent cover jalyn group sue anda applicant jalyn united states district court march genentech biogen idec file suit district delaware case consolidated group united states district court southern trial avodart case twoweek trial schedule district california allege group sale arzerra commence october induce contribute infringement patent claim treatment cll anticd monoclonal benlysta antibody group counterclaim patent invalid february court appeal uphold early high infringe october district court issue court decision revoke human genome sciences inc rule construe claim manner arzerra hgs patent ground infringe patent genentech biogen idec susceptible industrial application inventive step claim stipulate judgment infringement file appeal revocation bring eli lilly patent claim construction issue united states court claim cytokine bly antibody bind appeal federal circuit date set bly benlysta belimumab group licence appeal patent hgs party litigation avodartjalyn proceeding equivalent european patent uphold october final appeal european patent office november banner pharmacaps inc banner follow opposition proceeding file eli lilly hgs notify group file anda market generic group appeal decision november version avodart dutasteride banner notification contain supreme court reverse court appeal affirm paragraph certification allege patent expire validity patent ground supreme patent expiring patent covering court remand case court appeal compound dutasteride invalid infringe proceeding remain ground include banner propose generic dutasteride product sufficiency disclosure previously decide favour hgs court appeal decide hgs remain issue patent consider valid force gsk annual report financial note financial statement continue statement legal proceeding continue march pronova enter agreement apotex settle patent litigation usa related november eli lilly bring action patent lovaza settlement grant apotex license enter court revocation european patent own biogen idec market generic version lovaza quarter cover use antibody baff know early depend certain circumstance term lymphocyte stimulatory bly treatment autoimmune settlement confidential disease group hgs exclusively license trial involve teva par hold march april patent responsible defend action ruling issue pronova group european patent challenge parallel proceeding receive paragraph notice endo pharmaceuticals merck serono european patent office action endo mylan pharmaceuticals mylan advise endo early day patent number patent mylan submit anda fda lovaza protect benlysta prevent unlawful copying benlysta pronova choose assert patents endo outcome revocation action direct effect mylan await rule litigation teva ability hgs group market benlysta validity par united states district court district delaware patent cover benlysta trizivir epzicom viiv healthcare receive notice lupin ltd june viiv healthcare receive notice teva lupin file anda contain paragraph pharmaceutical teva amend anda epzicom certification trizivir triple combination lamivudine azt combination lamivudine abacavir contain paragraph abacavir allege patent list orange certification additional patent list orange book trizivir invalid unenforceable infringe book allege patent invalid unenforceable patent relate method treat hiv triple infringe patent challenge new certification relate combination expire hemisulfate salt abacavir method treat hiv combination expire expire certain crystal form lamivudine certain crystal form lamivudine expiring expire june viiv healthcare file suit august viiv healthcare file suit teva lupin patent cover triple combination challenge patent united states district court united states district court district delaware district delaware stay place fda approval october district court consolidated case tevas anda early december decision discovery viiv healthcare patent infringement suit involve adverse viiv healthcare matter district court teva pharmaceuticals epzicom pende court consolidated discovery epzicom case viiv healthcare stay place fda approval lupin anda patent infringement suit lupin ltd relate trizivir early november decision adverse viiv healthcare case involve patent covering combination matter lamivudine abacavir veramyst levitra november group receive notice sandoz inc group participate marketing levitra pursuant file anda paragraph certification veramyst copromotion agreement bayer healthcare july fluticasone furoate nasal spray challenge patent bayer bring suit teva pharmaceuticals teva list orange book veramyst invalid unenforceable united states district court district delaware infringe patent expire infringement patent relate levitra teva file december group file suit sandoz anda fda certification patent cover united states district court district delaware active ingredient levitra expire invalid patent stay fda approval sandozs generic unenforceable infringe party settle case product place early court decision dismiss november term adverse group confidential group party suit product liability lovaza preclinical clinical trial conduct march group receive notice teva development potential product determine safety pharmaceuticals usa inc teva par pharmaceuticals inc efficacy product use human follow approval par apotex inc apotex file andas regulatory body notwithstanding effort drug paragraph certification allege patent cover vaccine introduce marketplace unanticipate lovaza omegaacid ethyl ester invalid unenforceable safety issue believe evident infringe patent expire group group currently defendant number product licensee patent marketing right liability lawsuit relate group pharmaceutical usa puerto rico pronova biopharma norge pronova consumer healthcare product significant owner patent sue teva par apotex matter describe group able united states district court district delaware fda reliable estimate expect financial effect matter approval andas stay early discuss category include provision decision favourable generic group matter provision legal dispute party suit note note provision gsk annual report legal proceeding continue poligrip begin number product liability lawsuit claim avandia file group state federal court group name product liability lawsuit behalf usa include purport class action allege zinc individual assert personal injury claim arise poligrip cause copper depletion permanent neurologic injury use avandia federal case file group federal case denture cream adhesive multi multidistrict litigation proceed pende united district litigation mdl united states district court state district court eastern district pennsylvania case southern district florida establish june file number state court case file group procter gamble defendant state court philadelphia coordinate mass tort litigation include mdl purport class action program case state court california coordinate assert economic loss claim state consumer protection los angeles additionally number purport law claim medical monitor current class action seek economic damage behalf party exception state court case pennsylvania ohio payer consumer assert claim arise state tennessee state court case federal law include racketeer influence corrupt consolidated philadelphia mass tort program mtp organization act rico state unfair trade practice andor purport class action assert consumer fraud claim consumer protection law file canada group reach agreement principle settle vast majority current case lawsuit pende february group reach agreement settle mtp litigation settlement discussion substantial majority federal state case pende ongoing group voluntarily withdraw zinccontaine usa purport class action avandia pende formulation poligrip market canada purport class action israel sale marketing regulation paxil paxil group able reliable estimate group receive numerous lawsuit claim allege expect financial effect matter discuss category use paxil paroxetine cause variety injury include provision matter provision lawsuit recent year allege use paxil legal dispute note matter pregnancy result birth child birth defect group provision note note health issue lawsuit claim allege provision patient take paxil commit attempt commit suicide act violence patient suffer symptom colorado investigation discontinue treatment paxil february group receive subpoena group reach agreement settle substantial majority united states attorney office colorado group claim relate paxil use pregnancy sale promotional practice relate large february number claim relate use sell product period january pregnancy pende include schedule trial investigation later take united states attorney philadelphia mass tort program matter office district massachusetts expand dismiss payment remain purport class action present respect advair november group litigation canada concern use paxil pregnancy announce reach agreement principle united states government conclude group party file motion preliminary approval significant ongoing united states federal investigation propose class settlement certify statewide class action specifically colorado investigation group sale seek restitution allege violation california unfair marketing practice begin february united competition law relate symptom discontinue use state department justice investigation possible paxil inappropriate use nominal price exception public funding withdraw hundred medicaid rebate program iii department justice claimant receive funding pursue common issue investigation development marketing avandia litigation allege paroxetine cause suffer settlement payment billion final settlement withdrawal reaction dependency legal service corporate integrity agreement expect address civil commission decision withdraw funding appeal criminal liability group sale market special case review panel claimant outcome practice remain subject ongoing negotiation united appeal remain outstanding claimant state government expect finalised discontinued claim trial schedule commence settlement cover group exist early high court london vacate provision fund exist cash resource government inquire group response october letter fdas division drug marketing advertising communication request information group allege promotion wellbutrin offlabel use resolution enquiry agreement principle federal government describe gsk annual report financial note financial statement continue statement legal proceeding continue cidra puerto rico manufacturing site october group finalise agreement avandiarelate matter attorney office district massachusetts note november group reach department justice respect investigation agreement principle united states federal government group manufacturing facility cidra puerto rico resolve government investigation development agreement comprehensive settlement pende marketing avandia claim group arise investigation group pay total million million civil criminal attorney general office state louisiana penalty pharmco puerto rico inc subsidiary mississippi south carolina utah file suit group plead guilty certain charge group group assert statutory common law claim relate process negotiate corporate integrity agreement development marketing avandia multistate group office inspector general cover manufacture attorney general conduct investigation relate compliance matter development marketing avandia group cooperate office group defend june group announce agreement pay action county santa clara california total million states district bring californias consumer protection law seek columbia settle investigation relate event civil penalty restitution early manufacturing facility cidra puerto rico group admit wrongdoing liability average wholesale price settlement united states department justice doj number hiv division enquiry state putative class private payer year investigate andor bring civil litigation july group receive subpoena eastern allegation numerous pharmaceutical company include district new york attorney office sale group violate federal state fraud abuse law marketing practice hiv product educational result way average wholesale price awp programme grant payment physician wholesale acquisition cost wac determined drug treat hivinfecte adult group cooperating report drug reimburse medicare investigation provision matter medicaid insurance programmes group nominal pricing reach million civil settlement federal government resolve allegation relate pricing group advise department marketing zofran kytril doj settlement group justice investigate certain group nominal amend exist corporate integrity agreement price bundle sale arrangement nominal price requirement settlement group receive final exception good price reporting requirement approval million nationwide private payer class action medicaid drug rebate programme note settlement relate group price reporting multi november group reach agreement principle district litigation proceeding united states district court federal government resolve government district massachusetts investigation possible inappropriate use nominal price exception medicaid drug rebate programme number state respective attorney general settlement cover group exist provision county new york state file civil funded exist cash resource lawsuit state federal court group drug company claim damage restitution group receive subpoenas request document awp andor wac price report pharmaceutical product information delaware michigan relate covered state medicaid programme state seek group nominal price arrangement group cooperate recovery behalf state payer case investigation produce responsive document behalf instate patient consumer group anticipate delaware michigan investigation resolve federal settlement group group separately resolve awp claim state medicaid enter nominal price arrangement programme state doj december settlement separate negotiation litigation concern awp issue continue state gsk annual report legal proceeding continue antitrustcompetition group able reliable estimate programme expect financial effect matter discuss category group defend action file federal court include provision matter provision united states district court northern district legal dispute note matter california county santa clara county group provision note note sought represent putative class hospital clinic provision entities california eligible receive discount sector enquiry ceiling price pharmaceutical federal programme know programme plaintiff allege group january european commission announce numerous pharmaceutical manufacturer enquiry certain aspect competition pharmaceutical set ceiling price higher allow law sector july commission publish final report contract govern programme suggest defensive patenting strategy impose overcharged entity california eligible obstacle innovation innovator company employ participate programme measure hinder generic come market final report concede delay generic entry united states supreme court agree review issue fault regulatory environment innovator company entity stand sue manufacturer defensive strategy manufacturers contract government trial court stay proceeding case supreme january commission request information court decision march supreme court group number pharmaceutical company unanimously hold plaintiff thirdparty beneficiary relate patent settlement agreement affect european contract issue sue challenge union european economic area market request calculation programme ceiling price essentially end information second monitoring exercise commission plaintiff case party work finalise patent settlement agreement pharmaceutical sector dismissal case resolution potential claim result exercise publish july january commission repeat exercise lovaza patent settlement monitor exercise group april group receive subpoena office respond february provision inspector general department health matter human service request production document relate office fair trading competition act investigation group marketing promotion lovaza scope document request january present august office fair trading oft launch group respond subpoena provision formal investigation group pharmaceutical matter company potential infringement competition act investigation focus litigation settlement paxilseroxat group potential supplier generic paroxetine group settle lawsuit file new york state formulation enter attorney general office allege group fail disclose object effect prevention restriction distortion datum use paxil child adolescent competition group infringe group class settlement lawsuit bring dominant position make payment potential supplier consumer thirdparty payer respectively economic generic paroxetine aim restrict development damage allegedly result prescription paxil child generic competition group terminate adolescent group deny liability settlement agreement issue oft investigation cover issue plaintiff voluntarily dismiss similar purport class investigate european commission action file behalf governmental entity pay respect paroxetine european union prescription paxil minor remain similar purport european commission pharmaceutical class action canada seek economic damage behalf sector enquiry march commission announce individual party payer governmental entity formally conclude enquiry action purchase paxil use patient age group provide information documentation secdoj fcpa enquiry response oft request hold initial meeting securities exchange commission sec oft december group continue cooperate department justice conduct industrywide enquiry oft investigation provision pharmaceutical company engaged matter violation foreign corrupt practice act relate sale pharmaceutical include argentina brazil canada china germany italy poland russia saudi arabia group company ask respond enquiry cooperate sec doj provision matter gsk annual report financial note financial statement continue statement legal proceeding continue securitieserisa class action stiefel wellbutrin july class action suit bring behalf current december january february lawsuit employee stiefel laboratories inc stiefel purport class action file file united states district court southern district united states district court eastern district pennsylvania florida complaint allege stiefel officer group behalf direct indirect purchaser director violate employee retirement income security act wellbutrin complaint allege violation antitrust erisa federal state security law induce stiefel law sham litigation fraud patent office employee sell share employee stock plan group obtain enforce patent cover stiefel greatly undervalue price disclose wellbutrin complaint follow introduction employee stiefel sell group generic competition wellbutrin april district january defendant motion dismiss grant appellate court ruling generic manufacturer deny specifically district court infringe group patent determine erisa claim individual stiefel november district court approve group defendant federal security claim settlement certify class direct purchaser individual defendant stiefel forward district january group reach agreement principle court dismiss florida securities act common law settle claim indirect purchaser million breach fiduciary duty claim hold erisa preempt settlement present district court approval state common law malpractice claim near future stiefel accountant july district court deny plaintiff motion class certification october wellbutrin district court grant defendant motion summary action file biovail corporation biovail judgment dismiss remain plaintiff group purport class direct indirect purchaser litigation district court grant allege unlawful monopolisation antitrust defendant motion limine limit scope evidence violation relate enforcement biovail wellbutrin plaintiff offer trial additionally november patent file biovail citizen petition direct district court grant defendant daubert motion indirect purchaser class certify group mean plaintiff expert leave testify move reconsideration regard certification behalf trial trial schedule indirect purchas class oral argument group motion separate lawsuit stiefel charle stiefel schedule march trial date set ceo stiefel file individual flonase stiefel employee case assert claim similar contain class action purport direct indirect purchaser class action file united states district court eastern district december securities exchange pennsylvania allege group illegally maintain monopoly commission sec file formal complaint stiefel power market flonase charge plaintiff charles stiefel united states district court district supracompetitive price additionally suit file florida allege stiefel principal violate federal roxane laboratories inc generic competitor seek lose security law induce stiefel employee sell share profit group allege action unlawfully delay employee stock plan company greatly roxane entry market predicate undervalue price disclose employee allegation filing group allegedly sham citizen company sell group respond petition subsequent litigation district court grant secs complaint motion direct purchaser certify class hearing avandia erisa litigation certification indirect purchaser class hold february decision motion putative class action suit file group court group motion dismiss roxane complaint august united states district court deny trial suit bring putative class southern district new york direct indirect purchaser schedule october complaint allege group officer director commercial corporate certain employee mislead public statement avandia allege mislead statement group able reliable estimate expose value group stock drop plaintiff expect financial effect matter discuss bring suit behalf participant category include provision respect matter group retirement plan claim group provision legal dispute set note individual defendant breach fiduciary duty plan provision provision participant employee retirement income security follow matter act erisa gsk annual report legal proceeding continue plaintiff seek double damage overtime allegedly work group pharmaceutical sale representative plaintiff subsequently amend complaint add year period november district court allegation concern wellbutrin paxil include grant group motion summary judgment dismiss additional group defendant individual member lawsuit ground sale representative group benefit committee group file motion dismiss exempt employee outside sale exemption february district court rule flsa plaintiff appeal decision united states court favour group dismiss plaintiff complaint appeals ninth circuit prejudice june plaintiff file appeal february ninth circuit issue opinion united states court appeal second circuit favour group affirm judgment united states benlysta security litigation district court district arizona find group pharmaceutical sale representative exempt employee november class action suit file united outside sale exemption flsa entitle states district court district maryland allege overtime pay plaintiff file petition seek review human genome sciences inc hgs certain individual decision united states supreme court november officers directors group statement supreme court agree review case oral argument clinical trial benlysta fail disclose suicide supreme court schedule april trial participant withhold information defendant cause hgs stock artificially inflate harm november purport class action file purchase hgs stock inflate price group united states district court northern district november second action file federal new york behalf group pharmaceutical sale court lead plaintiff name case representative work new york previous year group evaluate complaint plaintiff make similar allegation set forth flsa case claim new york wage hour wage hour claim law closely follow fair labor standard act january december purport class action file plaintiff file similar purport class action florida state group behalf group entire pharmaceutical court allege group pharmaceutical sale representative sale representative action file entitle overtime flsa court issue stay transfer united states district court central activity new york case party agree district california initially allege representative ask court stay activity florida case exempt employee california law andor fair united states supreme court decide applicability labor standard act flsa consequently entitle outside sale exemption pharmaceutical sale representative overtime pay thing plaintiff subsequently environmental matter amend complaint assert class action limit solely pharmaceutical sale representative work california group notify potential responsibility relate assert claim california wage hour law past operation past waste disposal practice certain site primarily usa matter subject suit seek variety compensatory punitive statutory litigation include proceeding initiate federal damage group move summary judgment dismiss state government waste disposal site remediation cost claim putative class representative grind tort action bring private party exempt employee appeal pende united states court appeals ninth circuit case group advise responsible party involve manufacturer virtually factual approximately site appear national legal argument district court defer rule priority list create comprehensive environmental summary judgment motion stay activity response compensation liability act superfund case appellate court rule proceeding seek require operator hazardous waste company pende case ninth circuit defer rule facility transporter waste site generator company pende case california supreme hazardous waste dispose site clean site court issue opinion case address application reimburse government cleanup cost instances administrative exemption california state law group involve allege generator hazardous waste january california supreme court issue ruling superfund provide defendant jointly case request briefing effect rule severally liable cleanup cost proceeding frequently california supreme court company pende resolve basis nature quantity waste pharmaceutical sale representative case dispose generator site group case file united states district court proportionate liability cleanup cost substantially district arizona august seek establish determined site refer nationwide collective action behalf group entire group potential liability vary greatly site site pharmaceutical sale representative ground cost investigation study remediation representative exempt employee flsa site time substantial group routinely accrue amount relate share liability matter gsk annual report financial financial statement glaxosmithkline plc statement prepare gaap director statement responsibility relation disclosure information auditor company financial statement director office date report director responsible prepare parent company confirm glaxosmithkline plc financial statement remuneration far aware relevant audit report accordance applicable law regulation information company auditor unaware company law require director prepare financial take step ought statement financial year law director take director aware elect prepare parent company financial statement relevant audit information establish company accordance united kingdom accounting standard auditor aware information applicable law united kingdom generally accept accounting practice company law director approve confirmation give interpret accordance parent company financial statement satisfied provision section company act true fair view state affair go concern basis company period make enquiry director reasonable prepare financial statement director expectation company adequate resource continue require operational existence foreseeable future reason select suitable accounting policy apply continue adopt go concern basis prepare consistently financial statement judgement accounting estimate corporate governance code reasonable prudent board consider glaxosmithkline plc apply state regard parent company financial statement principle provision corporate governance code applicable accounting standard follow maintain financial reporting council describe subject material departure disclose explain corporate governance section page parent company financial statement comply provision disclose require financial service authoritys list rule director responsible keep adequate accounting auditor consider director statement compliance record sufficient explain companys relation point corporate governance code transaction disclose reasonable accuracy time specify review financial position company enable ensure parent company financial statement remuneration report comply company act responsible safeguarding asset sir christopher gent company take reasonable step chairman prevention detection fraud irregularity march parent company financial statement year end december comprise balance sheet year end december support note set page report responsibility auditor relation parent company financial statement set independent auditor report financial statement year end december include annual report publish hard copy print form available website director responsible maintenance integrity annual report website accordance legislation govern preparation dissemination financial statement access website available outside comparable legislation different gsk annual report independent auditor report opinion matter prescribed company act member glaxosmithkline plc opinion audit parent company financial statement glaxosmithkline plc year end december director remuneration report audit comprise company balance sheet gaap properly prepare accordance company relate note financial reporting framework act apply preparation applicable law information give director report financia united kingdom accounting standard united kingdom year parent company financial statement generally accept accounting practice prepare consistent parent company financial respective responsibility director auditor statement explain fully director statement matter require report responsibility set director responsible exception preparation parent company financial statement report respect follow matter satisfied true fair view company act require report responsibility audit express opinion opinion parent company financial statement accordance applicable law international standard audit dequate accounting record keep parent ireland standard require comply auditing company return adequate audit practice board ethical standard auditor receive branch visit report include opinion prepare parent company financial statement company member body accordance director remuneration report audit chapter company act agreement accounting record return purpose give opinion accept assume ertain disclosure director remuneration specify law responsibility purpose person report show hand come save expressly agree prior consent write receive information explanation require audit scope audit financial statement matter audit involve obtain evidence amount disclosure financial statement sufficient reasonable report separately group financial statement assurance financial statement free material glaxosmithkline plc year end december misstatement cause fraud error include company pass resolution accordance section assessment accounting policy appropriate company act senior statutory parent company circumstance consistently auditor state apply adequately disclose reasonableness significant accounting estimate director overall presentation financial statement addition read financial nonfinancial information annual pricewaterhousecooper llp report identify material inconsistency audit charter accountant statutory auditor financial statement aware apparent london material misstatement inconsistency consider march implication report opinion financial statement opinion parent company financial statement true fair view state company affair december properly prepare accordance united kingdom generally accept accounting practice prepare accordance requirement company act gsk annual report financial financial statement glaxosmithkline plc statement prepare gaap company balance sheet gaap december note fix asset investment debtor cash bank current asset creditor amount year net current assetsliabilitie net asset capital reserve call share capital share premium account reserve profit loss account equity shareholder fund approve board march sir christopher gent chairman glaxosmithkline plc register number gsk annual report note company balance sheet expenditure gaap expenditure recognise respect good service receive supply accordance contractual term presentation financial statement provision obligation exist future liability description business respect past event obligation reliably estimate glaxosmithkline plc parent company gsk major global healthcare group engage creation discovery investment subsidiary company development manufacture marketing pharmaceutical investment subsidiary company hold cost product include vaccine overthecounter otc medicine provision impairment healthrelate consumer product impairment investment preparation financial statement carry value investment review impairment financial statement prepare go concern indication investment basis draw accordance generally accept impair provision result impairment review accounting principle gaap accounting charge income statement year concern presentation december comparative figure december appropriate comparative share base payment figure reclassify ensure consistent presentation issuance company subsidiary grant current year information company option represent additional capital contribution permit company act profit company subsidiarie additional investment loss account company present annual report subsidiary result correspond increase shareholder equity additional capital contribution base fair accounting convention standard value grant issue allocate underlying grant balance sheet prepare historical cost vest period convention complie applicable accounting taxation standard current tax provide amount expect pay accounting principle policy apply tax rate enact substantially enact preparation balance sheet conformity generally balance sheet date accept accounting principle require management company account taxation defer estimate assumption affect report amount accelerate reason timing difference originate asset liability disclosure contingent asset reverse balance sheet date defer tax asset liabilitie date balance sheet actual amount recognise extent consider differ estimate recoverable future taxable profit balance sheet prepare accordance defer tax measure average tax rate company accounting policy approve board expect apply period time difference describe note expect reverse defer tax liability asset accounting policy discount foreign currency transaction financial guarantee foreign currency transaction record exchange rate liability relate guarantee issue company behalf rule date transaction forward rate hedge subsidiary initially recognise fair value forward exchange contract foreign currency asset amortise life guarantee liability translate rate exchange ruling balance perate profit sheet date forward rate fee relate audit dividend pay receive company charge operate profit dividend pay receive include account period relate dividend actually pay receive gsk annual report financial financial statement glaxosmithkline plc statement prepare gaap note company balance sheet gaap continue fix asset share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relate share base payment debtor amount year corporation tax recoverable amount owe group undertaking amount year amount owe group undertaking creditor amount year bank overdraft amount owe group undertaking creditor company guarantee debt issue subsidiary company receive annual fee subsidiary aggregate company outstanding guarantee billion debt instrument subsidiary company relation guarantee fee recover life bond disclose debtor note gsk annual report note company balance sheet gaap continue share capital share premium account share ordinary share premium number share capital authorise december december share capital issue fully pay january issue employee share scheme december issue employee share scheme share capital purchase cancel december december december number share issuable outstanding option number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme total million share purchase company cost million year million share cancel million share add treasury share company expect share repurchase billion exact time purchase share hold treasury share cancel determined company dependent market condition factor share purchase period january february period february march million share purchase cost million reserve profit reserve loss account total january loss attributable shareholder dividend shareholder capital contribution relate share base payment december profit attributable shareholder dividend shareholder share purchase cancel hold treasury share capital contribution relate share base payment december profit glaxosmithkline plc year million loss million dividend million million give retain profit million loss million cost share purchase cancel hold treasury share million nil profit loss account reserve december stand million million million unrealised million gsk annual report shareholder information shareholder information quarterly trend unaudite analysis group result pharmaceutical vaccine sale therapeutic area provide quarter sterle financial year income statement total month cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement result major restructure total turnover cost sale sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny dilute earning share penny calculation result major restructuring describe note financial statement presentation financial statement gsk annual report quarterly trend unaudite analysis group result pharmaceutical vaccine sale therapeutic area provide quarter sterle financial year income statement total month cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement result major restructure total turnover cost sale sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny dilute earning share penny calculation result major restructuring describe note financial statement presentation financial statement gsk annual report shareholder quarterly trend continue information pharmaceutical vaccine turnover therapeutic area total usa europe emerge market rest world therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir cer represent growth constant exchange rate represent growth actual exchange rate turnover quarter give page gsk annual report pharmaceutical vaccine turnover therapeutic area total usa europe emerge market rest world therapeutic area restate growth growth growth growth growth major product cer cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report shareholder quarterly trend information pharmaceutical vaccine turnover total group cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report pharmaceutical vaccine turnover usa cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report shareholder quarterly trend continue information pharmaceutical vaccine turnover europe cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report pharmaceutical vaccine turnover emerge market cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report shareholder quarterly trend continue information pharmaceutical vaccine turnover rest world cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin xyzal zyrtec antiviral hepsera relenza valtrex zeffix central nervous system imigranimitrex keppra lamictal requip seroxatpaxil treximet wellbutrin cardiovascular urogenital arixtra avodart coreg fraxiparine lovaza vesicare volibris metabolic avandia product bonvivaboniva antibacterial augmentin oncology emesis arzerra hycamtin promacta tyverbtykerb votrient vaccine boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix dermatological bactroban dermovate duac soriatane zovirax viiv healthcare hiv combivir epivir epzicomkivexa lexiva selzentry trizivir pharmaceutical turnover include copromotion income gsk annual report consumer healthcare turnover cer cer cer cer overthecounter medicines oral healthcare nutritional healthcare cer cer cer cer usa europe rest world gsk annual report shareholder year record information record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board turnover division pharmaceutical exclude vaccine vaccine pharmaceutical vaccine consumer healthcare group turnover geographic region usa europe emerge markets asia pacific japan group turnover segment pharmaceutical vaccines usa europe emerge markets asia pacific japan viiv healthcare hiv trading unallocated pharma pharmaceutical vaccine consumer healthcare pharmaceutical vaccine turnover therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine dermatology viiv healthcare hiv consumer healthcare turnover otc medicine oral healthcare nutritional healthcare gsk annual report financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share financial result major restructuring turnover operate profit profit taxation profit taxation pence pence pence adjust earning share adjust diluted earning share million million million million million weight average number share issue basic diluted return capital employ return capital employ calculated total profit taxation percentage average net asset year balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity gsk annual report shareholder year record continue information number employee usa europe emerge markets asia pacific japan manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day year mar feb jan dec nov oct sep high low december federal reserve bank new york cease publish noon buying rate bank england buy rate subsequent calculation buy rate march gsk annual report pharmaceutical vaccine product development pipeline key inlicense alliance relationship party maa marketing authorisation application europe month submission nda new drug application usa month regulatory approval maa month positive opinion approval letter phase evaluation clinical pharmacology usually conduct volunteer month complete response letter receive indicate phase determination dose initial evaluation efficacy conduct ultimately approval give subject resolution small number patient outstanding query phase iii large comparative study compound versus placebo andor establish bla biological license application treatment patient establish clinical benefit safety maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound type indication phase maa ndabla biopharmaceutical monoclonal antibody type diabete inflammatory bowel disease neurite outgrowth inhibitor nogoa amyotrophic lateral sclerosis multiple sclerosis monoclonal antibody tumour necrosis factor receptor tnfr acute lung injury domain antibody glucagon like peptide glp agonist obesity halflife improve domain antibody recombinant human angiotensin convert acute lung injury enzyme amp immunomodulator solid tumour otelixizumab monoclonal antibody rheumatoid arthritis myelinassociate glycoprotein monoclonal stroke antibody beta amyloid monoclonal antibody geographic retinal atrophy albiglutide glp agonist heart failure mepolizumab monoclonal antibody severe asthma nasal polyposis ofatumumab human monoclonal antibody multiple sclerosis ofatumumab human monoclonal antibody rheumatoid arthritis sirukumab human monoclonal antibody rheumatoid arthritis albiglutide glp agonist type diabete iii arzerra ofatumumab human monoclonal antibody chronic lymphocytic leukaemia line therapy use iii relapse patient arzerra ofatumumab human monoclonal antibody diffuse large cell lymphoma relapse patient iii arzerra ofatumumab human monoclonal antibody follicular lymphoma refractory relapse patient iii benlysta belimumab lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody benlysta belimumab lymphocyte stimulator monoclonal systemic lupus erythematosus approve jul mar antibody xgeva denosumab receptor activator nuclear kappa rank bone metastatic disease approve ligand human monocional antibody cardiovascular metabolic sodium dependent glucose transport sglt type diabetes inhibitor ileal bile acid transfer inhibitor type diabete high affinity nicotinic acid receptor hma metabolic disorders agonist motilin receptor agonist delay gastric empty prolyl hydroxylase inhibitor peripheral arterial disease prolyl hydroxylase inhibitor anaemia associated chronic renal disease losmapimod kinase inhibitor acute coronary syndrome copd retosiban oxytocin antagonist threaten preterm labour ronacaleret calcium receptor antagonist allogeneic haematopoietic stem cell mobilisation darapladib lppla inhibitor atherosclerosis diabetic macular oedema iii immunoinflammation transient receptor potential vanilloid trpv pruritis antagonist topical signal inhibitor systemic lupus erythematosus antiinflammatory macrolide conjugate oral inflammatory bowel disease sirt activator psoriasis ccx ccr chemokine receptor antagonist rheumatoid arthritis ccr chemokine receptor antagonist crohn disease iii gsk annual report shareholder pipeline continue information achieve regulatory review milestone compound type indication phase maa ndabla infectious disease type topoisomerase inhibitor bacterial infection leucyl trna synthetase inhibitor oral bacterial infection polypeptide deformylase inhibitor bacterial infection leucyl trna synthetase inhibitor bacterial infections hepatitis virus inhibitor hepatitis tafenoquine aminoquinoline plasmodium vivax malaria relenza zanamivir neuraminidase inhibitor influenza iii neuroscience phoshodiesterase inhibitor huntington disease orexin antagonist sleep disorder antagonist dementia firategrast dual alpha integrin antagonist vla multiple sclerosis rilapladib lppla inhibitor alzheimer disease ipx dopamine precursor dopa decarboxylase parkinson disease iii inhibitor horizant gabapentin voltagegate calcium channel modulator postherpetic neuralgia submit aug enacarbil horizant gabapentin voltagegate calcium channel modulator restless leg syndrome approve apr enacarbil trobaltpotiga neuronal potassium channel opener epilepsy partial seizure approve mar jun retigabineezogabine oncology akt protein kinase inhibitor cancer focal adhesion kinase inhibitor cancer phosphatidylinositol kinase pik inhibitor cancer trametinib mitogenactivate protein kinase inhibitor cancer bkm mek pik inhibitor vestipitant neurokinin antagonist post operative nausea vomit akt protein kinase inhibitor langerhan cell histiocytosis dabrafenib braf protein kinase inhibitor nonsmall cell lung cancer foretinib mesenchymalepithelial transition factor papillary renal cell carcinoma cancer cmet kinase inhibitor revoladepromacta thrombopoietin receptor agonist haemeoncologyrelated thrombocytopaenia eltrombopag trametinib mek inhibitor kras mutant nonsmall cell lung cancer second line therapy trametinib mek inhibitor pancreatic cancer line therapy trametinib mek inhibitor akt protein kinase cancer inhibitor trametinib mek inhibitor braf protein kinase metastatic melanoma dabrafenib inhibitor dabrafenib braf protein kinase inhibitor metastatic melanoma iii trametinib mek inhibitor metastatic melanoma iii revoladepromacta thrombopoietin receptor agonist hepatitis induce thrombocytopaenia iii eltrombopag tyverbtykerb lapatinib human epidermal growth factor receptor breast cancer adjuvant therapy iii epidermal growth factor receptor egfr dual kinase inhibitor tyverbtykerb lapatinib egfr dual kinase inhibitor gastric cancer iii tyverbtykerb lapatinib egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii votrient pazopanib multikinase angiogenesis inhibitor ovarian cancer maintenance therapy iii votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer adjuvant therapy iii tyverbtykerb lapatinib egfr dual kinase inhibitor metastatic breast cancer combination trastuzumab submit feb feb votrient pazopanib multikinase angiogenesis inhibitor sarcoma submit jul jun ophthalmology darapladib lppla inhibitor diabetic macular oedema atheroscierosis pazopanib multikinase angiogenesis inhibitor agerelate macular degeneration cancer eye drop indication gsk annual report achieve regulatory review milestone compound type indication phase maa ndabla respiratory cxcr chemokine receptor antagonist copd urotensin antagonist asthma tolllike receptor agonist asthma phosphoinositide kinase inhibitor asthma sodium channel blocker cough muscarinic antagonist beta agonist copd lipoxygenaseactivate protein flap asthma inhibitor dilmapimod kinase inhibitor acute lung injury acute respiratory distress syndrome losmapimod kinase inhibitor oral copd cardiovascular disease muscarinic acetylcholine antagonist copd iii vilanterol muscarinic acetylcholine antagonist long copd iii act beta agonist glucocorticoid agonist asthma iii vilanterol longacting beta agonist copd iii relovair longacte beta agonist glucocorticoid asthma iii vilanterol agonist relovair longacte beta agonist glucocorticoid copd iii vilanterol agonist paediatric vaccine malaria improve recombinant malaria prophylaxis plasmodium falciparum mmr live attenuate measle mump rubella prophylaxis nov pneumoniae paediatric recombinant conjugate streptococcus pneumoniae disease prophylaxis generation mosquirix malaria rtss recombinant malaria prophylaxis plasmodium falciparum iii menhibrix hibmencyttconjugate neisseria meningitis group haemophilus influenzae submit sep type disease prophylaxis nimenrix menacwytt conjugate neisseria meningitis groups disease prophylaxis submit feb vaccines flu pandemic cellculture base vaccine pandemic influenza prophylaxis staphylococcus aureus recombinant conjugate staphylococcus aureus prophylaxis hiv recombinant hiv disease prophylaxis hiv recombinant hiv disease immunotherapy tuberculosis recombinant tuberculosis prophylaxis zoster recombinant herpe zoster prevention iii flu pre pandemic inactivated split monovalent quebec prepandemic pandemic influenza prophylaxis submit sjun canada flu vaccine inactivate split quadrivalent seasonal influenza prophylaxis submit feb pumarix inactivate split monovalent quebec pandemic influenza prophylaxis approve mar antigen specific cancer immunotherapeutic asci nyeso recombinant treatment metastatic melanoma prame recombinant treatment metastatic melanoma prame recombinant treatment resectable nonsmall cell lung cancer recombinant treatment breast cancer recombinant treatment acute myelogenous leukaemia magea recombinant treatment bladder cancer magea recombinant treatment melanoma iii magea recombinant treatment nonsmall cell lung cancer iii gsk annual report shareholder pipeline continue information achieve regulatory review milestone compound type indication phase maa ndabla rare disease antisense oligonucleotide duchenne muscular dystrophy iii exvivo stem cell gene therapy adenosine deaminase severe combine immune deficiency iii adascid migalastat hcl pharmacological chaperone fabry disease iii stiefel latestage asset novel glucocorticoid agonist topical atopic dermatitis duac low dose clindamycinbenzoyl peroxide gel acne vulgaris submit nov nov sorilux vitamin analog scalp psoriasis submit nov calcipotriene foam tazarotene foam retinoid foam acne vulgaris submit jul hiv viiv healthcare sgsk hiv integrase inhibitor longacte parenteral hiv infection formulation lersivirine nonnucleoside reverse transcriptase inhibitor hiv infections dolutegravir hiv integrase inhibitor hiv infections iii sgsk dolutegravir hiv integrase inhibitor reverse transcriptase hiv infection iii sgsk inhibitor fix dose combination abacavir sulphate lamivudine brand name appear italic trademark own andor license glaxosmithkline associate company optionbase alliance party include asset phase later development company disease area phase cancer research cancer chemocentryx inflammatory disease concert pharmaceutical hiv dynavax technology cutaneous systemic lupus erythematosus isis pharmaceutical transthyretinmediate amyloidosis oncome pharmaceutical oncology prosensa therapeutic neuroscience ranbaxy laboratory respiratory telethon institute gene therapy stem cell gene therapy affiris alzheimer disease treatment vaccine nabi nicotine vaccine iii ccx asset gsk annual report pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brands usa respiratory veramyst fluticasone propionate rhinitiscopd nasacort flixotideflovent fluticasone propionate asthmacopd qvar singulair expire expire compound compound expire diskus device diskus device hfadevice hfadevice formulation formulation seretideadvair salmeterol xinafoat asthmacopd singulair symbicort expire fluticasone propionate spiriva asmanex combination combination pulmicort foster expire diskus device diskus device hfadevice hfadevice formulation formulation serevent salmeterol xinafoate asthmacopd foradil spiriva expire expire compound compound expire diskus device diskus device hfadevice formulation ventolin hfa albuterol sulphate asthmacopd generic company hfadevice hfadevice formulation formulation antiviral relenza zanamivir influenza tamiflu valtrex valaciclovir genital herpe coldsore famvir expire expire shingles zeffixepivirhbv lamivudine chronic hepatitis hepsera expire use use central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire requip ropinirole parkinson disease mirapex expire formulation seroxatpaxil paroxetine depression effexor cymbalta expire expire anxiety disorder lexapro treximet sumatriptan naproxen migraine zomig maxalt relpax combination use wellbutrin bupropion depression effexor cymbalta expire expired lexapro cardiovascular urogenital arixtra fondaparinux deep vein thrombosis lovenox fragmin expire expire pulmonary embolism innohep avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride benlysta belimumab systemic lupus erychematosus coreg carvedilol phosphate mildtosevere heart failure toprol hypertension leave ventricular formulation dysfunction post fraxiparine nadroparin deep vein thrombosis lovenox fragmin expire expire pulmonary embolism innohep outlook detail uncertainty time followon competition generic competition possible generic competition possible gsk annual report shareholder pharmaceutical product competition intellectual property information major patent expiry date product compound indication competitor brands usa lovaza omega acid ethyl ester high triglyceride tricor formulation volibris ambrisentan pulmonary hypertension tracleer revatio antibacterials augmentin amoxicillinclavulanate common bacterial generic product expire potassium infection oncology arzerra ofatumumab refractory chronic mabtherarituxan pende lymphocytic leukaemia hycamtin topotecan ovarian cancer small cell doxil gemzar expire expired lung cancer cervical cancer promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura tykerbtyverb lapatanib advanced metastatic herceptin breast cancer positive patient votrient pazopanib metastatic renal cell carcinoma sutent nexavar afinitor vaccines boostrix diphtheria tetanus acellular booster vaccination adacel pertussis infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentacel pediacel polio hepatitis hepb polio hepatitis hepb pentaxim pentavac inactivated antigen cervarix hpv virus like particle human papilloma virus gardasil silgard vlp adjuvant mpl type aluminium hydroxide fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip subtype type antigen fluzone influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip subtype type antigen fluzone influvac aggripal fluad pandemrix derive split inactivated ahnv influenza focetria celvapan influenza virus antigen prophylaxis emerflu adjuvant prepandrix derive split inactivated influenza prophylaxis aflunov influenza virus antigen adjuvant synflorix conjugate pneumococcal invasive pneumococcal prevenar prevnar polysaccharide disease hiv combivir lamivudine zidovudine hivaids truvada atripla combination combination epivir lamivudine hivaids truvada atripla expire expire epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination lexiva fosamprenavir hivaids prezista kaletra reyataz selzentry maraviroc hivaids isentress intelence prezista trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination note financial statement legal proceeding generic competition begin december gsk annual report consumer healthcare product competition intellectual property brand product application market competition oral healthcare sensodyne toothpastes toothbrushes prevention dental global colgatepalmolive mouthwashe sensitivity colgate pro relief polident denture adhesive denture improve comfort global globally poligrip cleanser fit denture corega clean dentures aquafresh toothpastes toothbrushe prevention carie gum global colgatepalmolive colgate disease bad breath procter gamble crest otc medicine panadol tablet capulet infant drop paracetamolbase treatment global usa reckittbenckiser nurofen headache joint pain fever cold symptom nicoderm gum patch mini lozenge treatment nicotine global novartis nicotinell niquitin original lozenge withdrawal aid nicorette europe nicabate quit smoking retailer brand nicorette usa nutritional healthcare lucozade energy sport drink energy hydration ireland pepsicos gatorade markets cocacolas powerade red bull horlick malt milkbase drink nutrition ireland india krafts bournvita food nestle milo gsk annual report shareholder share price dividend information share company list london stock exchange dividend ad new york stock exchange nyse form american table set dividend ad dollar depositary share ad detail list debt year translate dollar applicable list refer note financial statement net debt exchange rate share price year dividend supplemental january december increasedecrease high year low year supplemental dividend relate disposal certain noncore table set middle market closing price otc brand north america pay fourth quarter company share price increase compare ordinary dividend decrease ftse index year share price march dividend calendar quarter exdividend date record date payment date february february april supplemental february february april july august august october november november january financial reporting calendar publication date result announcement share price ad price quarter april quarter july market capitalisation quarter october market capitalisation base share issue exclude preliminaryquarter february treasury shares gsk december billion annual reportsummary februarymarch date gsk fifth large company market capitalisation ftse index result announcement dividend result announcement issue london stock exchange available news service send gsk pay dividend quarterly continue increase cash securities exchange commission nyse issue return shareholder dividend policy ongoing medium available website longterm share buyback programme dividend remain essential component total shareholder return gsk financial report commit increase dividend longterm detail gsk publish annual report shareholder dividend declare amount payment date need detail annual report summary give note financial statement dividend document available website date dividend share publication summary send shareholder shareholder elect receive annual report contact registrar table set dividend share alternatively shareholder elect receive notification year email publication financial report register wwwshareviewcouk year dividend pence copy previous financial report available gsk supplemental website print copy obtain registrar gsk response center usa contact detail supplemental dividend relate disposal certain noncore otc brand north america pay fourth quarter ordinary dividend gsk annual report corporate responsibility report taxation publish corporate responsibility report online general information concern tax effect march outline gsk approach share ownership set page taxation performance corporate responsibility area include access information shareholder healthcare research business ethic environmental internet sustainability community investment information company include detail share nature trading market price available website wwwgskcom information follow table set period indicate high available website constitute low middle market closing quotation pence share annual report london stock exchange high low close annual general meeting price dollar ad nyse pence share queen elizabeth conference centre ordinary share high low broad sanctuary westminster london swp quarter end march february agm company principal forum communication january private shareholder addition formal business december presentation ceo performance november group future development october opportunity question ask board chairman september board committee question relate quarter end december committee quarter end september investor hold share nominee service arrange quarter end june nominee service appoint proxy respect quarter end march shareholding order attend vote meeting quarter end december quarter end september adr holder wish attend meeting obtain proxy quarter end june bank new york mellon enable quarter end march attend vote business transact adr holder year end december instruct bank new york mellon way year end december share represent adr vote year end december complete return voting card provide bank document display dollar ad ad high low article association company document quarter end march refer annual report available inspection february company register office website january exchange control limitation affect december security holder november october certain economic sanction place september time time currently law decree quarter end december regulation restrict import export capital affect quarter end september remittance dividend payment holder quarter end june company share nonresident similarly quarter end march certain economic sanction force quarter end december time time limitation relate quarter end september nonresident english law company quarter end june articles association right holder vote quarter end march respect company share year end december duplicate publication year end december year end december contact registrar receive duplicate copy gsk publication march gsk annual report shareholder investor relation registrar information investor relation share scam alert investor relation contact follow receive unsolicited phone offering sell buy share extra care caller highly organise financial scam great west road brentford middlesex shareholder contact financial service tel authority information similar usa activity consumer helpline franklin plaza box philadelphia tel tel toll free glaxo wellcome smithkline beecham tel outside usa corporate pep registrar share centre limit company registrar oxford house oxford road aylesbury buck equiniti limit tel aspect house spencer road lance west sussex adr programme administrator wwwshareviewcouk adr programme administer tel bank new york mellon tel outside box line open monday friday pittsburgh exclude public holiday wwwbnymelloncomshareowner equiniti provide follow service tel toll free shareview service enable shareholder create free tel outside usa online portfolio balance detail movement update email shrrelationsbnymelloncom address dividend payment instruction register vote administrator provide global buydirect direct ad cast agm wwwshareviewcouk purchasesale dividend reinvestment plan adr holder investment account individual saving account isa glaxosmithkline corporate sponsor nominee gsk response center share deal service tel toll free dividend reinvestment plan provision detail intend share deal service invitation inducement engage investment activity advice share dealing obtain stockbroker shareholder trade share hold certificate independent financial adviser corporate sponsor nominee internet telephone shareview deal share deal service provide equiniti financial service limited internet transaction log wwwshareviewcouk deal telephone transaction tel tel outside investment account isa service log wwwshareviewcoukdeale telephone transaction tel tel outside line open monday friday note market trading hour gsk annual report number total total number analysis shareholding december account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bank new york mellon hold hold bny nominees limited represent company adr programme ad represent ordinary share nominal value march bny nominees limit hold ordinary share represent issue share capital exclude treasury share hold date march number holder shares usa holdings share number register holder ad holding ad certain share ad hold broker nominee result number holder record register holder usa representative number beneficial holder residence beneficial holder taxation information shareholder taxation capital gain shareholder liable tax gain disposal summary certain tax federal income tax share adr disposal individual subject consequence holder share adr citizen availability exemption relief annual exempt usa set complete analysis taxable capital gain accrue disposal share possible tax consequence purchase ownership adr tax allowable deduction sale security intend general guide shareholder taxable income tax year exceed basic rate holder advise consult adviser respect tax income tax limit case taxable capital gain accrue consequence purchase ownership sale share disposal share adr tax adr consequence state local tax law combination rate corporation taxpayer entitle usa implications current ukus tax convention indexation allowance apply reduce capital gain holder adr generally treat owner extent gain arise inflation indexation allowance underlie share purpose current usauk double reduce chargeable gain create allowable loss taxation convention relate income gain income tax inheritance tax convention estate gift taxis estate gift tax convention purpose internal revenue code individual shareholder liable inheritance tax amend code transfer share adr tax charge value shareholder estate reduce result shareholder transfer way gift disposal summary apply resident shareholder hold market value gift disposal subject share capital asset inheritance tax estate gift tax estate gift tax convention generally provide tax pay usa taxation dividend credit tax payable resident shareholder generally subject income stamp duty tax dividend pay gross tax credit tax credit set stamp duty stamp duty reserve tax sdrt subject individual income tax liability respect gross dividend certain exemption payable transfer share rate repayable shareholder tax liability consideration transfer associate tax credit tax year subsequent tax year additional rate income tax dividend impose taxpayer income resident shareholder corporation taxpayer note dividend generally entitle exemption corporation tax gsk annual report shareholder taxation information shareholder information shareholder estate gift taxis summary apply shareholder citizen resident estate gift tax convention shareholder usa domestic corporation person generally subject inheritance tax subject federal income tax net income basis respect stamp duty share adr hold share adr capital assets resident tax purpose hold stamp duty sdrt subject certain exemption share purpose trade profession vocation payable issue transfer share adr carry branch agency custodian depository rate price issue consideration provide transfer sale summary address tax treatment holder value transfer consideration subject special tax rule bank taxexempt entity insurance company dealer security currency sdrt payable transfer agreement person hold share adr integrate transfer adr stamp duty payable investment include straddle comprise share adr transfer adr provide instrument transfer position person directly execute remain time outside stamp duty indirectly vote stock gsk transfer adr payable rate consideration transfer sale underlie share taxation dividend subject certain exception result liability stamp gross dividend receive treat foreign source duty case sdrt rate dividend income tax purpose eligible dividend receive deduction allow corporation dividend adr payable dollar dividend share payable sterling dividend pay pound sterling include income dollar calculate reference exchange rate day dividend receive holder subject certain exception shortterm hedge position individual eligible holder subject taxation maximum rate respect qualified dividend receive taxation capital gain generally holder subject capital gain tax subject tax capital gain realise sale disposal share adr gain longterm capital gain subject reduce rate taxation individual holder share adr hold year information report backup withholding dividend payment proceed sale share adr pay usa certain usrelated financial intermediary subject information reporting subject backup withholding holder corporation exempt recipient provide taxpayer identification number certifie loss exemption occur nonus holder generally subject information report backup withholding require provide certification nonus status connection payment receive amount withhold allow refund credit holder federal income tax liability provide require information furnish irs gsk annual report glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan finance lease capital lease freehold ownership absolute right perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay shareholder fund shareholder equity share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity glaxosmithkline hold majority shareholding andor exercise control treasury share treasury stock turnover revenue corporate governance code guideline require listing rule financial service authority address principal aspect corporate governance gsk annual report shareholder index information accounting principle policy inventory acquisition disposal investment associate joint venture adjustment reconcile profit tax operating investor relation cash flow key accounting judgement estimate annual general meeting key performance indicator asset hold sale latestage pipeline summary associate joint venture legal proceeding board longterm incentive plans business review major restructure programme cash cash equivalent movement equity chairmans statement net debt chief executive review new accounting requirement commitment access nonexecutive director term condition commitment nonexecutive director fee committee report note financial statement competition operating profit consolidate balance sheet intangible asset consolidate cash flow statement investment consolidated income statement noncurrent asset consolidate statement change equity noncurrent liability consolidated statement comprehensive income operating income contingent liability provision corporate executive team outlook corporate governance pension postemployment benefit critical accounting policy post balance sheet event director senior management presentation financial statement director emolument total remuneration principal group company director interest product development pipeline director interest contract product director statement responsibilitie property plant equipment dividend quarterly trend donation political organisation reconciliation net cash flow movement net debt political expenditure registrar earning share relate party transaction employee cost relation shareholder employee share scheme remuneration report employee research development exchange rate responsible business executive director term condition risk factor finance cost segment information finance income segment review financial instrument relate disclosure share capital control financial position resource share capital share premium account financial review share price financial review shareholder information financial statement glaxosmithkline plc prepare strategy gaap taxation year record taxation information shareholder foreign exchange risk management trade payable global manufacturing supply trade receivables glossary term trademark goodwill treasury operation governance policy corporate governance code independent auditor report law regulation intellectual property world market interest rate risk management gsk annual report official laboratory service provider gsk challenge inspire mission improve quality human life enable people feel well live long glaxosmithkline plc incorporate english public limited company december form merger glaxo wellcome plc smithkline beecham plc gsk acquire english company december merger arrangement share list london stock exchange new york stock exchange scientist work small entrepreneurial team focus specific disease area science george brooks ceo sir andrew witty hear patient visit hospital uganda tom whipps gsk official laboratory service provider london olympic paralympic games outreach programme scientist sport aim inspire young people science demonstrate role science play games david tett children seven african country take trial evaluate candidate malaria vaccine john michael maas cover employ university student oneyear placement experience workplace student support community programme george brooks september lucozade start fiveyear partnership vodafone mclaren mercede formula lat photographicsteven teewwwgskcom find downloadable pdfs annual report corporate responsibility report head office register office glaxosmithkline plc great west road brentford middlesex united kingdom tel register number print amadeus offset recycle paper fsc certification pulp deinked postconsumer waste elemental chlorine free ecf manufacturing mill hold iso ecolabel certificate environmental management mill zero landfill extremely low carbon emission lead wwf approve paper environmentally sustainable uncoated recycle paper